

Barb
only please

Access DB# 93044

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Dwayne C. Jones Examiner # 712-99 Date: 02 MAY 03
Art Unit: 1619 Phone Number 308-4639 Serial Number: 101671639
Mail Box and Bldg/Room Location: 2001 CM1 Results Format Preferred (circle) PAPER DISK E-MAIL
2001 CM1

If more than one search is submitted, please prioritize searches in order of need. me

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names): 11

Earliest Priority Filing Date: 11

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1 and 2

Point of Contact:
Barb O'Brien
Technical Information Specialist
STIC CM1 6A05 308-4291

RECEIVED
MAY 2 2003
STIC

BEST AVAILABLE COPY

STAFF USE ONLY

Searcher: BOB
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 5-9-03
Searcher Prep & Review Time: 50
Clerical Prep Time: _____
Online Time: 23

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) 3
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN 690
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

THIS PAGE BLANK (USPTO)

=> fil reg; d stat que 122; fil cap1; d que nos 126; d que nos 130; s 126 or 130; fil uspatf; d que nos 137

CAS REGISTRY ENTERED AT 10:53:35 ON 09 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 MAY 2003 HIGHEST RN 511677-22-8

DICTIONARY FILE UPDATES: 7 MAY 2003 HIGHEST RN 511677-22-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>.

L7 STR



*full file search done on
this structure*

VAR G1=O/N

VPA 11-1/2/5/6 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L8 STR



*this structure "NOT" -cd out
of answer set to meet proviso*

VAR G1=O/N

VPA 11-1/2/5/6 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE

L12 372567 SEA FILE=REGISTRY ABB=ON 333.151.57/RID
L14 5594 SEA FILE=REGISTRY SUB=L12 SSS FUL (L7 NOT L8)
L15 5579 SEA FILE=REGISTRY ABB=ON L14/COMPLETE
L20 STR



A = any non-hydrogen atom
A ~ G2 ~ Cy
@13 14 15

*subset search done on
this structure*

VAR G1=O/N

REP G2=(0-20) A

VPA 11-1/2/5/6 U

VPA 13-7/8/9 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

~~122~~ 2951 SEA FILE=REGISTRY SUB=L15 SSS FUL L20

100.0% PROCESSED 5579 ITERATIONS

2951 ANSWERS

SEARCH TIME: 00.00.02

FILE 'CAPLUS' ENTERED AT 10:53:35 ON 09 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 May 2003 VOL 138 ISS 20

FILE LAST UPDATED: 8 May 2003 (20030508/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

L7 STR
 L8 STR
 L12 372567 SEA FILE=REGISTRY ABB=ON 333.151.57/RID
 L14 5594 SEA FILE=REGISTRY SUB=L12 SSS FUL (L7 NOT L8)
 L15 5579 SEA FILE=REGISTRY ABB=ON L14/COMPLETE
 L17 260094 SEA FILE=CAPLUS ABB=ON NEOPLASM#/CW
 L18 154453 SEA FILE=CAPLUS ABB=ON ANTITUMOR AGENTS+OLD/CT
 L20 STR
 L22 2951 SEA FILE=REGISTRY SUB=L15 SSS FUL L20
 L23 400 SEA FILE=CAPLUS ABB=ON L22
 L25 192 SEA FILE=CAPLUS ABB=ON L23(L) (THU OR DMA OR PKT OR PAC OR
 BAC)/RL
 L26 44 SEA FILE=CAPLUS ABB=ON L25 AND (L17 OR L18)

↓ Roles

THU = Therapeutic use
 DMA = drug mechanism of action
 PKT = pharmacokinetics
 PAC = pharmacology
 BAC = biological activity

L7 STR
 L8 STR
 L12 372567 SEA FILE=REGISTRY ABB=ON 333.151.57/RID
 L14 5594 SEA FILE=REGISTRY SUB=L12 SSS FUL (L7 NOT L8)
 L15 5579 SEA FILE=REGISTRY ABB=ON L14/COMPLETE
 L20 STR
 L22 2951 SEA FILE=REGISTRY SUB=L15 SSS FUL L20
 L23 400 SEA FILE=CAPLUS ABB=ON L22
 L27 1607 SEA FILE=CAPLUS ABB=ON PRECANCEROUS
 L28 21610 SEA FILE=CAPLUS ABB=ON TRANSFORMATION, NEOPLASTIC/CT
 L29 137 SEA FILE=CAPLUS ABB=ON PRE CANCEROUS
 L30 1 SEA FILE=CAPLUS ABB=ON L23 AND (L27 OR L28 OR L29)

L41 44 L26 OR L30

FILE 'USPATFULL' ENTERED AT 10:53:36 ON 09 MAY 2003
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 May 2003 (20030506/PD)
 FILE LAST UPDATED: 6 May 2003 (20030506/ED)
 HIGHEST GRANTED PATENT NUMBER: US6560778
 HIGHEST APPLICATION PUBLICATION NUMBER: US2003084495
 CA INDEXING IS CURRENT THROUGH 6 May 2003 (20030506/UPCA)
 ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 May 2003 (20030506/PD)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003.

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
 >>> original, i.e., the earliest published granted patents or <<<
 >>> applications. USPAT2 contains full text of the latest US <<<
 >>> publications, starting in 2001, for the inventions covered in <<<
 >>> USPATFULL. A USPATFULL record contains not only the original <<<
 >>> published document but also a list of any subsequent <<<
 >>> publications. The publication number, patent kind code, and <<<
 >>> publication date for all the US publications for an invention <<<
 >>> are displayed in the PI (Patent Information) field of USPATFULL <<<
 >>> records and may be searched in standard search fields, e.g., /PN, <<<
 >>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
 >>> through the new cluster USPATALL. Type FILE USPATALL to <<<
 >>> enter this cluster. <<<
 >>> <<<
 >>> Use USPATALL when searching terms such as patent assignees, <<<

>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

L7 STR
L8 STR
L12 372567 SEA FILE=REGISTRY ABB=ON 333.151.57/RID
L14 5594 SEA FILE=REGISTRY SUB=L12 SSS FUL (L7 NOT L8)
L15 5579 SEA FILE=REGISTRY ABB=ON L14/COMPLETE
L20 STR
L22 2951 SEA FILE=REGISTRY SUB=L15 SSS FUL L20
L31 1619 SEA FILE=REGISTRY ABB=ON L22 AND USPATFULL/LC
L32 171 SEA FILE=USPATFULL ABB=ON L31
L33 17805 SEA FILE=USPATFULL ABB=ON NEOPLASM#/IT
L34 18070 SEA FILE=USPATFULL ABB=ON ANTITUMOR AGENTS/CT OR NEOPLASM
INHIBITORS/CT
L35 348 SEA FILE=USPATFULL ABB=ON TRANSFORMATION, NEOPLASTIC/CT
L36 59 SEA FILE=USPATFULL ABB=ON (PRECANCEROUS OR PRE CANCEROUS)/IT
L37 27 SEA FILE=USPATFULL ABB=ON L32 AND (L33 OR L34 OR L35 OR L36)

=> dup rem 141,137

FILE 'CAPLUS' ENTERED AT 10:53:47 ON 09 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 10:53:47 ON 09 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L41
PROCESSING COMPLETED FOR L37

L42 63 DUP REM L41 L37 (8 DUPLICATES REMOVED)
ANSWERS '1-44' FROM FILE CAPLUS
ANSWERS '45-63' FROM FILE USPATFULL

=> d ibib abs hitstr 1-63; fil cao; d que nos 140; fil hom

L42 ANSWER 1 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1
ACCESSION NUMBER: 2002:575744 CAPLUS
DOCUMENT NUMBER: 137:135069
TITLE: Method for reducing or preventing the establishment,
growth or metastasis of cancer by administering indole
peptidomimetics PAR-1 antagonist and optionally PAR-2
antagonists
INVENTOR(S): D'Andrea, Michael; Derian, Claudia; Woodrow, Hal Brent
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S.
Ser. No. 603,231.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103138	A1	20020801	US 2001-865824	20010525
PRIORITY APPLN. INFO.:			US 1999-141550P P	19990629
			US 2000-603231 A2	20000626
OTHER SOURCE(S):		MARPAT 137:135069		

AB The authors have discovered a method of modifying the tumor cell microenvironment to reduce or prevent the establishment, growth or metastasis of malignant cells comprising administering to a patient having malignant cells a pharmaceutically effective amt. of a PAR-1 (proteinase-activated receptor 1) inhibitor and optionally a PAR-2 (proteinase-activated receptor 2) inhibitor to prevent or reduce activation of normal cells within the tumor microenvironment. This method also has the effect in some patients of modulating the immune system to facilitate a more efficient immune response to malignant cells and maybe coupled with cytokine therapy and T-cell therapy to enhance the patient's immune response to the malignant cells.


IT **316152-77-9P**, L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)- **316152-79-1P**, L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- **316152-81-5P**, D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- **316152-83-7P**, L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- **316152-85-9P**, D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)-
 RL: **PAC (Pharmacological activity)**; **SPN (Synthetic preparation)**;
THU (Therapeutic use); **BIOL (Biological study)**; **PREP (Preparation)**; **USES (Uses)**

(inhibition of growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonists and combined with PAR-2 antagonists and other agents in relation to immunostimulant activity)

RN 316152-77-9 CAPLUS

CN L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-79-1 CAPLUS

CN L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-81-5 CAPLUS

CN D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-83-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-85-9 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L42 ANSWER 2 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 2
ACCESSION NUMBER: 2002:483072 CAPLUS
DOCUMENT NUMBER: 137:47109
TITLE: Preparation of trisubstituted indole derivatives for inhibiting neoplastic cells
INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 76 pp., Cont.-in-part of U. S. 6,046,199. *ap*
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6410584	B1	20020625	US 1998-199860	19981125
US 6046199	A	20000404	US 1998-7098	19980114

US 2002143022 A1 20021003 US 2002-71639 20020207
PRIORITY APPLN. INFO.: US 1998-7098 A2 19980114
US 1998-199860 A3 19981125
OTHER SOURCE(S): MARPAT 137:47109
GI



AB Title compds. I [R1-3 = H, alkyl, alkylthio alkoxy, with the proviso that R1-3 are not simultaneously hydrogen atoms; R4 = H, alkyl; R5 = carboxy, an esterified carboxy group, or an amidated carboxy group] were prepd. For instance, 6-methoxycarbonyl-2-methylindole was N-alkylated with 2-chlorobenzyl bromide (DMF, K2CO3, 80.degree.C, 18 h); the product sapond. and the resulting acid coupled to benzenesulfonamide (DMF, CDI, DBU) to afford II. I are used for inhibiting the growth of neoplastic cells (no data).


IT 206066-22-0P, 1-(2-Chlorobenzyl)-6-methoxycarbonyl-2-methylindole
206066-23-1P, 6-Carboxy-1-(2-chlorobenzyl)-2-methylindole
206066-26-4P, 1-(2,4-Dichlorobenzyl)-6-methoxycarbonyl-2-methylindole 206066-27-5P, 6-Carboxy-1-(2,4-dichlorobenzyl)-2-methylindole 206066-28-6P, 1-(2,4-Dichlorobenzyl)-2-ethyl-6-methoxycarbonylindole 206066-29-7P, 6-Carboxy-1-(2,4-dichlorobenzyl)-2-ethylindole 206066-30-0P, 1-(2,4-Dichlorobenzyl)-6-methoxycarbonylindole 206066-31-1P, 6-Carboxy-1-(2,4-dichlorobenzyl)indole 206066-32-2P, 3-(2,4-Dichlorobenzyl)-5-methoxycarbonylindole 206066-33-3P, 5-Carboxy-3-(2,4-dichlorobenzyl)indole 206066-34-4P, 1-(2,4-Dichlorobenzyl)-5-methoxycarbonylindole 206066-35-5P, 5-Carboxy-1-(2,4-dichlorobenzyl)indole 206066-36-6P, 3-(2,4-Dichlorobenzyl)-5-methoxycarbonyl-2-methylindole 206066-38-8P, 5-Carboxy-3-(2,4-dichlorobenzyl)-2-methylindole 206066-40-2P, 3-(2,4-Dichlorobenzyl)-5-methoxycarbonyl-1-methylindole 206066-41-3P, 5-Carboxy-3-(2,4-dichlorobenzyl)-1-methylindole 206066-43-5P, 3-(2,4-Dichlorobenzyl)-6-(methoxycarbonyl)-2-methylindole 206066-45-7P, 3-(Biphenyl-4-ylmethyl)-5-(methoxycarbonyl)-2-methylindole 206066-48-0P, 3-(2-Chlorobenzyl)-5-(methoxycarbonyl)-2-methylindole 206066-50-4P, 3-(2,4-Dichlorobenzoyl)-5-(methoxycarbonyl)-2-methylindole 206066-52-6P, 3-(4-Benzyloxybenzyl)-5-(methoxycarbonyl)-2-methylindole 206066-54-8P, 3-(2,4-Dichlorobenzyl)-5-(methoxycarbonyl)-2-propylindole 206066-55-9P, 3-(2,4-Dichlorobenzyl)-2-ethyl-5-(methoxycarbonyl)indole 206066-58-2P, 3-((1-Bromonaphthalen-2-yl)methyl)-5-(methoxycarbonyl)-2-methylindole 206066-60-6P, 3-[(3-Chloropyridin-4-yl)methyl]-5-(methoxycarbonyl)-2-methylindole 206066-62-8P, 3-[(4-Chloroisoquinolin-3-yl)methyl]-5-(methoxycarbonyl)-2-methylindole 206066-63-9P, 3-[(4-Bromoisoquinolin-3-yl)methyl]-5-(methoxycarbonyl)-2-methylindole 206066-65-1P, 1-(2,4-Dichlorobenzyl)-6-methoxycarbonyl-3-methylindole 206066-66-2P, 3-(Biphenyl-4-ylmethyl)-5-carboxy-2-methylindole 206066-67-3P, 5-Carboxy-3-(2-chlorobenzyl)-2-

methylindole 206066-68-4P, 5-Carboxy-3-(2,4-dichlorobenzoyl)-2-methylindole 206066-69-5P, 3-(4-(Benzyloxy)benzyl)-5-carboxy-2-methylindole 206066-70-8P, 5-Carboxy-3-(2,4-dichlorobenzyl)-2-propylindole 206066-71-9P, 5-Carboxy-3-(2,4-dichlorobenzyl)-2-ethylindole 206066-72-0P, 3-((1-Bromonaphthalen-2-yl)methyl)-5-carboxy-2-methylindole 206066-73-1P, 5-Carboxy-3-[(3-chloropyridin-4-yl)methyl]-2-methylindole 206066-75-3P, 5-Carboxy-3-[(4-chloroisoquinolin-3-yl)methyl]-2-methylindole 206066-76-4P, 3-[(4-Bromoisoquinolin-3-yl)methyl]-5-carboxy-2-methylindole 206066-77-5P, 6-Carboxy-2-(2,4-dichlorobenzyl)-3-methylindole 206066-78-6P, 6-Carboxy-1-(2,4-dichlorobenzyl)-3-methylindole 206066-79-7P, 3-(2-Chloro-4-phenylbenzyl)-5-methoxycarbonyl-2-methylindole 206066-80-0P, 5-Carboxy-3-(2-chloro-4-phenylbenzyl)-2-methylindole 206066-81-1P, 3-(2,4-Dichlorobenzyl)-5-methoxycarbonyl-2-methylthioindole 206066-82-2P, 5-Carboxy-3-(2,4-dichlorobenzyl)-2-methylthioindole 206066-83-3P, 3-(2,4-Dichlorobenzyl)-5-methoxycarbonyl-2-(methoxymethyl)indole 206066-84-4P, 5-Carboxy-3-(2,4-dichlorobenzyl)-2-(methoxymethyl)indole 438003-06-6P, 1-(Biphenyl-4-ylmethyl)-2-ethyl-6-methoxycarbonylindole 438003-07-7P, 1-(Biphenyl-4-ylmethyl)-6-carboxy-2-ethylindole 438003-13-5P, 2-(2,4-Dichlorobenzoyl)-6-(methoxycarbonyl)-3-methylindole 438003-14-6P, 6-Carboxy-3-(2,4-dichlorobenzyl)-2-methylindole 438003-15-7P, (E)-5-Carboxy-2-methyl-3-[4-(2-phenylethenyl)benzyl]indole

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (drug, reactant; prepn. of trisubstituted indole derivs. for inhibiting neoplastic cells)


RN 206066-22-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-23-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-26-4 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-27-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)




RN 206066-28-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-2-ethyl-,
methyl ester (9CI) (CA INDEX NAME)




RN 206066-29-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-2-ethyl- (9CI)
(CA INDEX NAME)




RN 206066-30-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-, methyl ester
(9CI) (CA INDEX NAME)




RN 206066-31-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 206066-32-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-33-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 206066-34-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-35-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 206066-36-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-38-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-40-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-41-3 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-43-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-,
methyl ester (9CI) (CA INDEX NAME)




RN 206066-45-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-,
methyl ester (9CI) (CA INDEX NAME)




RN 206066-48-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2-chlorophenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-50-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-(2,4-dichlorobenzoyl)-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-52-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-methyl-3-[[4-(phenylmethoxy)phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-54-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-55-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-58-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-60-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(3-chloro-4-pyridinyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-62-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(4-chloro-3-isoquinolinyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-63-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(4-bromo-3-isoquinolinyl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-65-1 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-66-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-([1,1'-biphenyl]-4-ylmethyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-67-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(2-chlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-68-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-(2,4-dichlorobenzoyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-69-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-methyl-3-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 206066-70-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-propyl-
(9CI) (CA INDEX NAME)


RN 206066-71-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl- (9CI)
(CA INDEX NAME)

RN 206066-72-0 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)

RN 206066-73-1 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[(3-chloro-4-pyridinyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)

RN 206066-75-3 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[(4-chloro-3-isoquinolinyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)




RN 206066-76-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(4-bromo-3-isoquinolinyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)




RN 206066-77-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2-[(2,4-dichlorophenyl)methyl]-3-methyl-
(9CI) (CA INDEX NAME)



RN 206066-78-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-3-methyl-
(9CI) (CA INDEX NAME)




RN 206066-79-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-80-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-81-1 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-82-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 206066-83-3 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-(methoxymethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 206066-84-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 438003-06-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 438003-07-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-([1,1'-biphenyl]-4-ylmethyl)-2-ethyl- (9CI) (CA INDEX NAME)



RN 438003-13-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 2-(2,4-dichlorobenzoyl)-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 438003-14-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-
(9CI) (CA INDEX NAME)



RN 438003-15-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-methyl-3-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 206064-94-0P, 6-((Benzenesulfonyl)carbamoyl)-1-(2-chlorobenzyl)-2-methylindole 206064-98-4P, 6-((Butanesulfonyl)carbamoyl)-1-(2,4-dichlorobenzyl)-2-methylindole 206065-00-1P, 1-(2,4-Dichlorobenzyl)-2-methyl-6-((pentanesulfonyl)carbamoyl)indole 206065-01-2P, 6-((Butanesulfonyl)carbamoyl)-1-(2,4-dichlorobenzyl)-2-ethylindole 206065-03-4P, 6-((Butanesulfonyl)carbamoyl)-1-(2,4-dichlorobenzyl)indole 206065-04-5P, 5-((Butanesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)indole 206065-07-8P, 5-((Butanesulfonyl)carbamoyl)-1-(2,4-dichlorobenzyl)indole 206065-09-0P, 5-((Butanesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole 206065-11-4P, 3-(2,4-Dichlorobenzyl)-5-((pentanesulfonyl)carbamoyl)indole 206065-12-5P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 206065-13-6P, 6-((Butanesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole 206065-14-7P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((propanesulfonyl)carbamoyl)indole 206065-15-8P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((octanesulfonyl)carbamoyl)indole 206065-16-9P, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole 206065-17-0P, 3-(2,4-Dichlorobenzyl)-5-((hexanesulfonyl)carbamoyl)-2-methylindole 206065-20-5P, 5-((Butanesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole 206065-22-7P, 3-(2,4-Dichlorobenzyl)-5-((2-methoxyethanesulfonyl)carbamoyl)-2-methylindole 206065-23-8P, 3-(4-(Benzyloxy)benzyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 206065-24-9P, 3-(2,4-Dichlorobenzyl)-5-((pentanesulfonyl)carbamoyl)-2-propylindole 206065-25-0P, 3-(2,4-Dichlorobenzyl)-2-ethyl-5-((pentanesulfonyl)carbamoyl)indole 206065-26-1P, 3-((1-Bromonaphthalen-2-yl)methyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 206065-27-2P, 3-[(3-Chloropyridin-4-yl)methyl]-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 206065-29-4P, 3-(2,4-Dichlorobenzyl)-5-((ethanesulfonyl)carbamoyl)-2-propylindole 206065-30-7P,

3-(2,4-Dichlorobenzyl)-2-methyl-5-((thiophene-2-ylsulfonyl)carbamoyl)indole **206065-31-8P**, 3-(2,4-Dichlorobenzyl)-5-[[4-methoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-32-9P**, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-ethylindole **206065-33-0P**, 3-[(4-Chloroisoquinolin-3-yl)methyl]-2-methyl-5-((pentanesulfonyl)carbamoyl)indole **206065-34-1P**, 3-[(4-Bromoisoquinolin-3-yl)methyl]-2-methyl-5-((pentanesulfonyl)carbamoyl)indole **206065-36-3P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((trifluoromethanesulfonyl)carbamoyl)indole **206065-37-4P**, 3-(2,4-Dichlorobenzyl)-5-((2,2-dimethylpropanesulfonyl)carbamoyl)-2-methylindole **206065-38-5P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((quinoline-8-ylsulfonyl)carbamoyl)indole **206065-39-6P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[2-phenylethane)sulfonyl]carbamoyl]indole **206065-41-0P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((benzylsulfonyl)carbamoyl)indole **206065-43-2P**, 5-((Cyclohexane)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-45-4P**, 5-((3-Chloropropane)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-49-8P**, 6-((Butanesulfonyl)carbamoyl)-2-(2,4-dichlorobenzyl)-3-methylindole **206065-51-2P**, 1-(2,4-Dichlorobenzyl)-3-methyl-6-((pentanesulfonyl)carbamoyl)indole **206065-53-4P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-methylbenzene)sulfonyl]carbamoyl]indole **206065-55-6P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-nitrobenzene)sulfonyl]carbamoyl]indole **206065-57-8P**, 5-[[4-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-59-0P**, 5-[[3-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-61-4P**, 5-[[2-Chlorobenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-63-6P**, 3-(2,4-Dichlorobenzyl)-5-[[4-fluorobenzene)sulfonyl]carbamoyl]-2-methylindole **206065-64-7P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[2-naphthalene)sulfonyl]carbamoyl]indole **206065-65-8P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[naphthalen-1-yl)sulfonyl]carbamoyl]indole **206065-66-9P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[2-methylbenzene)sulfonyl]carbamoyl]indole **206065-68-1P**, 5-(((4-Bromobenzene)sulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylindole **206065-69-2P**, (E)-3-(2,4-Dichlorobenzyl)-2-methyl-5-((styrenesulfonyl)carbamoyl)indole **206065-70-5P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-vinylbenzene)sulfonyl]carbamoyl]indole **206065-71-6P**, 5-[[4-(Phenylazo)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-72-7P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-(4-trifluoromethylbenzene)sulfonyl]carbamoyl]indole **206065-74-9P**, 3-(2,4-Dichlorobenzyl)-5-[[3,4-dimethoxybenzene)sulfonyl]carbamoyl]-2-methylindole **206065-76-1P**, 5-[[4-tert-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-77-2P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[3-methylbenzene)sulfonyl]carbamoyl]indole **206065-79-4P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[octan-2-yl)sulfonyl]carbamoyl]indole **206065-81-8P**, 3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-phenylbenzene)sulfonyl]carbamoyl]indole **206065-82-9P**, 3-(2-Chloro-4-phenylbenzyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole **206065-83-0P**, 5-((Benzenesulfonyl)carbamoyl)-3-[2-chloro-4-phenylbenzyl]-2-methylindole **206065-85-2P**, 5-[[4-n-Butylbenzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-86-3P**, 5-[[4-(Butoxy)benzene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole **206065-88-5P**, 5-((Benzenesulfonyl)carbamoyl)-3-(2,4-dichlorobenzyl)-2-methylthioindole **206065-89-6P**, 3-(2,4-Dichlorobenzyl)-2-methylthio-5-((pentanesulfonyl)carbamoyl)indole **206065-92-1P**, (E)-3-(2,4-Dichlorobenzyl)-2-methyl-5-[[4-methyl-(E)-styrene)sulfonyl]carbamoyl]indole **206065-93-2P**, (E)-3-(2,4-Dichlorobenzyl)-5-[[4-methoxystyrene)sulfonyl]carbamoyl]-2-


methylindole 206065-94-3P, 3-(2,4-Dichlorobenzyl)-2-methoxymethyl-5-((pentanesulfonyl)carbamoyl)indole 206065-95-4P, (E)-3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[(E)-styrene)sulfonyl]carbamoyl]indole 206065-96-5P, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole 206065-98-7P, 5-[[Benzenesulfonyl]carbamoyl]-3-[(1-bromonaphthalen-2-yl)methyl]-2-methylindole 206065-99-8P, (E)-3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[(styrene)sulfonyl]carbamoyl]indole 206066-00-4P, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[(4-vinylbenzene)sulfonyl]carbamoyl]indole 206066-02-6P, 3-[2-Chloro-4-phenylbenzyl]-2-methyl-5-[[[4-methylphenylsulfonyl]carbamoyl]indole 206066-03-7P, 3-(4-Bromo-2-chlorobenzyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 206066-04-8P, 3-(4-Bromo-2-chlorobenzyl)-2-methyl-5-[[[(5-chlorothien-2-yl)sulfonyl]carbamoyl]indole 206121-26-8P 438003-08-8P, 1-(Biphenyl-4-ylmethyl)-6-((butanesulfonyl)carbamoyl)-2-ethylindole 438003-16-8P, 3-(Biphenyl-4-ylmethyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 438003-17-9P, 3-(2-Chlorobenzyl)-2-methyl-5-((pentanesulfonyl)carbamoyl)indole 438003-18-0P, 3-(2,4-Dichlorobenzyl)-2-methyl-5-((3-methylbutanesulfonyl)carbamoyl)indole 438003-19-1P, (E)-2-Methyl-5-((pentanesulfonyl)carbamoyl)-3-[4-(2-phenylethenyl)benzyl]indole 438003-20-4P, (E)-3-(2,4-Dichlorobenzyl)-2-methyl-5-((pent-1-enesulfonyl)carbamoyl)indole 438003-21-5P, 3-(2,4-Dichlorobenzyl)-5-(((2,5-dimethylbenzene)sulfonyl)carbamoyl)-2-methylindole 438003-22-6P, (E)-3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(4-methylpent-1-ene)sulfonyl]carbamoyl]indole 438003-26-0P, 3-(2,4-Dichlorobenzyl)-5-[[[(4-ethylbenzene)sulfonyl]carbamoyl]-2-methylindole 438003-29-3P, (E)-3-(2,4-Dichlorobenzyl)-2-methylthio-5-[[[(pent-1-ene)sulfonyl]carbamoyl]indole 438003-30-6P, (E,E)-3-(2,4-Dichlorobenzyl)-2-methyl-5-[[[(pentan-1,3-diene)sulfonyl]carbamoyl]indole 438003-32-8P, (E)-5-[[[(2-Cyclopropylethylene)sulfonyl]carbamoyl]-3-(2,4-dichlorobenzyl)-2-methylindole 438003-36-2P, 3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[p-toluenesulfonyl]carbamoyl]indole 438003-37-3P, (E)-3-[(1-Bromonaphthalen-2-yl)methyl]-2-methyl-5-[[[(pent-2-ene)sulfonyl]carbamoyl]indole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug; prepn. of trisubstituted indole derivs. for inhibiting neoplastic cells)


RN 206064-94-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206064-98-4 CAPLUS

CN 1H-Indole-6-carboxamide, N-(butylsulfonyl)-1-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-00-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-01-2 CAPLUS

CN 1H-Indole-6-carboxamide, N-(butylsulfonyl)-1-[(2,4-dichlorophenyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 206065-03-4 CAPLUS

CN 1H-Indole-6-carboxamide, N-(butylsulfonyl)-1-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 206065-04-5 CAPLUS


CN 1H-Indole-5-carboxamide, N-(butylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 206065-07-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-(butylsulfonyl)-1-[(2,4-dichlorophenyl)methyl]-
(9CI) (CA INDEX NAME)

RN 206065-09-0 CAPLUS


CN 1H-Indole-5-carboxamide, N-(butylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-
2-methyl- (9CI) (CA INDEX NAME)

RN 206065-11-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-(pentylsulfonyl)-
(9CI) (CA INDEX NAME)


RN 206065-12-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-
(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-13-6 CAPLUS

CN 1H-Indole-6-carboxamide, N-(butylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-14-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(propylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-15-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(octylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-16-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-17-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-(hexylsulfonyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-20-5 CAPLUS

CN 1H-Indole-5-carboxamide, N-(butylsulfonyl)-3-(2,4-dichlorobenzoyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-22-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2-methoxyethyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-23-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-methyl-N-(pentylsulfonyl)-3-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 206065-24-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-(pentylsulfonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 206065-25-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-26-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-27-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro-4-pyridinyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-29-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-(ethylsulfonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 206065-30-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-31-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-methoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-32-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-ethyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-33-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(4-chloro-3-isoquinolinyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-34-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(4-bromo-3-isoquinolinyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-36-3 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-37-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,2-dimethylpropyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-38-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(8-quinolinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-39-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-phenylethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-41-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-(cyclohexylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-43-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-(cyclohexylsulfonyl)-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-45-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chloropropyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-49-8 CAPLUS

CN 1H-Indole-6-carboxamide, N-(butylsulfonyl)-2-[(2,4-dichlorophenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 206065-51-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-53-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-55-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(4-nitrophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-57-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-59-0 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(3-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-61-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(2-chlorophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-63-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-fluorophenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-64-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-65-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-66-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-68-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-bromophenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-69-2 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1E)-2-phenylethenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 206065-70-5 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-71-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(phenylazo)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-72-7 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-74-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(3,4-dimethoxyphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-76-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[[4-(1,1-dimethylethyl)phenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-77-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-79-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1-methylheptyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206065-81-8 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(1,1'-biphenyl)-4-ylsulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-82-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-83-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206065-85-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butylphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-86-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[(4-butoxyphenyl)sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206065-88-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-(methylthio)-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-89-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-(methylthio)-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-92-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1E)-2-(4-methylphenyl)ethenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 206065-93-2 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(1E)-2-(4-methoxyphenyl)ethenyl]sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 206065-94-3 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-(methoxymethyl)-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-95-4 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(1E)-2-phenylethenylsulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 206065-96-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 206065-98-7 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 206065-99-8 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(1E)-2-phenylethenylsulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 206066-00-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-N-[(4-ethenylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206066-02-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 206066-03-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(4-bromo-2-chlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 206066-04-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(4-bromo-2-chlorophenyl)methyl]-N-[(5-chloro-2-thienyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 206121-26-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(3-chloro[1,1'-biphenyl]-4-yl)methyl]-2-methyl-N-(1-pentenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 438003-08-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-4-ylmethyl)-N-(butylsulfonyl)-2-ethyl- (9CI) (CA INDEX NAME)




RN 438003-16-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 438003-17-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2-chlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)



RN 438003-18-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(3-methylbutyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 438003-19-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-methyl-N-(pentylsulfonyl)-3-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 438003-20-4 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1E)-1-pentenylsulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 438003-21-5 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(2,5-dimethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-22-6 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1E)-4-methyl-1-pentenyl]sulfonyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 438003-26-0 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-N-[(4-ethylphenyl)sulfonyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 438003-29-3 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-(methylthio)-N-[(1E)-1-pentenylsulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 438003-30-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(2,4-dichlorophenyl)methyl]-2-methyl-N-[(1E,3E)-1,3-pentadienylsulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 438003-32-8 CAPLUS


CN 1H-Indole-5-carboxamide, N-[(1E)-2-cyclopropylethenyl]sulfonyl]-3-[(2,4-dichlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 438003-36-2 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 438003-37-3 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[(1-bromo-2-naphthalenyl)methyl]-2-methyl-N-[(2E)-2-pentenylsulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 438003-12-4P, (E)-5-(Methoxycarbonyl)-2-methyl-3-[4-(2-phenylethenyl)benzyl]indole
RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(prepn. of trisubstituted indole derivs. for inhibiting neoplastic cells)
RN 438003-12-4 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-methyl-3-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 3 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 3
ACCESSION NUMBER: 2002:213824 CAPLUS
DOCUMENT NUMBER: 136:247492
TITLE: Preparation of indolecarboxylates as neoplasm inhibitors.
INVENTOR(S): ~~Pamukcu, Rifat; Piazza, Gary A.~~
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
SOURCE: U.S., 45 pp., Cont. of U.S. Ser. No. 200,139, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6358992	B1	20020319	US 1999-443395	19991119
PRIORITY APPLN. INFO.:			US 1998-200139	B1 19981125
OTHER SOURCE(S):		MARPAT 136:247492		
GI				




AB Claimed is a method of treating a mammal having precancerous lesions comprising administration of title compds. [I, R1 = H, halo, NO2, (protected) carboxy, acyl, cyano, hydroxyiminoalkyl, alkenyl optionally substituted with oxo, alkyl optionally substituted with protected carboxy, carboxy, OH; R2 = H, halo, alkenyl, acyl, alkyl optionally substituted with protected carboxy, carboxy, alkoxy, OH; R1R2 = atoms to form a 4-7 membered (oxo)carbocyclic ring; R3 = (substituted) alkenyl, alkyl; R4 = (protected) carboxy, acyl, cyano, halo, heterocyclyl, amino optionally substituted with acyl or protected carboxy, alkyl optionally substituted with (protected) carboxy, acyl] (no data). Thus, Me 3-acetyl-2-propylindole-6-carboxylate in DMF was treated with NaH then with 2-chlorobenzyl bromide followed by stirring for 1 h to give Me 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate.

IT 184147-63-5P 184147-86-2P 184148-12-7P
184148-20-7P 184148-42-3P 184148-64-9P
184148-72-9P 184148-77-4P 184148-81-0P
184149-11-9P 184150-27-4P 184150-38-7P
184150-41-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of indolecarboxylates as neoplasm inhibitors)


RN 184147-63-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184147-86-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-12-7 CAPLUS

CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-20-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-42-3 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-64-9 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl-,
methyl ester (9CI) (CA INDEX NAME)




RN 184148-72-9 CAPLUS
CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 184148-77-4 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-81-0 CAPLUS
CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 184149-11-9 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 184150-27-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl- (9CI) (CA INDEX NAME)




RN 184150-38-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 184150-41-2 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-2-propyl- (9CI) (CA
INDEX NAME)



IT 184147-49-7P 184147-55-5P 184147-58-8P
184147-60-2P 184147-65-7P 184147-67-9P
184147-69-1P 184147-72-6P 184147-75-9P
184147-78-2P 184147-80-6P 184147-84-0P
184147-88-4P 184147-90-8P 184147-92-0P
184147-94-2P 184147-96-4P 184147-98-6P
184148-00-3P 184148-02-5P 184148-03-6P
184148-05-8P 184148-06-9P 184148-07-0P
184148-08-1P 184148-09-2P 184148-10-5P
184148-11-6P 184148-13-8P 184148-14-9P
184148-15-0P 184148-16-1P 184148-17-2P
184148-18-3P 184148-19-4P 184148-21-8P
184148-22-9P 184148-23-0P 184148-24-1P
184148-25-2P 184148-26-3P 184148-27-4P
184148-28-5P 184148-29-6P 184148-30-9P
184148-31-0P 184148-32-1P 184148-33-2P
184148-34-3P 184148-35-4P 184148-36-5P
184148-37-6P 184148-38-7P 184148-39-8P
184148-40-1P 184148-41-2P 184148-43-4P
184148-44-5P 184148-45-6P 184148-46-7P
184148-47-8P 184148-48-9P 184148-49-0P
184148-50-3P 184148-51-4P 184148-52-5P
184148-53-6P 184148-54-7P 184148-55-8P
184148-56-9P 184148-57-0P 184148-58-1P
184148-59-2P 184148-60-5P 184148-61-6P
184148-62-7P 184148-63-8P 184148-65-0P
184148-66-1P 184148-67-2P 184148-68-3P
184148-69-4P 184148-70-7P 184148-71-8P
184148-73-0P 184148-74-1P 184148-75-2P
184148-76-3P 184148-78-5P 184148-79-6P
184148-80-9P 184148-82-1P 184148-83-2P
184148-84-3P 184148-85-4P 184148-86-5P
184148-87-6P 184148-88-7P 184148-89-8P
184148-90-1P 184148-95-6P 184148-96-7P
184148-99-0P 184149-00-6P 184149-01-7P
184149-02-8P 184149-03-9P 184149-04-0P

184149-12-0P 184149-13-1P 184149-14-2P
184149-15-3P 184149-16-4P 184149-17-5P
184149-18-6P 184149-22-2P 184149-23-3P
184149-24-4P 184149-25-5P 184149-26-6P
184149-27-7P 184149-28-8P 184149-29-9P
184149-30-2P 184149-31-3P 184149-34-6P
184149-35-7P 184149-36-8P 184149-38-0P
184149-39-1P 184149-40-4P 184149-41-5P
184149-43-7P 184149-44-8P 184149-45-9P
184149-48-2P 184149-49-3P 184149-50-6P
184149-51-7P 184149-52-8P 184149-53-9P
184149-56-2P 184149-57-3P 184149-58-4P
184149-59-5P 184149-60-8P 184149-61-9P
184149-62-0P 184149-63-1P 184149-64-2P
184149-65-3P 184149-66-4P 184149-67-5P
184149-71-1P 184149-72-2P 184149-73-3P
184149-74-4P 184149-77-7P 184149-78-8P
184149-79-9P 184149-80-2P 184149-81-3P
184149-82-4P 184149-83-5P 184149-84-6P
184149-85-7P 184149-86-8P 184149-87-9P
184149-88-0P 184149-89-1P 184149-90-4P
184149-91-5P 184149-93-7P 184149-94-8P
184149-95-9P 184149-96-0P 184149-97-1P
184150-00-3P 184150-02-5P 184150-03-6P
184150-04-7P 184150-05-8P 184150-06-9P
184150-09-2P 184150-10-5P 184150-12-7P
184150-13-8P 184150-14-9P 184150-15-0P
184150-18-3P 184150-19-4P 184150-20-7P
184150-21-8P 184150-22-9P 184150-23-0P
184150-24-1P 184150-25-2P 184150-26-3P
184150-28-5P 184150-29-6P 184150-30-9P
184150-31-0P 184150-32-1P 184150-33-2P
184150-34-3P 184150-35-4P 184150-37-6P
184150-39-8P 184150-40-1P 184150-42-3P
184150-43-4P 184150-44-5P 184150-45-6P
184150-46-7P 184150-49-0P 184150-50-3P
184150-53-6P 184150-54-7P 184150-55-8P
184150-56-9P 184150-57-0P 184150-58-1P
184150-59-2P 184150-60-5P 184150-61-6P
184150-62-7P 184150-63-8P 184150-64-9P
184150-65-0P 184150-66-1P 184151-82-4P
184151-84-6P 184160-76-7P 404355-25-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of indolecarboxylates as neoplasm inhibitors)

RN 184147-49-7 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184147-55-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-

(9CI) (CA INDEX NAME)




RN 184147-58-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(9CI) (CA INDEX NAME)


RN 184147-60-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184147-67-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184147-69-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184147-72-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184147-75-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184147-78-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 184147-80-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 184147-84-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184147-88-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184147-90-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 184147-92-0 CAPLUS

CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 184147-94-2 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 184147-96-4 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-

oxopropyl)- (9CI) (CA INDEX NAME)




RN 184147-98-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-00-3 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-N,N-dimethyl-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-02-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-N-(cyclopropylmethyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-03-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 184148-05-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-N-(phenylsulfonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-06-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-N-(phenylsulfonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-07-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl-N-1H-tetrazol-5-yl- (9CI) (CA INDEX NAME)




RN 184148-08-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-N-hydroxy-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-09-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-N-methoxy-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-10-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)-2-propyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 184148-11-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-13-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-14-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(phenylmethyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-15-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-16-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 184148-17-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-2-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-18-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(5-chloro-2-thienyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-phenylethyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-21-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-22-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-23-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-24-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-25-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-26-3 .CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-27-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-28-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-29-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-30-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-31-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-32-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-33-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-34-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-35-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-36-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-37-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-38-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(2-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-39-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-40-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2,3-diethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-41-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-43-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(phenylacetyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184148-44-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-45-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-46-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-47-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-48-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-49-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-50-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-51-4 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-52-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-53-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 184148-54-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-55-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-56-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-57-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-58-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-59-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 184148-60-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (9CI) (CA INDEX NAME)




RN 184148-61-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-62-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(phenylacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-63-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-65-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 184148-66-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-67-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-68-3 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-69-4 CAPLUS
CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 184148-70-7 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-71-8 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-73-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-74-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-75-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-76-3 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl-
(9CI) (CA INDEX NAME)




RN 184148-78-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 184148-79-6 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-80-9 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184148-82-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (9CI)
(CA INDEX NAME)




RN 184148-83-2 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl-
(9CI) (CA INDEX NAME)




RN 184148-84-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-benzoyl-2-propyl-
(9CI) (CA INDEX NAME)




RN 184148-85-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(9CI) (CA INDEX NAME)




RN 184148-86-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(phenylacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-87-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-88-7 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(2-pyridinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 184148-89-8 CAPLUS
CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]- (9CI) (CA INDEX NAME)




RN 184148-90-1 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[[2-(aminocarbonyl)phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184148-95-6 CAPLUS
CN 1H-Indole-2-butanolic acid, 1-[(2-chlorophenyl)methyl]-6-(methoxycarbonyl)- (9CI) (CA INDEX NAME)




RN 184148-96-7 CAPLUS
CN 1H-Indole-2-propanoic acid, 1-[(2-chlorophenyl)methyl]-6-(methoxycarbonyl)-
(9CI) (CA INDEX NAME)




RN 184148-99-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(chloroacetyl)-1-[(2-chlorophenyl)methyl]-2-
propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 184149-00-6 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxo-2-butenyl)-2-
propyl- (9CI) (CA INDEX NAME)




RN 184149-01-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(4-
morpholinylacetyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-02-8 CAPLUS

CN 1H-Indole-3,6-dicarboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl-,
6-methyl ester (9CI) (CA INDEX NAME)




RN 184149-03-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-, methyl
ester (9CI) (CA INDEX NAME)




RN 184149-04-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl-,
methyl ester (9CI) (CA INDEX NAME)




RN 184149-12-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(hydroxyacetyl)-2-
propyl- (9CI) (CA INDEX NAME)




RN 184149-13-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(2-chlorobenzoyl)-3-(2-methyl-1-oxopropyl)-2-propyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 184149-14-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(2-chlorobenzoyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-15-3 CAPLUS

CN 1H-Indole-3-carboxylic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 184149-16-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184149-17-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-chloro-1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-18-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-bromo-1-[(2-bromophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-22-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-hydroxy-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 184149-23-3 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[1-(hydroxyimino)ethyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-24-4 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[[2-[[[(methylamino)carbonyl]amino]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 184149-25-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-26-6 CAPLUS
CN 1H-Indole-2-butanoic acid, 1-[(2-chlorophenyl)methyl]-6-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-27-7 CAPLUS

CN 1H-Indole-2-propanoic acid, 1-[(2-chlorophenyl)methyl]-6-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-28-8 CAPLUS

CN 1H-Indole-7-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-29-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-30-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-31-3 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-34-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-35-7 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[[2-(acetamino)phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-36-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-formyl-, methyl ester (9CI) (CA INDEX NAME)



RN 184149-38-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-39-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-40-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(2-benzothiazolylmethyl)-2-ethyl-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-41-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-43-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-44-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-[1-(acetyloxy)propyl]-1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-45-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-48-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-bromophenyl)methyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-49-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-50-6 CAPLUS


CN 1H-Indole-6-carboxylic acid, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-51-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-52-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 184149-53-9 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-butenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184149-56-2 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-57-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-58-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-59-5 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-60-8 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 184149-61-9 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-62-0 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-63-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-64-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methyl-1-oxo-2-butenyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-65-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methyl-1-oxo-2-butenyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-66-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-67-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-71-1 CAPLUS

CN 1H-Indole-7-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-72-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-73-3 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-74-4 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-77-7 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-78-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylacetyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 184149-79-9 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-[(dimethylamino)carbonyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-80-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-81-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (9CI) (CA INDEX NAME)




RN 184149-82-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-formyl- (9CI) (CA INDEX NAME)




RN 184149-83-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 184149-84-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184149-85-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorobenzo[b]thien-3-yl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184149-86-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(2-benzothiazolylmethyl)-2-ethyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184149-87-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-88-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-89-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 184149-90-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-91-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-93-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propenyl)- (9CI) (CA INDEX NAME)




RN 184149-94-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 184149-95-9 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)- (9CI) (CA INDEX NAME)



RN 184149-96-0 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-

(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184149-97-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(ethoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-00-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-02-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 184150-03-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 184150-04-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 184150-05-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 184150-06-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-butenyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-09-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-10-5 CAPLUS

CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 184150-12-7 CAPLUS

CN 1H-Indole-7-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-13-8 CAPLUS


CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-14-9 CAPLUS
CN 1H-Indole-5-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-15-0 CAPLUS
CN 1H-Indole-4-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 184150-18-3 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-19-4 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-20-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-[(dimethylamino)carbonyl]-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-21-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-22-9 CAPLUS


CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-N3,N3-dimethyl-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-23-0 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-24-1 CAPLUS
CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI)
(CA INDEX NAME)




RN 184150-25-2 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (9CI) (CA INDEX NAME)




RN 184150-26-3 CAPLUS
CN 1H-Indole-6-carboxamide, 1-(2-chlorobenzoyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-28-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)



RN 184150-29-6 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorobenzo[b]thien-3-yl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184150-30-9 CAPLUS
CN 1H-Indole-6-carboxamide, 1-(2-benzothiazolylmethyl)-2-ethyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 184150-31-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-32-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-33-2 CAPLUS


CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 184150-34-3 CAPLUS
CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-
2-propyl- (9CI) (CA INDEX NAME)




RN 184150-35-4 CAPLUS
CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-
2-propyl- (9CI) (CA INDEX NAME)




RN 184150-37-6 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-
oxopropyl)-2-(1-propenyl)- (9CI) (CA INDEX NAME)




RN 184150-39-8 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-
oxobutyl)- (9CI) (CA INDEX NAME)




RN 184150-40-1 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-42-3 CAPLUS
CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 184150-43-4 CAPLUS
CN 1H-Indole-6-carboxamide, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 184150-44-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 184150-45-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (9CI) (CA INDEX NAME)




RN 184150-46-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-butenyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 184150-49-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[[[2-chloro-4-[(phenylsulfonyl)amino]carbonyl]phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-50-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(ethoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-53-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-54-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-55-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-56-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-57-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-58-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-59-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(methoxyacetyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184150-60-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)



RN 184150-61-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-2-propyl-1-(3-pyridinylmethyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-62-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-63-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-64-9 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(ethoxyacetyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-65-0 CAPLUS


CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-3-(ethoxyacetyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184150-66-1 CAPLUS
CN Benzoic acid, 4-[[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro-, methyl ester (9CI) (CA INDEX NAME)




RN 184151-82-4 CAPLUS
CN 1H-Indole-3,6-dicarboxylic acid, 1-[(2-chlorophenyl)methyl]-2-propyl- (9CI) (CA INDEX NAME)



RN 184151-84-6 CAPLUS
CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 184160-76-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 404355-25-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-propyl-, methyl ester (9CI) (CA INDEX NAME)



IT 184150-70-7P 184150-76-3P 184150-80-9P

184150-90-1P 184150-95-6P 184150-99-0P

184151-41-5P 184151-42-6P 184151-43-7P

184151-44-8P 184151-69-7P, 3-Cyclopropylcarbonyl-2-

propylindole-6-carboxylic acid 184151-70-0P,

3-Cyclobutylcarbonyl-2-propylindole-6-carboxylic acid 184151-71-1P

, 3-Cyclopentylcarbonyl-2-propylindole-6-carboxylic acid

184151-72-2P, 3-Cyclohexylcarbonyl-2-propylindole-6-carboxylic

acid 184151-74-4P, 3-Cyclopropylcarbonyl-2-propylindole-6-

carboxamide 184151-75-5P, 3-Cyclobutylcarbonyl-2-propylindole-6-

carboxamide 184151-76-6P, 3-Cyclopentylcarbonyl-2-propylindole-6-

carboxamide 184151-77-7P, 3-Cyclohexylcarbonyl-2-propylindole-6-


carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of indolecarboxylates as neoplasm inhibitors)


RN 184150-70-7 CAPLUS

CN 1H-Indole-1,6-dicarboxylic acid, 2-propyl-, 6-methyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 184150-76-3 CAPLUS


CN 1H-Indole-1,6-dicarboxylic acid, 2-(2-methylpropyl)-, 6-methyl 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 184150-80-9 CAPLUS
CN 1H-Indole-1,6-dicarboxylic acid, 2-ethyl-, 6-methyl 1-(phenylmethyl) ester
(9CI) (CA INDEX NAME)




RN 184150-90-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-benzoyl-2-propyl-, methyl ester (9CI) (CA
INDEX NAME)




RN 184150-95-6 CAPLUS
CN 1H-Indole-1,6-dicarboxylic acid, 2-methyl-, 6-methyl 1-(phenylmethyl)
ester (9CI) (CA INDEX NAME)




RN 184150-99-0 CAPLUS
CN 1H-Indole-1,6-dicarboxylic acid, 2-(methoxymethyl)-, 6-methyl
1-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 184151-41-5 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclopropylcarbonyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184151-42-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclobutylcarbonyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184151-43-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclopentylcarbonyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184151-44-8 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclohexylcarbonyl)-2-propyl-, methyl ester (9CI) (CA INDEX NAME)




RN 184151-69-7 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclopropylcarbonyl)-2-propyl- (9CI) (CA
INDEX NAME)




RN 184151-70-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclobutylcarbonyl)-2-propyl- (9CI) (CA
INDEX NAME)



RN 184151-71-1 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclopentylcarbonyl)-2-propyl- (9CI) (CA
INDEX NAME)




RN 184151-72-2 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(cyclohexylcarbonyl)-2-propyl- (9CI) (CA
INDEX NAME)




RN 184151-74-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(cyclopropylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184151-75-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(cyclobutylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 184151-76-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(cyclopentylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 184151-77-7 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(cyclohexylcarbonyl)-2-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 4 OF 63 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:10088 CAPLUS
DOCUMENT NUMBER: 134:71491



DUPLICATE 4

TITLE: Indoloylguanidine derivatives useful as inhibitors of Na⁺/H⁺ exchanger activity.
INVENTOR(S): Kitano, Masahumi; Nakano, Kazuhiro; Yagi, Hideki; Ohashi, Naohito; Kojima, Atsuyuki; Noguchi, Tsuyoshi; Miyagishi, Akira
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: U.S., 69 pp., Cont.-in-part of U.S. Ser. No. 230,223, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6169107	B1	20010102	US 1995-544292	19951017
US 6248772	B1	20010619	US 2000-604826	20000627

PRIORITY APPLN. INFO.: JP 1993-125085 A 19930428
US 1994-230223 B2 19940420
JP 1994-280025 A 19941018
US 1995-544292 A3 19951017

OTHER SOURCE(S): MARPAT 134:71491
GI



AB Indoloylguanidine derivs. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, halo, NO₂, acyl, CO₂H, alkoxy carbonyl, arom. group, (un)substituted OH, NH₂, SO₂NH₂, etc.; R2 = H, (un)substituted alkyl, cycloalkyl, OH, alkoxy, etc.] and their pharmaceutically acceptable acid addn. salts inhibit Na⁺/H⁺ exchanger activity, and are consequently useful in the treatment or prevention of diseases caused by increased Na⁺/H⁺ exchanger activity. These include hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders assocd. with ischemia or ischemic reperfusion, cerebro-ischemic disorders, and diseases caused by excessive cell proliferation. Over 250 synthetic examples and 22 precursor preps. are given, with bioassay results for most invention compds. For example, condensation of Me 1-methyl-2-indolecarboxylate with guanidine HCl in the presence of NaOMe at ltoreq. 130.degree. gave, after chromatog. and salification, 30.8% title compd. II. In an assay for inhibition of ischemia-and-reperfusion-induced cardiac arrhythmia in rats, II at 0.3 mg/kg reduced mortality from 76% (control) to 0%, whereas EIPA [5-(N-ethyl-N-isopropyl)amiloride] reduced mortality to only 44% at the same dose.


IT 167478-07-1P 178050-69-6P 178050-71-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)


(prepn. of indoloylguanidine derivs. as Na⁺/H⁺ exchanger inhibitors)

RN 167478-07-1 CAPLUS

CN 1H-Indole-5-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)


● HCl

RN 178050-69-6 CAPLUS

CN 1H-Indole-6-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 178050-71-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-,
monohydrochloride (9CI) (CA INDEX NAME)

HCl

REFERENCE COUNT:

85

THERE ARE 85 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 5 OF 63 CAPLUS COPYRIGHT 2003 ACS

DUPLICATE 5

Searched by Barb O'Bryen, STIC 308-4291

ACCESSION NUMBER: 1999:733040 CAPLUS
DOCUMENT NUMBER: 131:336940
TITLE: Preparation of indole derivatives as antagonists of
gonadotropin releasing hormone
INVENTOR(S): Goulet, Mark; Ujjainwalla, Feroze; Walsh, Thomas F.;
Wyvratt, Matthew J., Jr.; Young, Jonathan R.; Chu, Lin
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 32 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985901	A	19991116	US 1998-83479	19980522
PRIORITY APPLN. INFO.:			US 1998-83479	19980522
OTHER SOURCE(S):	MARPAT 131:336940			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alk-aryl-alk where alk = (un)substituted C0-4 alkylene; B = bond, O-alk, CO-alk, S(O)O-2-alk, etc.; R0, R2 = H, (un)substituted alkyl, aryl, or aralkyl; or R2A may form 5- to 7-membered ring; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms (un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)O-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkynylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Approx. 36 such compds. were prepd. and/or claimed, and a variety of intermediates were prepd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and reductive alkylation of the resultant sidechain amine with 4-(pyridin-3-yl)benzaldehyde and NaBH3CN, to give the title compd. II.



IT 217192-16-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)

RN 217192-16-0 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[[4-(3-pyridinyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 6 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 6
ACCESSION NUMBER: 1998:816108 CAPLUS
DOCUMENT NUMBER: 130:66389
TITLE: Preparation of indole derivatives as gonadotropin releasing hormone antagonists
INVENTOR(S): Goulet, Mark; Chu, Lin; Walsh, Thomas F.; Fisher, Michael H.; Gifotra, Narindar N.; Wyvratt, Matthew J.; Lin, Peter; Ashton, Wallace T.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 59 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5849764	A	19981215	US 1996-760817	19961205
PRIORITY APPLN. INFO.:			US 1996-760817	19961205
OTHER SOURCE(S):		MARPAT 130:66389		
GI				



I



II


AB The title compds. I [A = (halo)alkyl, (un)substituted cycloalkyl, alkenyl, or alkynyl, alkoxy, alkylthio, alkoxyalkyl, bond, etc.; R0 = H, (un)substituted alkyl, aryl, or aralkyl; R1 = various (un)substituted heterocycles; R2 = H, (un)substituted alkyl, aralkyl, aryl, etc.; R2 and A may form 5- to 7-atom ring; R3, R4, R5 = H, (un)substituted alkyl or alkenyl, cyano, nitro, halo; R6 = H, (un)substituted alkyl, aryl, cyano, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent; R8 = H, CO2H or derivs., NH2 or derivs., OH or SH or derivs., etc.; or R7 and R8 form a C3-7 carbocyclic ring; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; X = H, halo, N, O, S(O)0-2, CO, CH2, etc.; m = 0-3] (claimed) and similar compds. were prepd. as antagonists of gonadotropin releasing hormone (no data). The compds. are thus useful for treatment of a variety of conditions including hormone-dependent cancers, benign prostatic hypertrophy, endometriosis, irritable bowel syndrome, etc. For instance, amidation of 3-(1H-indol-5-yl)propionic acid with 2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethylamine using EDC and HOBT, and redn. of the amide product to a secondary amine using LiAlH4 in THF at 77.degree., gave the invention compd. II.

IT 192643-79-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of indole derivs. as gonadotropin releasing hormone antagonists)

RN 192643-79-1 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 192715-07-4P 192715-08-5P 192715-10-9P
 192715-12-1P 192715-13-2P 192715-14-3P
 192715-16-5P 192715-18-7P 192715-20-1P
 192715-22-3P 192715-24-5P 192715-26-7P
 192715-28-9P 192715-30-3P 192715-32-5P
 192715-34-7P 192715-36-9P 192715-38-1P
 192715-40-5P 192715-42-7P 192715-44-9P
 192715-46-1P 192715-47-2P 192715-48-3P
 192715-49-4P 192715-50-7P 192715-51-8P
 192715-52-9P 192715-53-0P 192715-54-1P
 192715-55-2P 192715-56-3P 192715-57-4P
 192715-58-5P 192715-59-6P 192715-60-9P
 192715-61-0P 192715-62-1P 192715-63-2P
 192715-64-3P 192715-65-4P 192715-66-5P
 192715-67-6P 192715-68-7P 192715-69-8P
 192715-70-1P 192715-71-2P 192715-72-3P
 192715-73-4P 192715-98-3P 192716-09-9P
 192716-10-2P 192716-11-3P 192716-12-4P
 192716-13-5P 192716-14-6P 192716-15-7P
 192716-16-8P 192716-17-9P 192716-18-0P
 192716-19-1P 192716-20-4P 192716-21-5P
 192716-22-6P 192716-23-7P 192716-24-8P
 192716-25-9P 192716-26-0P 192716-28-2P
 192716-30-6P 192716-31-7P 192716-32-8P
 192716-35-1P 192716-36-2P 192716-38-4P
 192716-48-6P 192716-50-0P 192716-51-1P
 192716-52-2P 192716-53-3P 192716-68-0P
 192716-69-1P 192716-70-4P 192716-71-5P
 192716-72-6P 192716-73-7P 192717-14-9P

RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of indole derivs. as gonadotropin releasing hormone
 antagonists)

RN 192715-07-4 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 192715-08-5 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192715-10-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-dimethyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-12-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-dimethyl-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-13-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-14-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-N,N-bis(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 192715-16-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(2-hydroxyethyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-18-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(2-hydroxyethyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-20-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methoxyethyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-22-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-hydroxypropyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-24-5 CAPLUS

CN 1H-Indole-5-carboxamide, N-cyclohexyl-2-(3,5-dimethylphenyl)-N-ethyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192715-26-7 CAPLUS


CN 1H-Indole-5-carboxamide, N-cyclohexyl-2-(3,5-dimethylphenyl)-N-ethyl-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192715-28-9 CAPLUS


CN 1H-Indole-5-carboxamide, N-cyclopentyl-2-(3,5-dimethylphenyl)-N-propyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)

[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-30-3 CAPLUS

CN 1H-Indole-5-carboxamide, N,N-dibutyl-2-(3,5-dimethylphenyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-32-5 CAPLUS

CN 1H-Indole-5-carboxamide, N,N-dibutyl-2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-34-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-(1-methylethyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-36-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-38-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(1-methylethyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-40-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(phenylmethyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-42-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(phenylmethyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-44-9 CAPLUS

CN 1H-Indole-5-carboxamide, N-(cyclopropylmethyl)-2-(3,5-dimethylphenyl)-N-propyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-46-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(3-methyl-1,2-benzisoxazol-5-yl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-47-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 6-chloro-2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 192715-48-3 CAPLUS


CN 1H-Indole-5-carboxamide, 6-chloro-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192715-49-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(4-methylphenyl)sulfonyl]-1H-indol-5-yl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

Me

RN 192715-50-7 CAPLUS
 CN 1H-Indole-5-carboxamide, N-cyclooctyl-2-(3,5-dimethylphenyl)-N-methyl-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-51-8 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 4-chloro-2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 192715-52-9 CAPLUS

CN 1H-Indole-5-carboxamide, 4-chloro-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-53-0 CAPLUS

CN 1H-Indole-5-carboxamide, 6-chloro-2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-54-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(3-methyl-5-isoxazolyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-55-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-56-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-57-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-(6-amino-3-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-58-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(6-methoxy-3-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-59-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(3-ethyl-5-isoxazolyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-60-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(3-propyl-5-isoxazolyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-61-0 CAPLUS

CN 3-Isoxazolecarboxylic acid, 5-[4-[[2-[5-[[bis(2-methylpropyl)amino]carbonyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]butyl]- (9CI) (CA INDEX NAME)




RN 192715-62-1 CAPLUS

CN 3-Isoxazolecarboxylic acid, 5-[4-[[2-[5-[[bis(2-methylpropyl)amino]carbonyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]butyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192715-63-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-[3-[(diethylamino)carbonyl]-5-isoxazolyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-64-3 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-(2-cyano-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-65-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-(1,6-dihydro-6-oxo-3-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-66-5 CAPLUS

CN 4-Isoxazolecarboxylic acid, 5-[4-[[2-[5-[[bis(2-methylpropyl)amino]carbonyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]butyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 192715-67-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-[2-(aminomethyl)-4-pyridinyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-(9CI) (CA INDEX NAME)




RN 192715-68-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[6-(methylthio)-3-pyridinyl]butyl]amino]ethyl]-(9CI) (CA INDEX NAME)




RN 192715-69-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-[4-[[2-[5-[[bis(2-methylpropyl)amino]carbonyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]butyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192715-70-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(2,3,5,6-tetrafluoro-4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-71-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[6-[(methylsulfonyl)amino]-3-pyridinyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192715-72-3 CAPLUS


CN 1H-Indole-5-carboxamide, 3-[2-[[4-(3,5-dichloro-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192715-73-4 CAPLUS
 CN 1H-Indole-5-carboxamide, 3-[2-[[4-(7-chloro-4-quinolinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 192715-98-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-09-9 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[3-[(3-ethyl-7-propyl-1,2-benzisoxazol-6-yl)oxy]propyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192716-10-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-hydroxy-4-(4-pyridinyl)cyclohexyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192716-11-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[3-(3-pyridinyloxy)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-12-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-3-(3-pyridinyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-13-5 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-14-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 192716-15-7 CAPLUS



CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 192716-16-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[3-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-17-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[3-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-18-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[2-(3-pyridinylmethoxy)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-19-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[2-methyl-4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-20-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(4-pyridinyl)pentyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-21-5 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[3-methyl-4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-22-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[1-methyl-2-(3-pyridinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-23-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[methyl[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-24-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[1,1-dimethyl-4-(3-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192716-25-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-hydroxy-1,1-dimethyl-4-(3-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI)
(CA INDEX NAME)




RN 192716-26-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-hydroxy-1,1-dimethyl-4-(3-pyridinyl)-2-butenyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 192716-28-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[2-(3-pyridinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-30-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-hydroxy-1,1-dimethyl-4-(4-pyridinyl)-2-butenyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 192716-31-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-hydroxy-1,1-dimethyl-4-(4-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 192716-32-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[1,1-dimethyl-4-(4-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 192716-35-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[2-methyl-4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-36-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[2-ethyl-4-(4-pyridinyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192716-38-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[2-(4-pyridinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-48-6 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dichlorophenyl)-N,N-diethyl-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-50-0 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2-(3,5-dichlorophenyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192716-51-1 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dichlorophenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-52-2 CAPLUS
CN 1H-Indole-5-carboxamide, N,N-dibutyl-2-(3,5-dichlorophenyl)-3-[2-[[4-(3-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192716-53-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dichlorophenyl)-N,N-diethyl-3-[2-[[4-(3-methyl-5-isoxazolyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-68-0 CAPLUS


CN 1H-Indole-5-carboxamide, N-(2-cyanoethyl)-N-cyclohexyl-2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-69-1 CAPLUS

CN Carbamic acid, [[4-[4-[[2-[5-[[bis(2-methylpropyl)amino]carbonyl]-2-(3,5-dimethylphenyl)-1H-indol-3-yl]ethyl]amino]butyl]-2-pyridinyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

— OBU-t


RN 192716-70-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[3-(3-pyridinyl)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192716-71-5 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[6-[[[(trifluoromethyl)sulfonyl]amino]-3-pyridinyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)





RN 192716-72-6 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[2-[[4-(5-cyano-3-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192716-73-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)-4-pyridinyl]butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 192717-14-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[[4-(7-chloro-1,2-dihydro-2-oxo-4-quinolinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 7 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 7
ACCESSION NUMBER: 1998:479019 CAPLUS
DOCUMENT NUMBER: 129:109094
TITLE: Antagonists of gonadotropin releasing hormone
INVENTOR(S): Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 47 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780437	A	19980714	US 1996-760816	19961205
US 6200957	B1	20010313	US 1998-115497	19980714
PRIORITY APPLN. INFO.:			US 1995-8633P	P 19951214
			US 1996-760816	A2 19961205

OTHER SOURCE(S): MARPAT 129:109094
GI



AB The title compds. [I; A = (un)substituted C1-6 alkyl, C3-7 cycloalkyl, alkenyl, etc.; R0 = H, (un)substituted C1-6 alkyl, aryl, etc.; R1 = arom. heterocyclyl; R2 = H, (un)substituted C1-6 alkyl, aralkyl, etc.; R3-R5 = H, (un)substituted C1-6 alkyl, alkenyl, etc.; R6 = H, (un)substituted C1-6 alkyl, aryl, etc.; R7 = H, (un)substituted C1-6 alkyl, etc.; R8 = CO2R20, CONR20R21, etc.; R20, R21 = H, (un)substituted C1-6 alkyl, aryl, etc.; R9, R9a = H, (un)substituted C1-6 alkyl or aryl, etc.; R10, R10a = H, (un)substituted C1-6 alkyl or aryl, aralkyl, etc.; X = N, O, CO, etc.; m = 0-3] and pharmaceutically acceptable salts thereof are prepd. I are useful as antagonists of gonadotropin-releasing hormone (GnRH) and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women (no data). Thus, [2-[2-(3,5-dimethylphenyl)-5-(morpholine-4-carbonyl)-1H-indol-3-yl]ethyl]-(4-pyridin-4-ylbutyl)carbamic acid benzyl ester (prepn. given) was hydrogenated over Pd/C to give 60% the title compd. (II).


IT 192643-04-2P 192643-05-3P 192643-06-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn of indole derivs. as antagonists of gonadotropin releasing hormone)

RN 192643-04-2 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 192643-05-3 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 192643-06-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 8 OF 63 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 8
ACCESSION NUMBER: 1998:394035 CAPLUS
DOCUMENT NUMBER: 129:41077
TITLE: Preparation of N-aralkyl-2-(substituted-aryl)indole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists
INVENTOR(S): Goulet, Mark; Chu, Lin; Ashton, Wallace T.; Fisher, Michael H.; Wyvratt, Matthew J.; Smith, Roy G.; Bugianesi, Robert L.; Ponpipom, Mitree M.; Yang, Yi Tien; Lin, Peter
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 53 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5756507	A	19980526	US 1996-760851	19961205
PRIORITY APPLN. INFO.:			US 1996-760851	19961205
OTHER SOURCE(S):	MARPAT 129:41077			
GI				




AB Title compds. I [R = H, (ar)alkyl, aryl, etc.; R4 = (CR9R9a)mCR10R10aNR2ZR1; R1 = (un)substituted Ph, -naphthyl, -biphenyl, etc.; R2 = H, (ar)alkyl, aryl, etc.; R3 = Ph with 2-3 substituents; R5 = H, halo, OR7, OR8, NR7R8, COR7, COR8, etc.; R6 = H, halo, (perfluoro)alkyl, aryl, etc.; R7 = H or (un)substituted alkyl; R8 = H, CO2H derivs., NH2 or derivs., etc.; R9, R9a = H, (ar)alkyl, aryl, etc.; R10, R10a = H, (ar)alkyl, aryl, etc.; Z = (un)substituted alk(en/yn)ylene, etc.; NR2Z = heterocyclene; m = 0-3] and their pharmaceutically acceptable salts are antagonists of GnRH (gonadotropin releasing hormone), and are useful for the treatment of a variety of sex-hormone-related and other conditions in both men and women (no data). Almost 300 invention compds. were prepd. and/or claimed. For instance, amidation of 3-(4-hydroxyphenyl)propionic acid with 2-[2-(3,4-dimethoxyphenyl)-1H-indol-3-yl]ethylamine using EDC and HOBt gave title compd. II.

IT 192773-15-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of N-aralkyl-2-arylindole-3-alkanamines and analogs as gonadotropin releasing hormone antagonists)

RN 192773-15-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 192773-13-0P 192773-14-1P 192773-16-3P
 192773-17-4P 192773-18-5P 192773-19-6P
 192773-20-9P 192773-21-0P 192773-22-1P
 192773-23-2P 192773-24-3P 192773-25-4P
 192773-26-5P 192773-27-6P 192773-28-7P


192773-29-8P 192773-30-1P 192773-31-2P
192773-32-3P 192773-33-4P 192773-43-6P
192773-44-7P 192773-45-8P 192773-46-9P
192773-47-0P 192773-48-1P 192773-52-7P
192773-53-8P 192773-54-9P 192773-55-0P
192773-56-1P 192773-57-2P 192773-58-3P
192773-59-4P 192773-60-7P 192773-61-8P
192773-62-9P 192773-63-0P 192773-64-1P
192773-65-2P 192773-66-3P 192773-67-4P
192773-68-5P 192773-69-6P 192773-70-9P
192773-71-0P 192773-72-1P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of N-aralkyl-2-arylindole-3-alkanamines and analogs as
gonadotropin releasing hormone antagonists)


RN 192773-13-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-[(4-(methylsulfonyl)amino)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192773-14-1 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[4-[(4-(methylsulfonyl)amino)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-16-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-hydroxyethyl)-3-[2-[[4-[(4-(methylsulfonyl)amino)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 192773-17-4 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-18-5 CAPLUS
CN 1H-Indole-5-carboxamide, N-cyclopropyl-2-(3,5-dimethylphenyl)-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-19-6 CAPLUS

CN 1H-Indole-5-carboxamide, N-butyl-2-(3,5-dimethylphenyl)-N-ethyl-3-[2-[[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-20-9 CAPLUS.

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(1-methylethyl)-3-[2-[[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-21-0 CAPLUS
 CN 1H-Indole-5-carboxamide, N-cyclohexyl-2-(3,5-dimethylphenyl)-N-ethyl-3-[2-
 [[4-[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX
 NAME)




RN 192773-22-1 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-(2-hydroxyethyl)-N-
 methyl-3-[2-[[4-[[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 192773-23-2 CAPLUS
 CN 1H-Indole-5-carboxamide, N-(1,1-dimethylethyl)-2-(3,5-dimethylphenyl)-N-methyl-3-[2-[[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI)
 (CA INDEX NAME)




RN 192773-24-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 192773-25-4 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-ethyl-N-(2-hydroxyethyl)-
 3-[2-[[4-[4-[(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA
 INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 192773-26-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-methyl-3-[2-[[4-[4-
 [(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]-N-phenyl- (9CI) (CA
 INDEX NAME)



RN 192773-27-6 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-dimethyl-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-28-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-(2-methoxyethyl)-N-methyl-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 192773-29-8 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-(2-methoxyethyl)-N-(1-methylethyl)-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 192773-30-1 CAPLUS
CN 1H-Indole-5-carboxamide, N-(1,1-dimethylethyl)-2-(3,5-dimethylphenyl)-N-(2-methoxyethyl)-3-[2-[[4-[4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]-(9CI) (CA INDEX NAME)

COCCN(C(C)(C)C)C(=O)c1ccc2c(c1)[C@H](c3ccc(C)c(C)c3)N2CCNCCCCc4ccc(N)cc4
$$\begin{array}{c} \text{O} \\ || \\ -\text{S}-\text{Me} \\ || \\ \text{O} \end{array}$$
CC(C)(C)N(CCC)C(=O)c1ccc2c(c1)c(c[nH]2)c3ccc(C)c(C)c3CCCNCCCCc4ccc(NC(=O)S(=O)(=O)C)cc4


Searched by Barb O'Bryen, STIC 308-4291




RN 192773-33-4 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-(methylsulfonyl)amino)phenyl]butyl]amino]ethyl]-N,N-bis(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)



RN 192773-43-6 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192773-44-7 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-45-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-46-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 192773-47-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 192773-48-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-hydroxyphenyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)





RN 192773-52-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-nitrophenyl)butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192773-53-8 CAPLUS


CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[ethyl[4-(4-(methylsulfonyl)amino]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192773-54-9 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-[(methylamino)sulfonyl]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-55-0 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-[(methylamino)sulfonyl]phenyl]butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192773-56-1 CAPLUS
 CN 1H-Indole-5-carboxamide, N-cyclohexyl-2-(3,5-dimethylphenyl)-N-ethyl-3-[2-[[4-[(methylamino)sulfonyl]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)


[[4-[4-[(methylamino)sulfonyl]phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 192773-57-2 CAPLUS
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-(4-nitrophenyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-58-3 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[2-[[4-(4-aminophenyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192773-59-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 2-(3,5-dimethylphenyl)-3-[2-[[4-[4-(methylthio)phenyl]butyl]amino]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 192773-60-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-[4-(methylthio)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-61-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-[4-(methylsulfinyl)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-62-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-diethyl-3-[2-[[4-[4-(methylsulfonyl)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-63-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[4-(methylthio)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-64-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[4-(methylsulfinyl)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-65-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)-3-[2-[[4-[4-(methylsulfonyl)phenyl]butyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 192773-66-3 CAPLUS
 CN 1H-Indole-5-carboxamide, 3-[2-[[4-[4-[[[(aminocarbonyl)amino] (methylamino) methylene]amino]phenyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 192773-67-4 CAPLUS
 CN 1H-Indole-5-carboxamide, 3-[2-[[4-[4-[[[(cyanoamino) (methylamino) methylene] amino]phenyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

— CN


RN 192773-68-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-fluorophenyl)butyl]amino]ethyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 192773-69-6 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-[2-[[4-[4-[(dimethylamino)sulfonyl]phenyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 192773-70-9 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[2-[[4-[4-[(dimethylamino)sulfonyl]phenyl]butyl
amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA
INDEX NAME)



RN 192773-71-0 CAPLUS
CN 1H-Indole-5-carboxamide, 3-[2-[[4-[4-[(dimethylamino)sulfonyl]phenyl]butyl
amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 192773-72-1 CAPLUS
CN 1H-Indole-5-carboxamide, N-cyclohexyl-3-[2-[[4-[4-
[(dimethylamino)sulfonyl]phenyl]butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-
N-ethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 9 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:154382 CAPLUS

DOCUMENT NUMBER: 138:187795

TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors

INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 1009 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JP8120	20020808
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, KR, KU, LV, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2001-241867 A 20010809

OTHER SOURCE(S): MARPAT 138:187795

GI



AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbobicyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prep'd. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxyethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, ~~Alzheimer's disease~~, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reprodn. disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction,

arteriosclerosis, circulation disorders or ulcers assocd. therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, redn. of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et₃N in THF at 0.degree. for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0.degree. to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE₂ to prostaglandin E₂ (PGE₂) receptor subtype EP₁, EP₂, EP₃, and EP₄ expressed in CHO cells with K_i of >10, >10, 0.27, and 0.038 .mu.M, resp. A tablet formulation contg. (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499149-01-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);


THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of aryl or heterocyclyl-substituted benzoic acid and alkanolic acid derivs. as antagonists of prostaglandin E₂ (PGE₂) receptors as therapeutic agents)

RN 499149-01-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[[(3-methyl-1-phenylbutyl)amino]carbonyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 10 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:97322 CAPLUS

DOCUMENT NUMBER: 138:142493

TITLE: Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient

INVENTOR(S): Maruyama, Toru; Kobayashi, Kaoru; Kambe, Tohru; Maruyama, Takayuki; Yoshida, Hideyuki; Nishiura, Akio; Abe, Nobutaka

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 474 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

Searched by Barb O'Bryen, STIC 308-4291

WO	2003009872	A1	20030206	WO	2002-JP7385	20020722	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM						
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FF, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						

PRIORITY APPLN. INFO.:

JP 2001-222148 A 20010723
JP 2001-239895 A 20010807
JP 2002-56449 A 20020301

OTHER SOURCE(S): MARPAT 138-142493

AB Disclosed are drugs for topical administration which contain an EP4 agonist as the active ingredient for preventing and/or treating diseases in assocn. with bone mass loss. The EP4 agonists typified by compds. with the prostaglandin skeleton have an effect of promoting osteogenesis. Thus, topical administration thereof is highly useful in preventing and/or treating diseases in assocn. with bone mass loss, e.g., bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Behcet's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone transplantation. A compd. (11.alpha.,15.alpha.,13E)-9-oxo-11,15-dihydroxy-16-(3-methoxymethylphenyl)-17,18,19,20-tetranor-5-thiaprost-13-enoic acid 2-nonanoyloxyethyl ester was prepd., and mixed with lactic acid-glycolic acid copolymer to obtain a microsphere. The obtained microsphere was administered to fracture bone part of a rat to examine the bone formation promoting effect.

IT 494223-73-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(remedies for diseases with bone mass loss contg. prostaglandin EP4 receptor agonists as active ingredients)

RN 494223-73-3 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[(2R)-2-[(1E,3S)-3-hydroxy-4-(3-methylphenyl)-1-butenyl]-5-oxo-1-pyrrolidiny]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 11 OF 63 CAPLUS · COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:428849 CAPLUS
DOCUMENT NUMBER: 137:5991
TITLE: Preparation of 4-phenoxyphenylacetic acids active at
the glucocorticoid receptor III
INVENTOR(S): Gillner, Mikael; Hagberg, Lars; Koch, Eva; Nilsson,
Marita; Wu, Jinchang
PATENT ASSIGNEE(S): Karo Bio Ab, Swed.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002044120	A1	20020606	WO 2001-IB2164	20011116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002012629	A5	20020611	AU 2002-12629	20011116
PRIORITY APPLN. INFO.:			GB 2000-29100	A 20001129
			WO 2001-IB2164	W 20011116
OTHER SOURCE(S):		MARPAT 137:5991		
GI				



AB The title compds. [I; R1 = CO₂H, heteroaryl; R2, R3 = H, halo, alkyl, provided that one of R2 or R3 is other than H atom; R4 = alkyl, cycloalkyl, alkenyl, alkynyl; R5 = H, alkyl, alkenyl, alkynyl; R6, R7 = aryl, heteroaryl, heterocycloalkyl] or pharmaceutically acceptable salts. that are liver selective glucocorticoid receptor antagonists, and are useful in therapy and in the regulation of metab., esp. lowering blood glucose levels, were prepd. Thus, reacting 3,5-dibromo-4-{2-[hydroxy(phenyl)methyl]-5-isopropyl-4-methoxyphenoxy}phenylacetic acid with phenol in the presence of SnCl₂ in CH₂Cl₂ afforded I [R1 = CO₂H; R2, R3 = Br; R4 = iso-Pr; R5 = Me; R6 = Ph; R7 = 4-HOC₆H₄]. The compds. I exhibit an affinity for the glucocorticoid receptor in the range between 0.1 and 5000 nM.


IT 433686-70-5P 433686-71-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)

(prepn. of 4-phenoxyphenylacetic acids active at the glucocorticoid receptor III)


RN 433686-70-5 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[[2-[2,6-dibromo-4-(carboxymethyl)phenoxy]-5-methoxy-4-(1-methylethyl)phenyl](3-methylphenyl)methyl]-, 4-methyl ester (9CI) (CA INDEX NAME)



RN 433686-71-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[[2-[2,6-dibromo-4-(carboxymethyl)phenoxy]-5-methoxy-4-(1-methylethyl)phenyl](3-methylphenyl)methyl]-, 5-methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 12 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:107321 CAPLUS

DOCUMENT NUMBER: 136:167373

TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

INVENTOR(S): Thuriereau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis

PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SOURCE: PCT Int. Appl., 369 pp

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010140	A2	20020207	WO 2001-US23959	20010731
WO 2002010140	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SD, TD, TG				
EP 1305294	A2	20030502	EP 2001-957342	20010731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-222584P P 20000801
WO 2001-US23959 W 20010731

OTHER SOURCE(S): MARPAT 136:167373
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Imidazole derivs. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mAl; Al = C(:Y)NX1X2; C(:Y)X2; C(:NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepd. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addn. of 2-((1S)-1-amino-2-(indol-3-yl)ethyl)-4-phenyl-1H-imidazole afforded 94% the title compd. V. Compds. I are effective at 0.01-10.0 mg/kg/day.

L42 ANSWER 13 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:10469 CAPLUS

DOCUMENT NUMBER: 136:85750

TITLE: Preparation of novel compounds possessing antibacterial, antifungal or antitumor activity

INVENTOR(S): Zhang, Wentao; Liehr, Sebastian Johannes R.; Velligan, Mark Douglas; Dyatkina, Natalia B.; Botyanszki, Janos; Shi, Dong-Fang; Roberts, Christopher Don; Khorlin, Alexander; Nelson, Peter Harold; Muchowski, Joseph Martin

PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000650	A2	20020103	WO 2001-US20334	20010626

WO 2002000650 A3 20021024

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002037856 A1 20020328 US 2001-892327 20010626

EP 1294713 A2 20030326 EP 2001-948740 20010626

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

NO 2002005720 A 20030226 NO 2002-5720 20021128

PRIORITY APPLN. INFO.:


US 2000-214478P P 20000627

WO 2001-US20334 W 20010626

OTHER SOURCE(S):

MARPAT 136:85750

GI



AB Compds. of formula $R1Z1COX1NHCOX2CONHX3COZ2R2$ ($Z1$ and $Z2$ = independently $NR3$, O ; $R3$ = H , alkyl; $R1$ and $R2$ = independently substituted alkyl or aryl, (un)substituted heteroaryl; $X2$ = (un)substituted aryl or heteroaryl, alkenyl, alkynyl, cycloalkyl, heterocyclic; $X1$ and $X3$ = independently (un)substituted aryl or heteroaryl, $CHR4$; $R4$ = (un)natural amino acid side chain) or their pharmaceutically acceptable salts were prepd. and possess one or more of the following activities: antibacterial, antifungal and antitumor activity. For example, 1H-Indole-2,5-dicarboxylic acid dipentafluorophenyl ester was reacted with at least two equiv. of 4-amino-1-methyl-1H-pyrrole-2-carboxylic acid (2-carbamimidoyl-ethyl)-amide in DMF to give compd. I. Compds. of this invention exhibited antibacterial and antifungal activity with some having minimal inhibitory concns. of $<45.5 \mu M$. Studies of their DNA binding properties demonstrated that they bind to DNA very tightly, with apparent K_d , app values below 100 nM for most compds. tested.

IT 386250-55-1P 386251-09-8P 386251-11-2P

386251-12-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological


study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of novel compds. possessing antibacterial, antifungal or antitumor activity)


RN 386250-55-1 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX
NAME)

PAGE 1-A




PAGE 1-B




RN 386251-09-8 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N-[2-[[2-(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N'-[2-[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-11-2 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-12-3 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 386250-57-3P 386250-58-4P 386250-59-5P
386250-60-8P 386250-61-9P 386250-63-1P
386250-65-3P 386250-67-5P 386250-85-7P
386250-86-8P 386250-87-9P 386250-88-0P
386250-91-5P 386250-94-8P 386250-95-9P
386250-97-1P 386250-99-3P 386251-01-0P
386251-02-1P 386251-03-2P 386251-06-5P
386251-10-1P 386251-13-4P 386251-24-7P
386251-25-8P 386251-26-9P 386251-27-0P
386251-28-1P 386251-29-2P 386251-30-5P
386251-31-6P 386251-32-7P 386251-33-8P
386251-34-9P 386251-35-0P 386251-36-1P
386251-37-2P 386251-38-3P 386251-39-4P
386251-40-7P 386251-41-8P 386251-42-9P
386251-43-0P 386251-44-1P 386251-45-2P

386251-46-3P 386251-47-4P 386251-48-5P
386251-49-6P 386251-50-9P 386251-51-0P
386251-52-1P 386251-53-2P 386251-54-3P
386251-55-4P 386251-56-5P 386251-57-6P
386251-58-7P 386251-59-8P 386251-60-1P
386251-61-2P 386251-62-3P 386251-63-4P
386251-66-7P 386251-67-8P 386251-68-9P
386251-69-0P 386251-70-3P 386251-71-4P
386251-72-5P 386251-99-6P 386252-00-2P
386252-01-3P 386252-02-4P 386252-03-5P
386252-04-6P 386252-05-7P 386252-06-8P
386252-07-9P 386252-08-0P 386252-09-1P
386252-10-4P 386252-11-5P 386252-12-6P
386252-13-7P 386252-14-8P 386252-15-9P
386252-16-0P 386252-17-1P 386252-18-2P
386252-34-2P 386252-36-4P 386252-37-5P
386252-38-6P 386252-40-0P 386252-41-1P
386252-42-2P 386252-44-4P 386252-46-6P
386252-47-7P 386252-60-4P 386252-61-5P
386252-62-6P 386252-63-7P 386252-64-8P
386252-65-9P 386252-66-0P 386252-67-1P
386253-08-3P 386253-09-4P 386253-10-7P
386253-11-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation);

THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)

(prepn. of novel compds. possessing antibacterial, antifungal or
antitumor activity)

RN 386250-57-3 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[(2-aminoethyl)amino]carbonyl]-1-
methyl-1H-pyrrol-3-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 386250-56-2

CMF C26 H31 N9 O4


PAGE 1-A




PAGE 1-B

—CH2—CH2—NH2


CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 386250-58-4 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

RN 386250-59-5 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-aminopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

 $-(CH_2)_3-NH_2$

RN 386250-60-8 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


 $-(CH_2)_3-NMe_2$

RN 386250-61-9 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[1-methyl-5-[[[3-(1-piperidiny)propyl]amino]carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386250-63-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[(3-amino-3-
 iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-,
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 386250-62-0
 CMF C29 H35 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 386250-65-3 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[(2-aminoethyl)amino]carbonyl]-1H-
 indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 386250-64-2
CMF C32 H31 N9 O4


PAGE 1-A



PAGE 1-B




CM 2

CRN 76-05-1
CMF C2 H F3 O2RN 386250-67-5 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)


CM 1

CRN 386250-66-4
CMF C28 H35 N13 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2





RN 386250-85-7 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[4-amino-4-
iminobutyl)amino]carbonyl]-1-(3-methylbutyl)-1H-pyrrol-3-yl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B





RN 386250-86-8 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[5-amino-5-
iminopentyl)amino]carbonyl]-1-(3-methylbutyl)-1H-pyrrol-3-yl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386250-87-9 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(ethylamino)ethyl]amino]carbo
nyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386250-88-0 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(propylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386250-91-5 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-iminopropyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-octyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



2 HCl


PAGE 1-B



RN 386250-94-8 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-propyl-,
dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386250-95-9 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl

PAGE 1-B



RN 386250-97-1 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]-, hexakis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386250-96-0

CMF C40 H51 N13 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 386250-99-3 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(3-aminopropyl)amino]propyl]amino]carbonyl]-1H-indol-5-yl]-, tetrakis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 386250-98-2
 CMF C40 H49 N11 O4

PAGE 1-A




PAGE 1-B




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 386251-01-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-aminoethyl]amino]carbonyl]-1-propyl-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386251-02-1 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386251-03-2 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-1-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 386251-06-5 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-3-
 iminopropyl]amino]carbonyl]-1H-indol-5-yl]-, dihydrochloride (9CI) (CA
 INDEX NAME)

PAGE 1-A




● 2 HCl

PAGE 1-B




RN 386251-10-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[2-[[[2-aminoethyl]amino]carbonyl]-1H-
 indol-5-yl]-N2-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-
 indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-13-4 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-aminopropyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-24-7 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-aminoethyl]amino]carbonyl]-1-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-25-8 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-26-9 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-27-0 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-(dimethylamino)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-28-1 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2,3-dihydro-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-29-2 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-(dimethylamino)propyl]amino]carbonyl]-2,3-dihydro-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-30-5 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-31-6 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-32-7 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● x HCl

PAGE 1-B




RN 386251-33-8 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-34-9 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(aminoiminomethyl)amino]-2-hydroxypropyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-35-0 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1-(ethoxymethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-36-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl]amino]carbonyl]-1-[(2-methoxyethoxy)methyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A


MeO-CH₂-_____

PAGE 1-B




RN 386251-37-2 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl]amino]carbonyl]-1-(methoxymethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-38-3 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




●x HCl


RN 386251-39-4 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




●x HCl


RN 386251-40-7 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-4-methyl-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-41-8 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-42-9 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2S)-2-amino-3-methyl-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-43-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoacetyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386251-44-1 CAPLUS


CN Pentanoic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-6,2-diylcarbonylimino-2,1-ethanediylimino)]bis[4-amino-5-oxo-, (4S,4'S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—CO₂H


RN 386251-45-2 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2,5-diamino-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C


—NH₂

RN. 386251-46-3 CAPLUS


CN L-Glutamine, N,N'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-6,2-diylcarbonylimino-2,1-ethanediyl)]bis[N2-acetyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C


—CO₂H

• x HCl


RN 386251-47-4 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2S)-2-amino-1-oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386251-48-5 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2S)-2,6-diamino-1-


oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

$$-\text{NH}_2$$


RN 386251-49-6 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2,3-diamino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-50-9 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,4-diamino-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-51-0 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN	386251-52-1	CAPLUS
CN	1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-5- [(aminoiminomethyl)amino]-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol- 6-yl]- (9CI) (CA INDEX NAME)	

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 386251-53-2 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,3-diamino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-54-3 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,4-diamino-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-55-4 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-56-5 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-57-6 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




=O

RN 386251-58-7 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoacetyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-59-8 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-(acetamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-60-1 CAPLUS
CN Pentanoic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-5,2-diylcarbonylimino-2,1-ethanediylimino)]bis[4-amino-5-oxo-, (4S,4'S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

CO₂H


RN 386251-61-2 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,6-diamino-1-oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-62-3 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[2S]-2-amino-3-methyl-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386251-63-4 CAPLUS


CN Butanoic acid, 4,4'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-5,2-diylcarbonylimino-2,1-ethanediylimino)]bis[3-amino-4-oxo-, (3S,3'S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-66-7 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386251-67-8 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[2-(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methylamino)carbonyl]-1H-indol-5-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


—CH₂—NH₂

RN 386251-68-9 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[2-(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-69-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]-N5-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-70-3 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-2,2-bis(hydroxymethyl)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-71-4 CAPLUS

CN Carbamic acid, [2-[[[5-[[[2-[[[2-[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-5-yl]carbonyl]amino]-1H-indol-2-yl]carbonyl]amino]ethyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386251-72-5 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-aminoethyl)amino]carbonyl]-1H-benzimidazol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● x HCl

PAGE 1-B



RN 386251-99-6 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(methylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 386252-00-2 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N2-[5-[[[(4-aminobutyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₄—NH₂


RN 386252-01-3 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[2-[(2-aminoethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-02-4 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]]-N2-[5-[[[3-[[3-[(3-aminopropyl)amino]propyl]amino]propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]]-(9CI). (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-03-5 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[(4-aminobutyl)amino]carbonyl]-1H-indol-5-yl]]-N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]]-(9CI). (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


Me




RN 386252-04-6 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[[2-[(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-05-7 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-06-8 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-07-9 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-08-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(methylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-09-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-10-4 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(octylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-11-5 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-12-6 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(octylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me




RN 386252-13-7 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(butylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-14-8 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-15-9 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-N2-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-16-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-2,2-dimethylpropyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-17-1 CAPLUS
 CN Carbamic acid, [2-[[[5-[[[2-[[[2-[[[2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-5-yl]carbonyl]amino]-1H-indol-2-yl]carbonyl]amino]ethyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-18-2 CAPLUS

CN 1H-Benzimidazole-2-carboxylic acid, 5-[[[5-[[[2-[[2-aminoethyl)amino]carbonyl]-1H-indol-6-yl]amino]carbonyl]-1H-indol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386252-34-2 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-aminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-octyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-33-1

CMF C36 H49 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386252-36-4 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[3-amino-3-aminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-propyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-35-3

CMF C31 H39 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 386252-37-5 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386252-38-6 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-37-5

CMF C34 H35 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386252-40-0 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-39-7

CMF C38 H43 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 386252-41-1 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386252-42-2 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-41-1

CMF C41 H49 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386252-44-4 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-1-propyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-43-3

CMF C35 H37 N9 O4

PAGE 1-A




PAGE 1-B.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 386252-46-6 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386252-47-7 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)


CM 1

CRN 386252-46-6
CMF C34 H33 N11 O4

PAGE 1-A




PAGE 1-B




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 386252-60-4 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N-[5-[[[(4-aminobutyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N'-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-
(9CI) (CA INDEX NAME)



RN 386252-61-5 CAPLUS
CN 1H-Indole-2,5-dicarboxamide, N-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N'-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂

RN 386252-62-6 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NMe₂

RN 386252-63-7 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— NMe₂


RN 386252-64-8 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[4-(aminobutyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Me




RN 386252-65-9 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[3-(dimethylamino)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-66-0 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



RN 386252-67-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[2-(2-hydroxyethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)




RN 386253-08-3 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N-[2-[[[(1R,2R)-2-aminocyclohexyl]amino]carbonyl]-1H-indol-5-yl]-N'-[2-[[[(1S,2S)-2-aminocyclohexyl]amino]carbonyl]-1H-indol-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386253-09-4 CAPLUS


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[(3-amino-3-

iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-(phenylmethyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386253-10-7 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386253-11-8 CAPLUS

CN 1H-Indole-2,4-dicarboxamide, N,N'-bis[2-[[[(3-aminopropyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)



L42 ANSWER 14 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:713343 CAPLUS

DOCUMENT NUMBER: 135:272894

TITLE: Preparation of .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-.alpha.

INVENTOR(S): Duan, Jingwu; King, Bryan W.; Decicco, Carl; Maduskuie, Thomas P., Jr.; Voss, Matthew E.

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 483 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070734	A2	20010927	WO 2001-US8336	20010315
WO 2001070734	A3	20020314		
W: AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, HU, IL, IN, JP, KR, LT, LU, LV, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001050850	A5	20011003	AU 2001-50850	20010315
EP 1263756	A2	20021211	EP 2001-924171	20010315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR				
US 2002013341	A1	20020131	US 2001-811116	20010316
US 6495565	B2	20021217		
PRIORITY APPLN. INFO.:				
US 2000-190183P P 20000317				
US 2000-235467P P 20000926				
US 2000-252062P P 20001120				
WO 2001-US8336 W 20010315				

OTHER SOURCE(S): MARPAT 135:272894

AB Novel .beta.-amino acid derivs. A-CR3R4aCR2R4NR1CO-X-Z-Ua-Xa-Ya-Za [A = CO2H, SH, CH2SH, S(O)Ra:NH (Ra = H, alkyl), P(O)(OH)2, etc.; X, Xa is absent or alkylene, alkenylene or alkynylene; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 [Ra1 = H, (un)substituted alkyl, alkenyl or alkynyl; Ra and Ra1 may form a ring], CO, CO2, O2C, CONRa1, S(O)p (p = 0-2), etc.; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, alkyl, Ph, benzyl; R2 is Q (Q is H, substituted carbocycle or heterocycle), alkylene-Q, (CRaRa1)r1O(CRaRa1)r-Q (r, r1 = 0-4), (CRaRa1)r1NRa(CRaRa1)r-Q, etc.; R3 = Q1 (Q1 is any group given for Q), alkylene-Q1, (CRaRa1)r1O(CRaRa1)r-Q1, (CRaRa1)r1NRa(CRaRa1)r-Q1, etc.;

R4, R4a = H, substituted alkyl, alkenyl or alkynyl; alternatively R1 and R2, R1 and R3, R3 and R4a may form rings (with provisos)] or a stereoisomer or pharmaceutically acceptable salt were prepd. as metalloprotease and TNF-.alpha. inhibitors. Thus, N-hydroxy-1-[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]acetyl]-3-azetidinecarboxamide was prepd. by a multistep procedure involving reactions of Me 4-hydroxyphenylacetate, 2-methyl-4-quinolinylmethanol, and 3-azetidinecarboxylic acid Me ester.


IT 362701-21-1P 362701-22-2P 362701-23-3P
362701-24-4P 362701-25-5P 362701-26-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of .beta.-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-.alpha.)

RN 362701-21-1 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-methyl-4-quinolinyl)methyl]-N-[tetrahydro-4-[2-(hydroxyamino)-2-oxoethyl]-2H-pyran-4-yl]- (9CI) (CA INDEX NAME)




RN 362701-22-2 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-methyl-4-quinolinyl)methyl]-N-[tetrahydro-4-[2-(hydroxyamino)-2-oxoethyl]-2H-pyran-4-yl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-21-1


CMF C27 H28 N4 O4



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362701-23-3 CAPLUS

CN 1H-Indole-5-carboxamide, N-[3-(hydroxyamino)-3-oxopropyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362701-24-4 CAPLUS

CN 1H-Indole-5-carboxamide, N-[3-(hydroxyamino)-3-oxopropyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362701-23-3


CMF C23 H22 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362701-25-5 CAPLUS

CN 1H-Indole-5-carboxamide, N-[4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362701-26-6 CAPLUS

CN 1H-Indole-5-carboxamide, N-[4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl]-1-[(2-methyl-4-quinolinyl)methyl]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 362701-25-5

CMF C27 H29 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L42 ANSWER 15 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:713294 CAPLUS

DOCUMENT NUMBER: 135:257169

TITLE: Preparation of cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-.alpha.

INVENTOR(S): Duan, Jingwu; Ott, Gregory; Chen, Linhua, Lu, Zhonghui; Maduskuie, Thomas P., Jr.; Voss, Matthew E.; Xue, Chu-Biao

PATENT ASSIGNEE(S): Dupont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070673	A2	20010927	WO 2001-US8334	20010315
WO 2001070673	A3	20020314		
W:	AT, AU, BR, CA, CH, CN, CZ, DE, DK, EE, ES, FI, HU, IN, JP, KR, LT, LU, LV, MX, NZ, PL, PT, RO, SE, SG, SI, SK, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
EP 1263755	A2	20021211	EP 2001-924170	20010315
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR			
US 2002016336	A1	20020207	US 2001-811233	20010316
PRIORITY APPLN. INFO.:			US 2000-190182P	P 20000317
			US 2000-233373P	P 20000918

Searched by Barb O'Bryen, STIC 308-4291

US 2000-255539P P 20001214
WO 2001-US8334 W 20010315

OTHER SOURCE(S): MARPAT 135:257169

AB Novel cyclic .beta.-amino acid derivs. A-CRR2aCRR2bNR1CO-Z-Ua-Xa-Ya-Za [A = CO₂H, CH₂CO₂H, SH, CH₂SH, S(O)Ra:NH (Ra = H, alkyl, Ph, benzyl), P(O)(OH)₂, etc.; CRCR is a substituted 3-13 membered nonarom. carbocyclic or heterocyclic ring; Z is absent or substituted C3-13 carbocycle or 5-14 membered heterocycle; Ua is absent or O, NRa1 (Ra1 = H, alkyl), CO, CO₂, O₂C, CONRa1, S(O)p (p = 0-2), etc.; Xa is absent or C1-10 alkylene, C2-10 alkenylene or alkynylene; Ya is absent or O, NRa1, S(O)p or CO; Za is H, substituted C3-13 carbocycle or 5-14 membered heterocycle; R1 is H, C1-4 alkyl, Ph, benzyl; R2a is H, C1-6 alkyl, ORa, NRaRa1 or S(O)pRa; R2b is H, C1-6 alkyl (with provisos)] or pharmaceutically acceptable salts were prepd. as metalloprotease and TNF-.alpha. inhibitors. Thus, (3S,4S)-N-hydroxy-1-isopropyl-4-[[4-[(2-methyl-4-quinolinyl)methoxy]benzoyl]amino]-3-pyrrolidinecarboxamide was prepd. by a multistep procedure starting with condensation of benzyl Me maleate, glycine, and paraformaldehyde to form 3,4-pyrroledicarboxylate diester and involving amidation of 4-[(2-methyl-4-quinolinyl)methoxy]benzoic acid.


IT 362491-05-2P 362491-06-3P 362491-08-5P
362491-09-6P 362491-26-7P 362491-27-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of cyclic .beta.-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-.alpha.)

RN 362491-05-2 CAPLUS

CN 1H-Indole-5-carboxamide, N-[4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-06-3 CAPLUS

CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl]carbonyl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362491-05-2


CMF C25 H25 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362491-08-5 CAPLUS

CN 1H-Indole-5-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-09-6 CAPLUS

CN 1H-Indole-5-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 362491-08-5
CMF C26 H26 N4 O3




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 362491-26-7 CAPLUS
CN 1H-Indole-4-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-27-8 CAPLUS

CN 1H-Indole-4-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 362491-26-7
CMF C26 H26 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



L42 ANSWER 16 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:661388 CAPLUS

DOCUMENT NUMBER: 135:226878

TITLE: Synthesis of N-benzyl-indolyl(benzyloxy) amido derivatives as PDE-IV inhibitors

INVENTOR(S): Labelle, Marc; Sturino, Claudio; Lachance, Nicolas;
MacDonald, Dwight

PATENT ASSIGNEE(S) : ~~Merck Frosst Canada + Co., Can.~~

SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent




LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001064639 A2 20010907 WO 2001-CA270 20010302
 WO 2001064639 A3 20020228
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
 HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2002068756 A1 20020606 US 2001-797083 20010301
 US 6436965 B2 20020820 EP 2001-913422 20010302
 EP 1263728 A2 20021211
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: US 2000-186571P P 20000302
 WO 2001-CA270 W 20010302
 OTHER SOURCE(S): MARPAT 135:226878
 GI



AB Title compds. I [A, B, D, E = N or CR₂ and the others = CR₂; q = 0 - 1; p, m = 0 - 2; R₁ = H, (hydroxy)alkyl; R₂ = H, halo, (halo)alkyl, hydroxyalkyl, CN, arom. or nonarom. ring system contg. 1 - 4 heteroatoms selected from O, S, N, alkoxy, oxyamide, etc.; X = cycloalkyl or Ar; Ar = (un)substituted (Ph, thienyl, thiazolyl, pyridyl, oxazolyl, tetrazolyl, pyrimidinyl, pyrazinyl and pyridazinyl)] were prepd. Over 150 compds. were disclosed. For instance, Me 2-aminobenzoate was alkylated with 4-fluorobenzyl bromide (K₂CO₃, MEK, reflux, 8 h.). The resulting ester was sapond. (NaOH, MeOHaq reflux, 2 h.), N-alkylated with Me bromoacetate (K₂CO₃, MeOHaq, reflux, 18 h.) and treated with CH₂N₂ to afford II. Diester II was cyclized (NaOMe, MeOH, reflux, 30 min.), O-alkylated with benzyl bromide (K₂CO₃, MEK, reflux, 2 h.), sapond. (NaOH, EtOHaq, 90.degree.C, 40 min.) and finally coupled to 3-aminopyridine (SOCl₂, i-Pr₂NEt, room temp., 3 h.) to yield III. I are PDE-IV inhibitors (no data) useful for treating, e.g., inflammation, muscle spasm, chronic bronchitis, etc.


IT 359002-36-1P 359002-38-3P 359002-42-9P
359002-44-1P 359002-48-5P 359002-50-9P
359002-54-3P 359002-56-5P 359002-60-1P
359002-62-3P 359002-66-7P 359002-68-9P
359002-72-5P 359002-74-7P 359002-78-1P
359002-80-5P 359002-84-9P 359002-86-1P
359002-90-7P 359002-92-9P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV
inhibitors)



RN 359002-36-1 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-(4-pyridinylmethoxy)-2-[(1H-tetrazol-5-
ylamino)carbonyl]-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX
NAME)





RN 359002-38-3 CAPLUS

CN 1H-Indole-2,7-dicarboxamide, N7,N7-dimethyl-3-(4-pyridinylmethoxy)-N2-1H-
tetrazol-5-yl-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX
NAME)




RN 359002-42-9 CAPLUS
 CN 1H-Indole-4-carboxylic acid, 3-(4-pyridinylmethoxy)-2-[(1H-tetrazol-5-ylamino)carbonyl]-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-44-1 CAPLUS
 CN 1H-Indole-2,4-dicarboxamide, N4,N4-dimethyl-3-(4-pyridinylmethoxy)-N2-1H-tetrazol-5-yl-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 359002-48-5 CAPLUS
 CN 1H-Indole-4-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-50-9 CAPLUS
 CN 1H-Indole-2,4-dicarboxamide, N4,N4-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-54-3 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-56-5 CAPLUS

CN 1H-Indole-2,4-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N4,N4-dimethyl-3-(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-60-1 CAPLUS

CN 1H-Indole-7-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-62-3 CAPLUS

CN 1H-Indole-2,7-dicarboxamide, N4,N4-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-66-7 CAPLUS

CN 1H-Indole-7-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-68-9 CAPLUS

CN 1H-Indole-2,7-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N7,N7-dimethyl-3-(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-72-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-74-7 CAPLUS

CN 1H-Indole-2,6-dicarboxamide, N6,N6-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-78-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-
2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-80-5 CAPLUS

CN 1H-Indole-2,6-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N6,N6-dimethyl-3-
(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-84-9 CAPLUS


CN 1H-Indole-5-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-
pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX
NAME)



RN 359002-86-1 CAPLUS
 CN 1H-Indole-2,5-dicarboxamide, N5,N5-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-90-7 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 359002-92-9 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N5,N5-dimethyl-3-(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)



L42 ANSWER 17 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:489393 CAPLUS

DOCUMENT NUMBER: 135:92542

TITLE: Preparation of N-(oxofuranyl or oxothienyl)-2-(1H-indol-3-yl)-2-oxoacetamides with antitumor activity

INVENTOR(S): Menta, Ernesto; Pescalli, Nicoletta

PATENT ASSIGNEE(S): Novuspharma S.P.A., Italy

SOURCE: PCT Int. Appl., 49 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047916	A1	20010705	WO 2000-EP13068	20001221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, T, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, US, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016553	A	20020917	BR 2000-16553	20001221
EP 1244652	A1	20021002	EP 2000-985225	20001221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NO 2002002976	A	20020620	NO 2002-2976	20020620
PRIORITY APPLN. INFO.:				
			IT 1999-MI2693	A 19991223
			WO 2000-EP13068	W 20001221
OTHER SOURCE(S):				
GI				
MARPAT 135:92542				




AB Title compds. (I) [wherein R1, R2, and R5 = independently H or alkyl; R3 = H (ar)alkyl, or (un)substituted Ph; R4 = H, (cyclo)alkyl, or (hetero)aralkyl; X = independently 1-4 groups selected from H, (halo)alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, acyloxyalkyl, OH, (halo)alkoxy, PhO, aralkoxy, acyloxy, halo, NO₂, CN, CF₃, CO₂H, alkoxyacetyl, (un)substituted carbamoyl, SH, alkylthio, alkylsulfinyl, alkylsulfonyl, (un)substituted amino, aminosulfonyl, or phosphonyl, etc.; Y = O or S; or isomers, enantiomers, or mixts. thereof; or pharmaceutically acceptable salts thereof] were prepd. as antitumor agents, which are esp. effective against solid colon and lung tumors. For example, II was formed by addn. of oxalyl chloride in Et₂O to 1-(4-fluorobenzyl)-1H-indole in Et₂O, followed by amidation with 4-amino-5H-furan-2-one in THF. II showed cytotoxic activity against human HT 29 colon adenocarcinoma, PC 3 prostate carcinoma, H 460M lung carcinoma, and MKN45 gastric carcinoma with IC₅₀ values of 0.0004 .mu.g/mL, 0.035 .mu.g/mL, 0.012 .mu.g/mL, and 0.088 .mu.g/mL, resp.

IT 348112-07-2P 348112-44-7P 348112-53-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of 2-(1H-indol-3-yl)-2-oxoacetamide antitumor agents by reaction of indoles with oxalyl chloride followed by amidation with aminothiophenones or aminofuranones)


RN 348112-07-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[[2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 348112-44-7 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 348112-53-8 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]- (9CI) (CA INDEX NAME)



IT 348112-05-0P 348112-31-2P 348112-55-0P


348112-56-1P 348112-57-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-(1H-indol-3-yl)-2-oxoacetamide antitumor agents by reaction of indoles with oxalyl chloride followed by amidation with aminothiophenones or aminofuranones)


RN 348112-05-0 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 348112-31-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[[2-(dimethylamino)ethyl]amino]oxoacetyl- (9CI) (CA INDEX NAME)




RN 348112-55-0 CAPLUS


CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-4-[[2-(dimethylamino)ethyl]amino]carbonyl-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 348112-56-1 CAPLUS
 CN 1H-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-4-
 [(diethylamino)carbonyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-.alpha.-oxo-
 (9CI) (CA INDEX NAME)



RN 348112-57-2 CAPLUS
 CN 1H-Indole-3-acetamide, 4-[[[(2-aminoethyl)amino]carbonyl]-1-[(4-
 chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-.alpha.-oxo- (9CI)
 (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 18 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:416939 CAPLUS

DOCUMENT NUMBER: 135:46203

TITLE: Preparation and effect of triazaspiro[5.5]undecane derivatives as active ingredients in remedy for inflammatory diseases

INVENTOR(S): Habashita, Hiromu; Hamano, Shinichi; Shibayam, Shiro; Takaoka, Yoshikazu

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 1149 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001040227	A1	20010607	WO 2000-JP8517	20001201
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001016506	A5	20010612	AU 2001-16506	20001201
EP 1236726	A1	20020904	EP 2000-979050	20001201
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
NO 2002002609	A	20020726	NO 2002-2609	20020531
PRIORITY APPLN. INFO.:			JP 1999-344967	A 19991203
			JP 2000-18673	A 20000127
			JP 2000-27968	A 20000204
			JP 2000-147882	A 20000519
			WO 2000-JP8517	W 20001201

OTHER SOURCE(S): MARPAT 135:46203

GI



AB Title compds. [I; R1 = H, aryl, arylalkyloxycarbonyl, alkenyloxycarbonyl, heterocyclylalkyl, alkyl, alkenyl, alkynyl; R2 = alkyl, alkynyl; R3 = H; R4 = alkyl; R5 = H, alkyl], stereoisomers, quaternary ammonium salts thereof, N-oxides thereof and nontoxic salts thereof, are prepd. via solid phase synthesis using divinylbenzene-polystyrene or divinylbenzene-Rink resin. Title compds. I, having controlling effects of chemokines/chemokine receptors, are useful in preventing and/or treating various inflammatory diseases, asthma, atopic dermatitis, urticaria, allergic diseases, nephritis, nephropathy, hepatitis, arthritis, rheumatoid arthritis, etc. Thus, the title compd. II.cntdot.HCl was prepd. and biol. tested.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 19 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:338492 CAPLUS

DOCUMENT NUMBER: 134:353315

TITLE: Preparation of indole derivatives as chymase inhibitors and drugs containing the same as the active ingredient

INVENTOR(S): Nishimura, Koji; Kuramoto, Yasuhiro; Tamura, Koichi; Hirao, Yuzo; Amano, Hirotaka; Osaki, Mitsuhiko; Yoshida, Jiro; Aoki, Shizuka; Sato, Kenji

PATENT ASSIGNEE(S): Wakunaga Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 167 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032621	A1	20010510	WO 2000-JP7590	20001027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.:

JP 1999-310066 A 19991029
JP 2000-129760 A 20000428

OTHER SOURCE(S):

MARPAT 134:353315

GI



AB Indole derivs. of general formula (I) or salts thereof [wherein R1 is an amino-protecting group or COR8 (wherein R8 is optionally substituted aryl or heteroaryl); R2 is H, optionally substituted alkyl or aryl; R3 is cyano, -COR9 (wherein R9 is H, optionally substituted alkyl, OH, alkoxy, aralkyloxy, carbamoyl, or cyclic aminocarbonyl), or S(O)n-R12 (wherein R12 is alkyl, aralkyl, or optionally substituted aryl or heteroaryl; and n is an integer of 0 to 2); and R4, R5, R6 and R7 are each independently H, alkyl, alkynyl, aralkyl, alkoxy, aralkyloxy, halogeno, trifluoromethanesulfonyloxy, aryl, or the like] are prepd. The compds. I or salts thereof exhibit an excellent chymase activity and are useful as preventive or therapeutic drugs for circulatory diseases, inflammation, immunol. diseases, allergic diseases, eye diseases, complications of diabetes, collagen disease, and obesity. They are also useful as protectants for mucous membrane and organs, preventives for cancer metastasis and infiltration, or improvers for survival rate after organ transplant. Thus, 3-[1-(4-dimethylaminobenzoyl)-3-phenylsulfonylindol-5-yl]-2,4(1H,3H)-quinazolinedione and 2-[[1-(3-dimethylamino-2-methylbenzoyl)-5-(2-sulfamoylphenyl)-2-methylindol-3-yl]sulfonyl]benzoic acid showed IC50 of 3 and 6, resp., against human chymase and that of 0.6 and 34,000, resp., against .alpha.-chymotrypsin.


IT 336187-25-8P 336187-26-9P 336187-27-0P
336187-45-2P 336187-70-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole derivs. as chymase inhibitors and drugs)


RN 336187-25-8 CAPLUS

CN 1H-Indole-6-carboxylic acid, 1-(4-chlorobenzoyl)-2-methyl-3-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 336187-26-9 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-(4-chlorobenzoyl)-2-methyl-3-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 336187-27-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-(4-chlorobenzoyl)-2-methyl-3-(phenylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 336187-45-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-(4-chlorobenzoyl)-2-methyl-3-(phenylsulfonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 336187-70-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-(4-chlorobenzoyl)-2-methyl-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 20 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:101128 CAPLUS

DOCUMENT NUMBER: 134:147599

TITLE: Preparation of 2-pyrazolin-5-ones as inhibitors of serine/threonine and tyrosine kinase activity

INVENTOR(S): Moset, Marina M.; Berlanga, Jose Maria Castellano; Fernandez, Isabel F.; Calderwood, David J.; Rafferty, Paul; Arnold, Lee

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 226 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009121	A2	20010208	WO 2000-US20628	20000728
WO 2001009121	A3	20020502		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KH, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000012896	A	20020618	BR 2000-12896	20000728
EP 1218373	A2	20020703	EP 2000-950852	20000728
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003506368	T2	20030218	JP 2001-514324	20000728
NO 2002000487	A	20020312	NO 2002-487	20020130
PRIORITY APPLN. INFO.:			US 1999-146563P P 19990730	
			WO 2000-US20628 W 20000728	

OTHER SOURCE(S): MARPAT 134:147599
GI



AB The title compds. [I; R = (un)substituted alkyl, aryl, cycloalkyl, etc.; R1 = H, AZ; R2 = H, (un)substituted alkyl, aryl, etc.; A = (CH2)n, (CH2)nNH, (CH2)nO, etc.; Z = H, alkyl, aralkyl, etc.] which are inhibitors of serine/threonine and tyrosine kinase activity, were prepd. and formulated. Thus, reacting 3-cyclopropyl-2-pyrazolin-5-one with 4,5-dimethylpyrrole-2-carboxaldehyde in the presence of piperidine in EtOH afforded 30% I [R = 4,5-dimethylpyrrol-2-yl; R1 = cyclopropyl]. All exemplified compds. I inhibit KDR kinase at 50 .mu.M and some of them also significantly inhibit other PTKs such as lck at .ltoreq. 50 .mu.M, and cdc2 at < 50 .mu.M. Several of the tyrosine kinases, whose activity is inhibited by the compds. I are involved in angiogenic processes. Thus, the compds. I can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor. These compds. I can be used to treat cancer and hyperproliferative disorders.


IT 324550-73-4P 324550-79-0P 324550-91-6P
324550-92-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-pyrazolin-5-ones as inhibitors of serine/threonine and tyrosine kinase activity)


RN 324550-73-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3-cyclopropyl-1,5-dihydro-5-oxo-4H-pyrazol-4-ylidene)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 324550-79-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[1,5-dihydro-3-(1-methylethoxy)-5-oxo-4H-pyrazol-4-ylidene)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 324550-91-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(1,5-dihydro-5-oxo-3-pyrazinyl-4H-pyrazol-4-ylidene)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 324550-92-7 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(1,5-dihydro-5-oxo-3-pyrazinyl-4H-pyrazol-4-ylidene)methyl]-1-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 21 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:12482 CAPLUS

DOCUMENT NUMBER: 134:71906

TITLE: Preparation of novel indole peptidomimetics as thrombin receptor antagonists

INVENTOR(S): Zhang, Han-cheng; Hoekstra, William J.; Maryanoff, Bruce E.; McComsey, David F.

PATENT ASSIGNEE(S): Ortho-Mcneil Pharmaceutical, Inc., USA; Cor Therapeutics, Inc.

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000657	A2	20010104	WO 2000-US18018	20000629
WO 2001000657	A3	20010712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-141550P P 19990629
US 2000-603231 A 20000626

OTHER SOURCE(S): MARPAT 134:71906
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Indole derivs. I [A1 and A2 are certain D- or L-amino acid residues which may be substituted; R1 = amino, alkylamino, arylamino, heteroalkyl, etc.; R2 = H, halo, alkyl, cycloalkyl, alkenyl, alkynyl, arylalkyl, aryl, heteroaryl; R3, R4 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroalkyl, indanyl, etc. or R3R4N = (un)substituted piperidinyl, piperazinyl, morpholino, or pyrrolidinyl; R5 = (un)substituted aryl, arylalkyl, cycloalkyl, heteroaryl; R6 = H, alkyl; X = O, S; m = 0-3; n = 1 or 2; p = 0 or 1] were prepd. as thrombin receptor antagonists for the treatment of diseases assocd. with thrombosis, restenosis, hypertension, heart failure, arrhythmia, inflammation, angina, stroke, atherosclerosis, ischemic conditions, angiogenesis related disorders, cancer, and neurodegenerative disorders. Thus, compd. II, prepd. by a multistep procedure starting from 6-nitroindole (scheme given), showed IC50 = 0.28 and 0.47 .mu.M, resp., in the thrombin-induced gel-filtered platelet aggregation and thrombin receptor binding assays.

IT 316152-77-9P 316152-79-1P 316152-81-5P
316152-83-7P 316152-85-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel indole peptidomimetics as thrombin receptor antagonists)

RN 316152-77-9 CAPLUS

CN L-Argininamide, O-methyl-N-[[1-[(4-methylphenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-tyrosyl-N-(phenylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-79-1 CAPLUS

CN L-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-L-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-81-5 CAPLUS

CN D-Alaninamide, N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidin-1-ylmethyl)-1H-indol-6-yl]carbonyl]-3,4-difluoro-D-phenylalanyl-N-(2-aminoethyl)-3-(4-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-83-7 CAPLUS

CN L-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-L-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 316152-85-9 CAPLUS

CN D-Alaninamide, 4-chloro-N-[[1-[(2,6-dichlorophenyl)methyl]-3-(1-pyrrolidinylmethyl)-1H-indol-6-yl]carbonyl]-D-phenylalanyl-N-(2-aminoethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L42 ANSWER 22 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:884149 CAPLUS

DOCUMENT NUMBER: 134:42147

TITLE: Preparation and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors

INVENTOR(S) : Rafferty, Paul; Calderwood, David; Arnold, Lee D.;
Gonzalez Pascual, Beatriz; Ortego Martinez, Jose L.;
Perez de Vega, Maria J.; Fernandez, Isabel F.

PATENT ASSIGNEE(S) : Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075139	A2	20001214	WO 2000-US15324	20000602
WO 2000075139	A3	20010329		
W:	AU, BG, BR, CA, CN, CZ, HR, HU, ID, IL, IN, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, UA, US, ZA			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
EP 1181282	A2	20020227	EP 2000-936476	20000602
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
BR 2000011063	A	20020416	BR 2000-11063	20000602
JP 2003501429	T2	20030114	JP 2001-502421	20000602
NO 2001005899	A	20020130	NO 2001-5899	20011203
RITY APPLN. INFO.:			US 1999-137410P P	19990603
			WO 2000-US15324 W	20000602

OTHER SOURCE(S) : MARPAT 134:42147

GI




AB Title compds. [I; Q = N, CR2; X = S, O, NOR3; Y = S, O, SO, SO2; R, R1 independently = H, aliph., aryl, heterocyclyl; R2 = H, CH3; R3 = H, COR4; R4 = alkyl, alkenyl, alkynyl, aryl; n = 0, 1; R5 = 7-Cl, 7-CH3, 6-CF3, 6-CH3, 6-Cl, 7-OCH3, 6-CH3CONH, 7-OH, etc.] are prepd. Title compds. and physiol. acceptable salts are inhibitors of receptor tyrosine kinase or non-receptor tyrosine kinase activity which involve in angiogenic process. Thus, title compds. can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor and can be used to treat cancer and hyperproliferative disorders. Title compd. II was prepd.

IT 312972-43-3P 312972-44-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312972-43-3 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312972-44-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 312970-56-2P 312970-68-6P 312970-70-0P
 312970-71-1P 312970-72-2P 312970-76-6P
 312970-78-8P 312970-87-9P 312970-88-0P
 312970-89-1P 312970-90-4P 312970-91-5P
 312970-92-6P 312970-93-7P 312970-94-8P
 312970-95-9P 312970-96-0P 312970-97-1P
 312971-27-0P 312971-32-7P 312972-45-5P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)


RN 312970-56-2 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 312970-68-6 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312970-70-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 312970-71-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 312970-72-2 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 312970-76-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312970-78-8 CAPLUS


CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 312970-87-9 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 312970-88-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-methyl-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 312970-89-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)



RN 312970-90-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-(2-hydroxyethyl)-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 312970-91-5 CAPLUS


CN 1H-Indole-6-carboxamide, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 312970-92-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 312970-93-7 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 312970-94-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 312970-95-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 312970-96-0 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 312970-97-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 312971-27-0 CAPLUS

CN 1H-Indole-7-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312971-32-7 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312972-45-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)

ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L42 ANSWER 23 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:824102 CAPLUS

DOCUMENT NUMBER: 134:4859

TITLE: Preparation of 3-(dibenzylaminoethyl)indoles as gonadotropin releasing hormone antagonists

INVENTOR(S): Goulet, Mark; Walsh, Thomas F.; Ujjainwalla, Feroze; Wyvratt, Matthew J., Jr.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069433	A1	20001123	WO 2000-US12764	20000510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CC, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6156772	A	20001205	US 1999-312192	19990514
PRIORITY APPLN. INFO.:			US 1999-312192	A2 19990514
			US 1997-48739P	P 19970605
			US 1998-83492	A2 19980522

OTHER SOURCE(S): MARPAT 134:4859

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. (I) [wherein A = (un)substituted R22(aryl)R22; B = null or OR22, C(O)R22,, S(O)nR22, NR18R22, OC(O)R22, C(O)OR22, OS(O)nR22, or S(O)nOR22; R0 = H or (un)substituted alkyl; R1 = (un)substituted


heteroaryl, esp. pyridyl; R2 = (un)substituted heteroaryl(alkyl); R3, R4, and R5 = independently H, CN, NO2, alkoxyalkyl, alkylsulfonylalkyl, halo, or (un)substituted alkyl, alkenyl, aryl, or aralkyl, etc.; R6 = H, CN, NO2, alkoxyalkyl, or (un)substituted alkyl or aryl, etc.; R7 = H, or (un)substituted alkyl; R8 = H, (un)substituted carboxy, carboxamido, amino, acyl, or sufonamido, etc.; R9, R9a, R10, R10a = independently H or (un)substituted alkyl, aryl, or aralkyl; X = N, O, S(O)n, CO, (un)substituted alkylene, alkenyl, alkynyl, etc; R18 = H (un)substituted alkyl, carboxy, carboxamido, acyl, or alkylsulfonyl, etc.; R22 = (un)substituted alkyl; m = 0-3; n = 0-2] and pharmaceutically acceptable salts thereof were prepd. as gonadotropin releasing hormone (GnRH) antagonists for the treatment of a variety of sex-hormone related and other conditions in both men and women (no data). For example, II was formed in a 6-step sequence involving (1) cycloaddn. of Et 2-(4-hydrazinophenyl)-2-methylpropionate and 3-chloropropyl 3,5-dimethylphenyl ketone to give Et 2-[3-(2-aminoethyl)-2-(3,5-dimethylphenyl)-1H-indol-5-yl]-2-methylpropionate, (2) N-protection with di-tert-Bu dicarbonate, (3) deesterification, (4) addn. of 7-azabicyclo[2.2.1]heptane.bul.HCl, (5) deprotection, and (6) addn. of 4-pyridin-3-ylbenzaldehyde. I may used in compns. contg. peptide compds. having luteinizing hormone relasing hormone (LH-releasing hormone) activity (no data).

IT 217189-14-5P, 3-[2-[Bis(4-pyridin-3-ylbenzyl)amino]ethyl]-2-(3,5-dimethylphenyl)-1H-indole-5-carboxylic acid diisopropylamide
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 3-(dibenzylaminoethyl)indole GnRH antagonists by cycloaddn. of Et (hydrozinophenyl)methylpropionate with chloropropyl Ph ketones followed by addn. of amines and benzaldehydes)

RN 217189-14-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[[4-(3-pyridinyl)phenyl]methyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 24 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:824101 CAPLUS
 DOCUMENT NUMBER: 134:5154

TITLE: Preparation of cyclic amine derivatives as remedies or preventives for diseases in association with chemokines or chemokine receptors

INVENTOR(S): Shiota, Tatsuki; Miyagi, Fuminori; Kamimura, Takashi; Ohta, Tomohiro; Takano, Yasuhiro; Horiuchi, Hideki

PATENT ASSIGNEE(S): Teijin Limited, Japan

SOURCE: ~~PCT Int. Appl.~~, 405 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069432	A1	20001123	WO 2000-JP3203	20000518
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1179341	A1	20020213	EP 2000-927808	20000518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO				
NO 2001005599	A	20011116	NO 2001-5599	20011116
PRIORITY APPLN. INFO.:				
			JP 1999-175856	A 19990518
			JP 1999-251464	A 19990906
			WO 2000-JP3203	W 20000518
OTHER SOURCE(S):			MARPAT 134:5154	
GI				



AB Remedies or preventives for diseases in assocn. with chemokines such as MIP-1.alpha. and/or MCP-1 or chemokine receptors such as CCR1 or CCR2 contain as the active ingredient N-acyl-amino acid N-cyclic amino or N-cyclic aminoalkyl-amide derivs. represented by general formula [I; (un)substituted Ph, C3-8 cycloalkyl, arom. heterocyclyl contg. 1-3 heteroatoms selected from O, S, and/or N; R2 = H, (un)substituted C1-6 alkyl, C2-7 alkoxycarbonyl, HO, (un)substituted Ph; p1, m1 = 0-2; m = 2-4; n = 0,1; R3 = H, (un)substituted C1-6 alkyl; R4, R5 = H, OH, (un)substituted Ph or C1-6 alkyl; or R4 and R5 are combined together to form a 3- to 5-membered hydrocarbonyl; p, q = 0,1; G = CO, SO2, CO2, NR7CO, CONR7, NR7SO2, or SO2NR7, NHCONH, NHCSNH, NH CO2, O2CNH; R7 = H, C1-6 alkyl; or R7 and R5 are combined together to form C2-5 alkylene; R6 = (un)substituted Ph, C3-8 cycloalkyl, C3-6 cycloalkenyl, CH2Ph, or arom. heterocyclyl contg. 1-3 heteroatoms selected from O, S, and/or N, wherein Ph, CH2Ph, or arom. heterocyclyl group is optionally fused with (un)substituted benzene or arom. heterocyclyl contg. 1-3 heteroatoms selected from O, S, and/or N], pharmaceutically acceptable acid-adducts thereof, or pharmaceutically acceptable C1-6 alkyl-adducts thereof. The above diseases include destruction of bone or cartilage (e.g. arthritis,

rheumatoid arthritis, osteoarthritis, osteoporosis, injury, and tumor), nephritis, kidney diseases, glomerulus or interstitial nephritis, nephrotic syndrome, demyelinating disease, or multiple sclerosis. Thus, N-3-ethoxybenzyl-D-methionine-N-[1-(4-chlorobenzyl)-4-piperazinylmethyl]amide in vitro inhibited the binding of human MIP-1.alpha. to THP-1 cells by >80% at 2 .mu.M.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 25 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:513697 CAPLUS

DOCUMENT NUMBER: 133:120238

TITLE: ~~Preparation of pyridinylindoles, pyridinylpyrrolopyridines, and related compounds as tyrosine kinase inhibitors.~~

INVENTOR(S): Fraley, Mark E.; Hungate, Randall W.; Tebben, Andrew J.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: PCT Int. Appl., 118 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000043393	A1	20000727	WO 2000-US1006	20000114
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6265403	B1	20010724	US 2000-480717	20000107
CA 2356349	AA	20000727	CA 2000-2356349	20000114
EP 1147107	A1	20011024	EP 2000-906932	20000114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002535331	T2	20021022	JP 2000-594809	20000114
PRIORITY APPLN. INFO.:			US 1999-116596P	P 19990120
			WO 2000-US1006	W 20000114
OTHER SOURCE(S):	MARPAT 133:120238			
GI				



AB Title compds. [I; W, X, Y, Z = CH, N; R1 = H, CF3, halo, cycloalkyl, (substituted) alkyl, aryl, heterocyclyl; R2 = H, (substituted) alkyl, aryl, heteroaryl, cycloalkyl; R3 = H, halo, cyano, alkoxy, alkoxyalkylene, (substituted) alkyl, aryl, heteroaryl, cycloalkyl, etc.], were prepd.

Thus, 3-bromo-5-thien-3-ylpyridine (prepn. given), 1-tosyl-3-indoleboronic acid, Pd(PPh₃)₄, and aq. Na₂CO₃ were refluxed 20 in dioxane to give 3-(5-thien-3-ylpyridin-3-yl)-1-tosylindole. This was refluxed with KOH in EtOH/H₂O to give 3-(5-thien-3-ylpyridin-3-yl)indole. I inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells with IC₅₀ = 0.01-5 .mu.M.

IT	286002-39-9P	286002-40-2P	286002-41-3P
	286002-43-5P	286002-44-6P	286002-47-9P
	286003-31-4P	286003-32-5P	286003-33-6P
	286003-35-8P	286003-36-9P	286003-39-2P
	286004-20-4P	286004-21-5P	286004-22-6P
	286004-24-8P	286004-25-9P	286004-28-2P
	286005-11-6P	286005-12-7P	286005-13-8P
	286005-15-0P	286005-16-1P	286005-19-4P
	286006-06-2P	286006-07-3P	286006-08-4P
	286006-10-8P	286006-11-9P	286006-15-3P
	286007-07-2P	286007-08-7P	286007-09-8P
	286007-11-2P	286007-12-3P	286007-15-6P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological substance, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


```



```


RN 286002-39-9 CAPLUS

1H-Indole-4-carboxylic acid, 1-[2-(4-morpholinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-40-2 CAPLUS

1H-Indole-4-carboxylic acid, 1-[2-(1-piperidinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-41-3 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[3-(1-piperidinyl)propyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-43-5 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[(1-methyl-3-piperidinyl)methyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-44-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[3-(4-methyl-1-piperazinyl)propyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-47-9 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-31-4 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-morpholinyl)ethyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-32-5 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-(5-phenyl-3-pyridinyl)-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-33-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-(5-phenyl-3-pyridinyl)-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-35-8 CAPLUS


CN 1H-Indole-4-carboxylic acid, 1-[(1-methyl-3-piperidinyl)methyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 286003-36-9 CAPLUS
CN 1H-Indole-4-carboxylic acid, 1-[3-(4-methyl-1-piperazinyl)propyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-39-2 CAPLUS
CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-20-4 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-21-5 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-22-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-24-8 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-25-9 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-28-2 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(3-methoxyphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-11-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-12-7 CAPLUS


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286005-13-8 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-15-0 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286005-16-1 CAPLUS


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286005-19-4 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(4-methoxyphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


|
OMe

RN 286006-06-2 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-07-3 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-08-4 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-10-8 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-11-9 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-15-3 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(4-cyano-1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-07-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-08-7 CAPLUS


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286007-09-8 CAPLUS
CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN	286007-11-2	CAPLUS
CN	1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)	



RN 286007-12-3 CAPLUS


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286007-15-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(4-cyano-1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

Cl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 26 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:314687 CAPLUS

DOCUMENT NUMBER: 132:334454

TITLE: Preparation of 2-amino-thiazole derivatives as antitumor agents

INVENTOR(S): Pevarello, Paolo; Amici, Raffaella; Traquandi, Gabriella; Villa, Manuela; Vulpetti, Anna; Isacchi, Antonella

PATENT ASSIGNEE(S): Pharmacia & Upjohn S.p.A., Italy

SOURCE: PCT Int. Appl., 115 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000026202	A1	20000511	WO 1999-EP8306	19991027
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MC, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,			

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1124810 A1 20010822 EP 1999-955931 19991027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 9914958 A 20011218 BR 1999-14958 19991027
JP 2002528537 T2 20020903 JP 2000-579591 19991027
NO 2001002057 A 20010628 NO 2001-2057 20010426


PRIORITY APPLN. INFO.:

GB 1998-23871 A 19981030
US 1998-823871 A 19981030
WO 1999-EP8306 W 19991027

OTHER SOURCE(S):

MARPAT 132:334454

GI



AB The title compds. [I; R = halo, NO₂, (un)substituted amino NH₂, etc.; R₁ = alkyl, alkenyl, 3-6 membered carbocycle, etc.], useful for treating cell proliferative disorders assocd. with an altered cell dependent kinase activity such as cancer, Alzheimer's disease, viral infections, autoimmune diseases or neurodegenerative disorders, were prepd. E.g., thiazole I [R = iso-Pr; R₁ = 4-Me₂NC₆H₄CH₂] showed Ki of 0.1 .mu.M against cdk2/cyclin A complex.


IT 267656-57-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-amino-thiazole derivs. as antitumor agents)

RN 267656-57-5 CAPLUS

CN 1H-Indole-5-carboxamide, N-[5-(1-methylethyl)-2-thiazolyl]-2-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 27 OF 63 CAPLUS COPYRIGHT-2003 ACS

ACCESSION NUMBER: 1999:595178 CAPLUS

DOCUMENT NUMBER: 131:243258



TITLE: Preparation of thieno[2,3-c]pyrans and thieno[2,3-c]pyridines as modulators of protein tyrosine phosphatases (PTPases)

INVENTOR(S): Moller, Niels Peter Hundahl; Andersen, Henrik Sune; Iversen, Lars Fogh; Olsen, Ole Hvilsted; Branner, Sven; Holsworth, Daniel Dale; Bakir, Farid; Judge, Luke Milburn; Axe, Frank Urban; Jones, Todd Kevin; Ripka, William Charles; Ge, Yu; Uyeda, Roy Teruyuki

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Ontogen Corporation
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946267	A1	19990916	WO 1999-DK121	19990311
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2323493	AA	19990916	CA 1999-2323493	19990311
AU 9927135	A1	19990927	AU 1999-27135	19990311
BR 9908726	A	20001121	BR 1999-8726	19990311
EP 1080095	A1	20010307	EP 1999-907332	19990311
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, FI, RO				
US 6262044	B1	20010717	US 1999-268490	19990311
JP 2002506072	T2	20020226	JP 2000-535645	19990311
ZA 9902036	A	19991001	ZA 1999-2036	19990312
NO 2000004527	A	20001107	NO 2000-4527	20000911
US 6410586	B1	20020625	US 2001-810266	20010316
US 2003069267	A1	20030410	US 2002-158464	20020528
PRIORITY APPLN. INFO.:				
			DK 1998-344	A 19980312
			DK 1998-480	A 19980403
			DK 1998-938	A 19980715
			DK 1998-1385	A 19981028
			DK 1998-1612	A 19981207
			US 1998-82915P	P 19980424
			US 1998-93525P	P 19980721
			US 1998-108747P	P 19981117
			US 1999-268490	A3 19990311
			WO 1999-DK121	W 19990311
			US 2001-810266	A3 20010316

OTHER SOURCE(S): MARPAT 131:243258
GI



AB Thieno[2,3-c]pyrans and thieno[2,3-c]pyridines (I) [A = atoms to complete various 5/5 and 5/6 bicyclic heterocycles, e.g., thienopridines, thieno(thio)pyrans, benzothiophenes, etc.; R1 and R2 = independently acyl, OH or derivs., CF3, NO2, cyano, SO3H, (un)substituted NH2 or PO3H2, or various 5-membered heterocycles; R4 = H, OH, alkyl, (un)substituted aryl]

or aralkyl, (un)substituted NH₂, alkoxy] were prep'd. as inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP.alpha., LAR, and HePTP. The compds. are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases. For instance, 2-amino-6-benzoyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic acid Et ester was amidated with Et oxalyl chloride in THF (84%), followed by hydrolysis of the ester function with NaOH in aq. soln. to give the title compd.(II) as the mono-Na salt (III) in 79% yield. In an in vitro test against PTP1B expressed in E. coli and purified by known methods, III had a K_i of 51 .mu.M.


IT 243966-17-8P 243966-18-9P 243967-47-7P
243967-51-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of thieno[2,3-c]pyrans and thieno[2,3-c]pyridines as modulators of protein tyrosine phosphatases (PTPases))

RN 243966-17-8 CAPLUS


CN 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-3-[[4-[3-(4-morpholinyl)-1-oxopropyl]-1-piperazinyl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


RN 243966-18-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-1-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 243967-47-7 CAPLUS

CN 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-3-[[4-[3-(4-morpholinyl)-1-oxopropyl]-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



RN 243967-51-3 CAPLUS

CN 1H-Indole-7-carboxylic acid, 6-[(carboxycarbonyl)amino]-1-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 28 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:595127 CAPLUS

DOCUMENT NUMBER: 131:228643

TITLE: Preparation of oxalylaminothiophene derivatives as modulators of protein tyrosine phosphatases (PTPases)

INVENTOR(S): Richter, Lutz Stefan; Andersen, Henrik Sune; Vagner, Josef; Jeppesen, Claus Bekker; Moller, Niels Peter Hundahl; Branner, Sven; Jeppesen, Lone; Olsen, Ole Hvilsted; Iversen, Lars Fogh; Holsworth, Daniel Dale; Axe, Frank Urban; Ge, Yu; Jones, Todd Kevin; Ripka, William Charles; Uyeda, Roy Teruyuki; Su, Jing; Bakir, Farid; Judge, Luke Milburn

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.; Ontogen Corporation; Richter, Birgith

SOURCE: PCT Int. Appl. 230 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946237	A1	19990916	WO 1999-DK126	19990312
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6225329	B1	20010501	US 1999-265069	19990309
US 2002019412	A1	20020214	US 1999-265316	19990309
AU 9927139	A1	19990927	AU 1999-27139	19990311

US 6262044	B1	20010717	US 1999-268490	19990311
US 2002002199	A1	20020103	US 1999-266395	19990311
CA 2323472	AA	19990916	CA 1999-2323472	19990312
ZA 9902029	A	19990927	ZA 1999-2029	19990312
ZA 9902032	A	19990927	ZA 1999-2032	19990312
ZA 9902038	A	19990927	ZA 1999-2038	19990312
ZA 9902036	A	19991001	ZA 1999-2036	19990312
BR 9908723	A	20001121	BR 1999-8723	19990312
EP 1080068	A1	20010307	EP 1999-907336	19990312
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, FI, RO				
NO 2000004526	A	20001108	NO 2000-4526	20000911
US 6410586	B1	20020625	US 2001-810266	20010316
US 2002165398	A1	20021107	US 2002-127043	20020419
US 2003069267	A1	20030410	US 2002-158464	20020528

PRIORITY APPLN. INFO.:

DK 1998-350	A	19980312
DK 1998-345	A	19980312
DK 1998-343	A	19980312
DK 1998-342	A	19980312
DK 1998-344	A	19980312
DK 1998-347	A	19980312
DK 1998-346	A	19980312
DK 1998-348	A	19980312
DK 1998-479	A	19980403
DK 1998-472	A	19980403
DK 1998-473	A	19980403
DK 1998-478	A	19980403
DK 1998-475	A	19980403
DK 1998-474	A	19980403
DK 1998-476	A	19980403
DK 1998-480	A	19980403
US 1998-82912P	P	19980424
DK 1998-667	A	19980515
US 1998-88115P	P	19980605
DK 1998-939	A	19980715
DK 1998-940		19980715
DK 1998-938		19980715
DK 1998-1385		19981028
DK 1998-1561		19981126
DK 1998-1612		19981207
US 1998-82365P	P	19980420
US 1998-82368P	P	19980420
US 1998-82371P	P	19980420
US 1998-82373P	P	19980420
US 1998-82913P	P	19980424
US 1998-82914P	P	19980424
US 1998-82915P	P	19980424
US 1998-93525P	P	19980721
US 1998-93620P	P	19980721
US 1998-93638P	P	19980721
US 1998-108747P	P	19981117
US 1999-115528P	P	19990112
US 1999-266395	B1	19990311
US 1999-268490	A3	19990311
WO 1999-DK126	W	19990312
US 2001-810266	A3	20010316

GI



AB Oxalylaminoheterocycles (e.g., oxalylaminothiophene and oxalylaminothienopyran derivs., etc.) were prepd. as inhibitors of Protein Tyrosine Phosphatases (PTPases), such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTP.alpha., PTP.epsilon., PTP.mu., PTP.delta., PTP.sigma., PTP.zeta., PTP.beta., PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP. These compds. are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases; and type I diabetes and type II diabetes. For instance, 2-amino-5-hydroxymethyl-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid tert-Bu ester (prepn. given) was reacted with phthalimide in THF, PPh3, and DIAD to form the 5-phthalimidomethyl deriv. (47%). The amine was amidated with imidazol-1-yloxoacetic acid tert-Bu ester in CH2Cl2 and TEA (99%), followed by hydrolysis of the ester function with TFA in CH2Cl2, to give 5-(1,3-dioxo-1,3-dihydroisoindol-2-ylmethyl)-2-(oxalylamino)-4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid (I) in 57% yield. In an in vitro test against PTP1B expressed in E. coli and purified by known methods, Ki values at various inhibitor concns. were detd. An anal. of selectivity of two PTPase inhibitors against PTP1B, PTP-LAR, PTP.epsilon., CD45, and PTP.beta. showed that one compd. of the invention is a non-selective inhibitor, whereas another behaves like a selective inhibitor.


IT 243966-17-8P 243966-18-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compd.; prepn. of oxalylaminothiophene derivs. as modulators of protein tyrosine phosphatases (PTPases))

RN 243966-17-8 CAPLUS


CN 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-3-[[4-[3-(4-morpholinyl)-1-oxopropyl]-1-piperazinyl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 243966-18-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 6-[(carboxycarbonyl)amino]-1-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 29 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:806656 CAPLUS
 DOCUMENT NUMBER: 130:52330
 TITLE: Antagonists of gonadotropin releasing hormone
 INVENTOR(S): Goulet, Mark; Ujjainwalla, Feroze; Walsh, Thomas F.; Wyvratt, Matthew J., Jr.
 PATENT ASSIGNEE(S): Merck & Co., Inc. USA
 SOURCE: PCT Int. Appl., 65 pp
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855479	A1	19981210	WO 1998-US11072	19980601
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9876056	A1	19981221	AU 1998-76056	19980601
AU 729663	B2	20010208		
EP 986557	A1	20000322	EP 1998-923865	19980601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002502422	T2	20020122	JP 1999-502633	19980601
PRIORITY APPLN. INFO.:			US 1997-48635P	P 19970605
			US 1997-48743P	P 19970605
			GB 1997-16865	A 19970808
			GB 1997-19391	A 19970911
			WO 1998-US11072	W 19980601
OTHER SOURCE(S):	MARPAT 130:52330			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alk-aryl-alk where alk = (un)substituted C0-4 alkylene; B = bond, O-alk, CO-alk, S(O)0-2-alk, etc.; R0 = H, (un)substituted alkyl, aryl, or aralkyl; or R2A may form 5- to 7-membered ring; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R2 = (un)substituted heteroaryl or heteroarylalkyl, -A-B-R1; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms

(un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)0-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkynylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Two such compds. were prepd. and/or claimed, and several intermediates were prepd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and double reductive alkylation of the resultant sidechain amine with 5-(pyridin-3-yl)thiophene-2-carbaldehyde and NaBH3CN, to give the title compd. II.


IT 217188-13-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)

RN 217188-13-1 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[[5-(3-pyridinyl)-2-thienyl]methyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 30 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:806648 CAPLUS

DOCUMENT NUMBER: 130:52329

TITLE: Preparation of indole derivatives as antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark; Ujjainwalla, Feroze; Walsh, Thomas F.; Wyvratt, Matthew J., Jr.; Young, Jonathan R.; Chu, Lin

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

Searched by Barb O'Bryen, STIC 308-4291

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855470	A1	19981210	WO 1998-US11203	19980601
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9878068	A1	19981221	AU 1998-78068	19980601
AU 729752	B2	20010208		
EP 986550	A1	20000322	EP 1998-926170	19980601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002502426	T2	20020122	JP 1999-502713	19980601
PRIORITY APPLN. INFO.:			US 1997-48639P	P 19970605
			US 1997-48742P	P 19970605
			GB 1997-19386	A 19970911
			GB 1997-19387	A 19970911
			WO 1998-US11203	W 19980601
OTHER SOURCE(S):	MARPAT 130:52329			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alk-aryl-alk where alk = (un)substituted C0-4 alkylene; B = bond, O-alk, CO-alk, S(O)0-2-alk, etc.; R0 = H, (un)substituted alkyl, aryl, or aralkyl; or R2A may form 5- to 7-membered ring; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R2 = H, (un)substituted alkyl, aryl, aralkyl; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl; or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms (un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)0-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkynylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Seven such compds. were prepd. and/or claimed, and several intermediates were prepd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and reductive alkylation of the resultant sidechain amine with 5-(pyridin-3-yl)thiophene-2-carboxaldehyde and NaBH3CN, to give the title compd. II.

IT 217199-91-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)

RN 217199-91-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[[5-(3-pyridinyl)-2-thienyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 31 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:804185 CAPLUS

DOCUMENT NUMBER: 130:52328

TITLE: Preparation of indole derivatives as antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark; Wyvratt, Matthew J., Jr.; Chu, Lin; Girotra, Narindar N.; Lin, Peter

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PEXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855123	A1	19981210	WO 1998-US11208	19980601
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 6156767	A	20001205	US 1998-83477	19980522
AU 9878071	A1	19981221	AU 1998-78071	19980601
AU 728811	B2	20010118		
EP 994708	A1	20000426	EP 1998-926173	19980601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002502428	T2	20020122	JP 1999-502717	19980601
PRIORITY APPLN. INFO.:			US 1997-48638P	P 19970605
			US 1997-48642P	P 19970605
			GB 1997-19840	A 19970918
			GB 1998-454	A 19980109
			WO 1998-US11208	W 19980601

OTHER SOURCE(S): MARPAT 130:52328

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alkylene, cycloalkylene, alkenylene, alkynylene, bind, etc; R0 = H, (un)substituted alkyl, aryl, or aralkyl; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R2 = (un)substituted heteroaryl or heteroaralkyl; or R2A may form 5- to 7-membered ring; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms (un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)0-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkynylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Fourteen such compds. were prep'd. and claimed, and a variety of intermediates were prep'd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and double reductive alkylation of the resultant sidechain amine with pyridin-3-ylacetaldehyde and NaBH3CN, to give the title compd. II.


IT 217316-02-4P 217316-08-0P 217316-13-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prep'n. of indole derivs. as non-peptide GnRH antagonists)


RN 217316-02-4 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(7-chloro-4-quinolinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 217316-08-0 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(3,5-dichloro-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 217316-13-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(3-chloro-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 32 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:804181 CAPLUS

DOCUMENT NUMBER: 130:52327

TITLE: Preparation of indole derivatives as antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark; Ujjainwalla, Feroze; Walsh, Thomas F.;
Wyvratt, Matthew J., Jr.; Young, Jonathan R.; Chu, Lin

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

Searched by Barb O'Bryen, STIC 308-4291

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855119	A1	19981210	WO 1998-US11204	19980601
W:			AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
AU 9878069	A1	19981221	AU 1998-78069	19980601
EP 1011667	A1	20000628	EP 1998-926171	19980601
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI	
JP 2002503252	T2	20020129	JP 1999-502714	19980601
PRIORITY APPLN. INFO.:			US 1997-48636P	P 19970605
			US 1997-48637P	P 19970605
			GB 1997-19839	A 19970918
			GB 1998-451	A 19980109
			WO 1998-US11204	W 19980601
OTHER SOURCE(S):		MARPAT 130:52327		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alk-aryl-alk where alk = (un)substituted C0-4 alkylene; B = bond, O-alk, CO-alk, S(O)0-2-alk, etc.; R0, R2 = H, (un)substituted alkyl, aryl, or aralkyl; or R2A may form 5- to 7-membered ring; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms (un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)0-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkenylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Approx. 36 such compds. were prepd. and/or claimed, and a variety of intermediates were prepd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and reductive alkylation of the resultant sidechain amine with 4-(pyridin-3-yl)benzaldehyde and NaBH3CN, to give the title compd. II.

IT 217192-16-0P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of indole derivs. as non-peptide GnRH

antagonists)

RN 217192-16-0 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[[4-(3-pyridinyl)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 33 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:804178 CAPLUS

DOCUMENT NUMBER: 130:52326

TITLE: Preparation of indole derivatives as antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark; Ujjainwalla, Feroze; Walsh, Thomas F.; Wyvratt, Matthew J., Jr.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855116	A1	19981210	WO 1998-US11207	19980601
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9877149	A1	19981221	AU 1998-77149	19980601
AU 728988	B2	20010125		
EP 986385	A1	20000322	EP 1998-925129	19980601
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 2002502427	T2	20020122	JP 1999-502716	19980601
PRIORITY APPLN. INFO.:			US 1997-48634P	P 19970605
			US 1997-48739P	P 19970605
			GB 1997-19841	A 19970918
			GB 1998-450	A 19980109
			WO 1998-US11207	W 19980601

OTHER SOURCE(S): MARPAT 130:52326

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB There are disclosed novel indole compds. I [A = (un)substituted alk-aryl-alk where alk = (un)substituted C0-4 alkylene; B = bond, O-alk, CO-alk, S(O)O-2-alk, etc.; R0, R2 = H, (un)substituted alkyl, aryl, or aralkyl; or R2A may form 5- to 7-membered ring; R1 = various (un)substituted and mostly N-contg. mono- and bicyclic heterocycles; R3, R4, R5 = H, (un)substituted alk(en)yl, aryl, or aralkyl, CN, nitro, perfluoroalkyl, halo, etc.; or R3R4 may form C3-7 carbocycle or an NOS-heterocycle; R6 = H, (un)substituted alkyl or aryl, perfluoroalkyl, CN, NO2, halo, etc.; R7 = H, (un)substituted alkyl, or is absent if X = H or halo; R8 = H, CO2H or derivs., NH2 or derivs., OH or derivs., SH or derivs.; or R7R8 forms (un)substituted NOS-heterocycle, C3-7 carbocycle, or oxo; R9, R9', R10, R10' = H, (un)substituted alkyl, aryl, or aralkyl; or R9R9' and/or R10R10' forms C3-7 carbocycle or oxo; addnl. rings possible; X = N, O, S(O)O-2, CO, (CH2)p or derivs., bond, (un)substituted alkenylene or alkynylene; m = 0-3; p = 0-4] and pharmaceutically acceptable salts thereof. The compds. are useful as antagonists of GnRH (no data), and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. Eight such compds. were prepd. and/or claimed, and a variety of intermediates were prepd. For instance, Et 2-(4-hydrazinophenyl)-2-methylpropionate (prepn. given) was cyclized with 3-chloropropyl 3,5-dimethylphenyl ketone to give a 2-[3-(2-aminoethyl)indol-5-yl]propionate deriv., which underwent a sequence of sidechain N-BOC protection, alk. sapon. of the Et ester, amidation with 7-azabicyclo[2.2.1]heptane-HCl, acidic deprotection, and double reductive alkylation of the resultant sidechain amine with 4-(pyridin-3-yl)benzaldehyde and NaBH3CN, to give the title compd. II.


IT 217189-14-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)

RN 217189-14-5 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[2-[bis[[4-(3-pyridinyl)phenyl]methyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 34 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:31981 CAPLUS

DOCUMENT NUMBER: 130:95474

TITLE: Preparation of bis-indoles having antimetastatic activity

PATENT ASSIGNEE(S): Boehringer Mannheim Italia S.P.A., Italy

SOURCE: Eur. Pat. Appl., 13 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 887348	A1	19981230	EP 1997-110336	19970625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
WO 9900381	A1	19990107	WO 1998-EP3837	19980623
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9886295	A1	19990119	AU 1998-86295	19980623
EP 991645	A1	20000412	EP 1998-937539	19980623
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810947	A	20000926	BR 1998-10947	19980623
JP 2002507206	T2	20020305	JP 1999-505271	19980623
ZA 9805482	A	19991224	ZA 1998-5482	19980624
MX 9911996	A	20000630	MX 1999-11996	19991217
PRIORITY APPLN. INFO.:			EP 1997-110336	A 19970625
			WO 1998-EP3837	W 19980623

OTHER SOURCE(S): MARPAT 130:95474

GI



AB The title compds. [I; R, R3 = H, OH, halo, etc.; R1, R2 = H, OH, CH2OH, etc.; A = (un)substituted Ph, naphthyl, 5-6 membered heterocycle contg. one or two heteroatoms selected from O, N or S, which can be optionally benzocondensed], useful as antitumor and antimetastatic agents, were prepd. Thus, condensation of 3-pyridinecarboxaldehyde with indole in the presence of AcOH afforded I [R-R3 = H; A = 3-pyridyl] which showed 31.4 spontaneous pulmonary metastases deriving from intrafootpad implanted murine Lewis Lung carcinoma at 200 mg/kg/day vs. 65.9 metastases for control (no compd. administered).


IT 219141-20-5P 219141-43-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of bis-indoles having antimetastatic activity)


RN 219141-20-5 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3,3'-[(8-hydroxy-2-quinolinyl)methylene]bis-, dimethyl ester (9CI) (CA INDEX NAME)



RN 219141-43-2 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3,3'-[3-(dimethylamino)propylidene]bis-, diethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L42 ANSWER 35 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:511777 CAPLUS

DOCUMENT NUMBER: 127:121742

TITLE: Preparation of heterocyclic compounds as antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Goulet, Mark; Ashton, Wallace T.; Chu, Lin; Fisher, Michael H.; Girotra, Narindar N.; Lin, Peter; Wyvratt, Matthew J.

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9721704	A1	19970619	WO 1996-US19444	19961210
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2240108	AA	19970619	CA 1996-2240108	19961210
AU 9714106	A1	19970703	AU 1997-14106	19961210
AU 707641	B2	19990715		
EP 873336	A1	19981028	EP 1996-944249	19961210
EP 873336	B1	20020327		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
CN 1208412	A	19990217	CN 1996-199872	19961210
JP 11506471	T2	19990608	JP 1996-522124	19961210
JP 2001106685	A2	20010417	JP 2000-257791	19961210
JP 3230818	B2	20011119	JP 1997-522124	19961210
AT 215081	E	20020415	AT 1996-944249	19961210
ES 2174129	T3	20021101	ES 1996-944249	19961210
ZA 9610536	A	19970814	ZA 1996-10536	19961213
NO 9802729	A	19980813	NO 1998-2729	19980612
PRIORITY APPLN. INFO.:			US 1995-8633P	P 19951214
			GB 1996-3242	A 19960216
			JP 1997-522124	A3 19961210
			WO 1996-US19444	W 19961210
OTHER SOURCE(S):	MARPAT 127:121742			
GI				



I



II

AB The title compds. I [A = alkyl, etc.; R = H, alkyl, etc.; R1 = heterocyclic ring (generic structures given); R2 = H, alkyl, etc.; or R2A = ring; R3, R4, R5 = H, (un)substituted alkyl, alkenyl, etc.; or R3R4 = ring; R6 = H, (un)substituted alkyl, etc.; R7 = H, (un)substituted alkyl; unless X is hydrogen or halo, then R7 is absent; R8 = heterocyclic ring, etc.; or R7R8 = heterocyclic ring; R9, R19 = H, (un)substituted alkyl; further details on R9R19 and R9A are given; R20, R10 = H, (un)substituted alkyl, etc.; further details on R20R10, and R9R20, R9R2, R20R2, R20A are given; m = 0 to 3; X = N, etc.], useful as antagonists of gonadotropin releasing hormone (no data), are prepd. I may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women. The title compd. II was prepd. in a multistep process.


IT 192643-04-2P 192643-05-3P 192643-06-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds. as antagonists of gonadotropin releasing hormone)


RN 192643-04-2 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 192643-05-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 192643-06-4 CAPLUS

CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-3-[2-[[4-(4-pyridinyl)butyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 36 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1997:257472 CAPLUS
 DOCUMENT NUMBER: 126:238304
 TITLE: Preparation of seco precursors of cyclopropylindoles
 as anticancer drugs
 INVENTOR(S): Denny, William Alexander; Tercel, Moana
 PATENT ASSIGNEE(S): Auckland Division Cancer Society of New Zealand Inc.,
 N. Z.; Denny, William Alexander; Tercel, Moana
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT-NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9707097	A1	19970227	WO 1996-NZ83	19960819
W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM			
AU 9667109	A1	19970312	AU 1996-67109	19960819
AU 707644	B2	19990715		
EP 850220	A1	19980701	EP 1996-927217	19960819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 11511113	T2	19990928	JP 1996-531337	19960819
US 5985909	A	19991116	US 1998-11883	19980218
PRIORITY APPLN. INFO.:			GB 1995-16943	19950818
			WO 1996-NZ83	19960819
OTHER SOURCE(S):	MARPAT 126:238304			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I and II; X = halo, OSO₂R (wherein R = H, (un)substituted by 1-4 OH groups lower alkyl, (un)substituted by 1-2 lower alkyl groups NH₂); Y = NH₂, NO₂, NHOH, etc.; E = N, CH; G = O, S, NH; Q = H, OR, NR₂, etc.; R₁ = R; P = III, IV, V (wherein Z = H, Me; n = 1-2; R₂ = R, CONHR, NHCOR, OR, SO₂R)], useful as prodrugs for antibody-directed enzyme-prodrug therapy (ADEPT) and gene-directed enzyme-prodrug therapy (GDEPT) for cancer, were prepd. Thus, two alternative 10-step syntheses of VI, which showed IC₅₀ of 0.32 .mu.M in AA8 cells, and against UV4 cells of 0.059 .mu.M, were described.


IT 188538-03-6P 188538-04-7P 188538-05-8P
188538-06-9P 188538-07-0P 188538-08-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of seco precursors of cyclopropylindoles as anticancer drugs)

RN 188538-03-6 CAPLUS


CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(2-pyridinyl)ethyl]-, hydrochloride (4:1) (9CI) (CA INDEX NAME)



● 1/4 HCl


RN 188538-04-7 CAPLUS

CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 188538-05-8 CAPLUS

CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(4-morpholinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 188538-06-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 188538-07-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 188538-08-1 CAPLUS
 CN Glycine, N-[[2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 37 OF 63 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:577724 CAPLUS
DOCUMENT NUMBER: 125:221574
TITLE: Preparation of hydrosoluble 3-arylidene-2-oxyindole
tyrosine kinase inhibitors
INVENTOR(S): Buzzetti, Franco; Brasca, Maria Gabriella; Longo,
Antonio; Ballinari, Dario
PATENT ASSIGNEE(S): Pharmacia S.P.A. Italy
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9622976	A1	19960801	WO 1995-EP5176	19951222
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2186508	AA	19960801	CA 1995-2186508	19951222
AU 9644363	A1	19960814	AU 1996-44363	19951222
AU 697673	B2	19981015		
EP 752985	A1	19970115	EP 1995-943238	19951222
EP 752985	B1	19990804		
R: CH, DE, ES, FR, GB, IT, LI, SE				
JP 09510993	T2	19971104	JP 1995-522571	19951222
ES 2137562	T3	19991216	ES 1995-943238	19951222
IL 116851	A1	20000601	IL 1996-116851	19960122
US 5840745	A	19981124	US 1996-704760	19960925
PRIORITY APPLN. INFO.:			GB 1995-1567	A 19950126
			WO 1995-EP5176	W 19951222

OTHER SOURCE(S): MARPAT 125:221574

GI For diagram(s), see printed CA Issue.

AB 3-Arylidene-2-oxindole derivs. [I; m = 0-2; A = (un)substituted bicyclic ring chosen from tetralin, naphthalene, quinoline and indole; R1 = H, alkyl, alkanoyl; one of R2 and R3 is H and the other is (un)substituted alkyl, (un)substituted alkoxy carbonyl, (un)substituted SO₃H, (CH₂)_nN(alkyl)₂, etc.; n = 2, 3], useful as tyrosine kinase inhibitors for the treatment of tumors, diabetic complications (no data), restenosis (no data), etc. (no data), are prepd. and I-contg. formulations presented. Thus, 3-carbethoxy-3-(5-methoxyindol-3-ylmethylene)-2-oxyndole was prepd. and demonstrated a IC₅₀ of 1.99 .mu.M against v-abl tyrosine kinase and a IC₅₀ of 2.34 .mu.M against the growth of K562 chronic myeloid leukemia cells.

IT 181222-47-9P 181223-83-6P 181223-87-0P


181223-91-6P 181223-94-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of hydrosol. 3-arylidene-2-oxyindole tyrosine kinase inhibitors)


RN 181222-47-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 181223-83-6 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 181223-87-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 181223-91-6 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 181223-94-9 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L42 ANSWER 38 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:467094 CAPLUS

DOCUMENT NUMBER: 125:114586

TITLE: Preparation of substituted 3-aryliden-7-azaoxindoles as tyrosine kinase inhibitors

INVENTOR(S): Buzzetti, Franco; Brasca, Gabriella Maria; Longo, Antonio; Ballinari, Dario

PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616964	A1	19960606	WO 1995-EP4247	19951030
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2180730	AA	19960606	CA 1995-2180730	19951030
AU 9539262	A1	19960619	AU 1995-39262	19951030
EP 741726	A1	19961113	EP 1995-937030	19951030
EP 741726	B1	19991117		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1139929	A	19970108	CN 1995-191374	19951030
HU 74875	A2	19970228	HU 1996-2357	19951030
JP 09508924	T2	19970909	JP 1995-518113	19951030
AT 186727	E	19991215	AT 1995-937030	19951030
ES 2140717	T3	20000301	ES 1995-937030	19951030
ZA 9509927	A	19960610	ZA 1995-9927	19951122
US 5719135	A	19980217	US 1996-669315	19960709
NO 9603066	A	19960723	NO 1996-3066	19960723
FI 9602954	A	19960724	FI 1996-2954	19960724
PRIORITY APPLN. INFO.:			GB 1994-23997	19941128
			WO 1995-EP4247	19951030
OTHER SOURCE(S):			CASREACT 125:114586; MARPAT 125:114586	
GI				




AB The prepn. of substituted 3-arylidene-7-azaoxindoles I [A = benzene, naphthalene, 5,6,7,8-tetrahydronaphthalene, quinoline, isoquinoline, indole or 7-azaindole rings; R1 = H, CN, various sulfates and sulfonamides, CO2R6, CONHCH2(CHOH)nCH2OH, various amides, NR7R8, N(CH2CH2OH)2, NHCH2(CH(OH))nCH2OH, NHCONH2, NHC(NH2):NH, NHCO(CH(OH))nCH2OH, NHSO2R9, OR10, OCH2(CH(OH))nCH2OH, OOC(CH(OH))nCH2OH, OPO(OH)2, CH2NH2, C(NH2):NH, CH2NHC(NH2):NH, CH2OH, CH2OOC(CH(OH))nCH2OH, CH2OPO(OH)2, PO(OH)2, etc.; R2 is C1-6 alkyl, halo, or OH; R3 = H or C1-6 alkyl; R4 = H, C1-6 alkyl or CH2(CH(OH))nCH2OH; R5 = H, C1-6 alkyl, CH2(CH(OH))nCH2OH or (CH2)mNMe2; R6 = H, C1-6 alkyl or CH2(CH(OH))nCH2OH; each of R7 and R8 independently is H or C1-6 alkyl; R9 = Me or tolyl; R10 = H, C1-6 alkyl or C2-6 alkanoyl; Z = CH2, O, NH or NCH2CH2OH; n = 0, 1; m = 2, 3; p = 1-3; q = 0-2] are described, and their pharmaceutically acceptable salts, for use as tyrosine kinase inhibitors. A variety of processes are claimed for the prepn. of I, including: (a) condensation of an aldehyde with an azaoxindole, (b) subjecting an amino-substituted 3-arylidene-7-azaoxindole to N-alkylation, N-acetylation, N-sulfonylation, N-amidation, or N-carbamoylation, (c) subjecting a hydroxy-substituted 3-arylidene-7-azaoxindole to O-alkylation, O-acylation, or O-phosphorylation, (d) esterification of a carboxy-substituted 3-arylidene-7-azaoxindole, (e) ammonia addn. to a cyano-substituted 3-arylidene-7-azaoxindole, and (f) amination of a chloromethyl-substituted 3-arylidene-7-azaoxindole. As an example of the condensation reaction, 7-azaoxindole was refluxed with 3,5-di-tert-butyl-4-hydroxybenzaldehyde in EtOH with added piperidine for 3 h to give 3-[(3,5-di-tert-butyl-4-hydroxyphenyl)methylene]-7-azaoxindole in 80% yield. Another compd., 3-[(7-azaindol-3-yl)methylene]-7-azaoxindole, exhibited inhibitory activity for the in vitro p45 v-abl kinase assay (IC50 = 1.05 .mu.M) and for the in vivo human chronic myeloid leukemia K562 cell growth inhibition assay (IC50 = 3.89). Pharmaceutical formulations of compds. I are claimed (2 examples).

IT 179341-45-8 179341-46-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. of substituted 3-arylidene-7-azaoxindoles as tyrosine kinase inhibitors)


RN 179341-45-8 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 179341-46-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 39 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:379686 CAPLUS

DOCUMENT NUMBER: 125:58312

TITLE: Indoloylguanidine derivatives useful as inhibitors of Na⁺/H⁺ exchanger activity.

INVENTOR(S): Kitanō, Masahumi; Nakano, Kazuhiro; Yagi, Hideki; Ohashi, Naohito; Kojima, Atsuyuki; Noguchi, Tsuyoshi; Miyagishi, Akira

PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan

SOURCE: Eur. Pat. Appl., 99 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 708091	A1	19960424	EP 1995-307409	19951018
EP 708091	A3	19960717		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
JP 08208602	A2	19960813	JP 1995-286772	19951006
CA 2160600	AA	19960419	CA 1995-2160600	19951016
CN 1136038	A	19961120	CN 1995-116169	19951017
CN 1067988	B	20010704		
TW 386991	B	20000411	TW 1995-84110984	19951018

PRIORITY APPLN. INFO.: JP 1994-280025 A 19941018

OTHER SOURCE(S): MARPAT 125:58312

GI



AB Indoloylguanidine derivs. I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, halo, NO2, acyl, CO2H, alkoxy carbonyl, arom. group, (un)substituted OH, NH2, SO2NH2, etc.; R2 = H, (un)substituted alkyl, cycloalkyl, OH, alkoxy, etc.] and their pharmaceutically acceptable acid addn. salts inhibit Na⁺/H⁺ exchanger activity, and are consequently useful in the treatment or prevention of diseases caused by increased Na⁺/H⁺

exchanger activity. For example, condensation of Me 1-methyl-2-indolecarboxylate in the presence of NaOMe at .1toreq. 130.degree. gave, after chromatog. and salification, 30.8% title compd. II. In an assay for inhibition of ischemia-and-reperfusion-induced cardiac arrhythmia in rats, II at 0.3 mg/kg reduced mortality from 76% (control) to .0%, whereas EIPA [5-(N-ethyl-N-isopropyl)amiloride] reduced mortality to only 44% at the same dose.

IT 167478-07-1P 178050-69-6P 178050-71-0P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indoloylguanidine derivs. as Na+/H+ exchanger inhibitors)

RN 167478-07-1 CAPLUS


CN 1H-Indole-5-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 178050-69-6 CAPLUS


CN 1H-Indole-6-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 178050-71-0 CAPLUS

CN 1H-Indole-4-carboxamide, N-(aminoiminomethyl)-1-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L42 ANSWER 40 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:995460 CAPLUS
 DOCUMENT NUMBER: 124:117103
 TITLE: Preparation of substituted .beta.-aryl and
 .beta.-heteroaryl-.alpha.-cyanoacrylamide derivatives
 as tyrosine kinase inhibitors
 INVENTOR(S): Buzzetti, Franco; Crugnola, Angelo; Longo, Antonio;
 Brasca, Gabriella Maria; Ballinari, Dario
 PATENT ASSIGNEE(S): Pharmacia S.p.A., Italy
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9526341	A1	19951005	WO 1995-EP758	19950302
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2163115	AA	19951005	CA 1995-2163115	19950302
AU 9518498	A1	19951017	AU 1995-18498	19950302
AU 685599	B2	19980122		
EP 700388	A1	19960313	EP 1995-910542	19950302
EP 700388	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
CN 1125942	A	19960703	CN 1995-190227	19950302
HU 73811	A2	19960930	HU 1995-3714	19950302
JP 08511562	T2	19961203	JP 1995-524920	19950302
AT 224371	E	20021015	AT 1995-910542	19950302
ZA 9502423	A	19951219	ZA 1995-2423	19950324
NO 9504692	A	19951120	NO 1995-4692	19951120
US 5652250	A	19970729	US 1995-537947	19951121
FI 9505661	A	19960119	FI 1995-5661	19951124
PRIORITY APPLN. INFO.:			GB 1994-6137	A 19940328
			GB 1994-6173	A 19940329
			WO 1995-EP758	19950302
OTHER SOURCE(S):		MARPAT 124:117103		
AB Title compds. R1CH: C(CN)CONH(CH ₂) _n R2 [I; R1 = (substituted) naphthyl, tetrahydronaphthyl, quinolyl, isoquinolyl; indolyl; R2 = pyridyl, thienyl, substituted Ph; n = 0-3] were prepd. and formulated. Condensation of 8-hydroxy-5-quinolinecarboxaldehyde with N-phenylcyanoacetamide in the presence of piperidine in boiling EtOH afforded 75% I (R1 =				

8-hydroxy-5-quinolyl; R2 = Ph; n = 0) which showed IC50 of 3.4 .mu.M in vitro against p45 v-abl kinase and 0.66 .mu.M in vivo against chronic myeloid leukemia K562 cell growth.

IT 173085-93-3P 173085-94-4P 173085-95-5P


173086-04-9P 173086-05-0P 173086-06-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of substituted .beta.-aryl and .beta.-heteroaryl-.alpha.-cyanoacrylamide derivs. as tyrosine kinase inhibitors)


RN 173085-93-3 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-(phenylamino)-1-propenyl]- (9CI) (CA INDEX NAME)




RN 173085-94-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-[(phenylmethyl)amino]-1-propenyl]- (9CI) (CA INDEX NAME)




RN 173085-95-5 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-[(2-phenylethyl)amino]-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173086-04-9 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[(4-hydroxyphenyl)amino]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173086-05-0 CAPLUS


CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[[4-(4-hydroxyphenyl)methyl]amino]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)

3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173086-06-1 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[[2-(4-hydroxyphenyl)ethyl]amino]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 41 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:813058 CAPLUS

DOCUMENT NUMBER: 123:208831

TITLE: Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

INVENTOR(S): Heath, William Francis Heat, Jr.; McDonald, John Hampton III; Brasca, Maria Gabriella; Orzi, Fabrizio; Crugnola, Angelo; Ballinari, Dario; Mariani, Mariangela

PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy

SOURCE: PCT Int. Appl., 104 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517181	A1	19950629	WO 1994-EP3664	19941108
W: AU, BY, CA, HU, JP, KR, KZ, NO, PL, RU, UA				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2155098	AA	19950629	CA 1994-2155098	19941108
AU 9480612	A1	19950710	AU 1994-80612	19941108
AU 676958	B2	19970327		
EP 684820	A1	19951206	EP 1994-931583	19941108
EP 684820	B1	20010816		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
HU 73176	A2	19960628	HU 1995-2761	19941108
JP 08507089	T2	19960730	JP 1994-517121	19941108
AT 204168	E	20010915	AT 1994-931583	19941108
ES 2162871	T3	20020116	ES 1994-931583	19941108
ZA 9410204	A	19951110	ZA 1994-10204	19941212
US 5576330	A	19961119	US 1994-354215	19941212
IL 112010	A1	19981030	IL 1994-112010	19941216
NO 9503146	A	19950810	NO 1995-3146	19950810

PRIORITY APPLN. INFO.: GB 1993-26136 A 19931222
WO 1994-EP3664 W 19941108

OTHER SOURCE(S): MARPAT 123:208831

GI




AB Compds. I (Ar = naphthalene, tetralin, quinoline, isoquinoline, indole; n = 0 or an integer of 1 to 3; R1 = H, C1-6 alkyl, C2-6 alkanoyl; R2 = H, halogen, C1-6 alkyl, cyano, carboxy, nitro, NHR; R = H, C1-6 alkyl; R3 = H, C1-6 alkyl; R4 = H, OH, C1-6 alkoxy, C2-6 alkanoyloxy, carboxy, nitro, NHR; R5 = H, C1-6 alkyl, halogen) or a pharmaceutically acceptable salt thereof are useful as angiogenesis inhibitors. Products contg. an angiogenesis inhibitor or a pharmaceutically acceptable salt thereof and an antitumor agent are used as a combined prepn. for anticancer therapy. A compn. (for 10,000 tablets) contg. 3-[(3'-hydroxy-2'-tetralyl)methylen]-2-oxindole 250, lactose 800, corn starch 415, talc 30 and Mg stearate 5 g, resp., was formulated.

IT 148563-52-4 148563-57-9

RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(oxindole derivs. as anti-angiogenic agents)


RN 148563-52-4 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-5-hydroxy-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 148563-57-9 CAPLUS

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 42 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:741641 CAPLUS

DOCUMENT NUMBER: 123:340823

TITLE: Novel 6-5 fused ring heterocycle antifolates with potent antitumor activity: bridge modifications and heterocyclic benzoyl isomers of 2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidine antifolate

AUTHOR(S): Kotake, Hoshihiko; Okauchi, Tatsuo; Iijima, Atsumi; Yoshimatsu, Kentaro; Nomura, Hiroaki

CORPORATE SOURCE: Res. Development Division, Eisai Company, Ltd., Ibaraki, 300-26, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1995), 43(5), 820-41



PUBLISHER: CODEN: CPBTAL; ISSN: 0009-2363
Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:340823

GI



AB Structural modifications of extremely potent cyclopenta[d]pyrimidine-based inhibitor I [X = (CH₂)₂, Z = p-C₆H₄ (1)] of dihydrofolate reductase (DHFR) activity and tumor cell growth have led to the synthesis of new cyclopenta[d]pyrimidine-based antifolates, including I [X = CH₂CHMe, CH₂CHEt, Z = p-C₆H₄ (2a, b)] with low alkyl substituted trimethylene bridges, I [X = CH₂O, CH₂NH, CH₂NMe, CH₂NEt, Z = p-C₆H₄ (2c-f)] with isosterically modified bridges, and I [X = CH₂, (CH₂)₂, Z = 1,5-indolediyl or 1,5-indolinediyl Q, 2,5-thiophenediyl (2g-i)] in which the benzene ring has been replaced by heterocyclic isosteres. These new analogs are highly potent as DHFR and cell growth inhibitors, and most of them are more potent than methotrexate (MTX) and 10-ethyl-10-deazapterin (10-EDAM) in inhibiting tumor cell growth (P388 MTX-sensitive and MTX-resistant, colon 26 and KB) on 72 h drug exposure. Among them, 2a and 2i were most potent, being 2- to 3-fold more potent than 10-EDAM. On 4 h drug exposure, the growth-inhibitory activity of these analogs was radically influenced by even minor structural changes. Compds. 1, 2a-e, g-i were much more cytotoxic in colon 26 cell line than were MTX and 10-EDAM, with 2d and 2i being most potent, followed by 2a. Structure-activity relationships and their possible significance are discussed.

IT 163915-73-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and antifolate and antitumor activity of cyclopentapyrimidine antifolates)

RN 163915-73-9 CAPLUS

CN L-Glutamic acid, N-[[1-[2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethyl]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L42 ANSWER 43 OF 63 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:621503 CAPLUS
 DOCUMENT NUMBER: 123:33085
 TITLE: Preparation of antitumor 6,7-dihydro-5H-cyclopenta[d]pyrimidine derivatives
 INVENTOR(S): Nomura, Masaaki; Kotake, Yoshihiko; Haneda, Tooru; Okauchi, Tatsuo; Kito, Kyosuke
 PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 27 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06239841	A2	19940830	JP 1993-30605	19930219
JP 3213426	B2	20011002		

PRIORITY APPLN. INFO.: JP 1993-30605 19930219
 OTHER SOURCE(S): MARPAT 123:33085
 GI



I



II

AB Title compds. I [R1 = OH, NH2; R2 = (un)substituted indolinediyl, indolediyl, indandiyl, indenediyl, n = 0-4] and their pharmacol. acceptable salts were prepd. by condensation of carboxylic acids II with H2NCH(CO2R3)CH2CH2CO2R4 (R3, R4 = carboxyl protecting group) followed by acid or alk. hydrolysis or catalytic hydrogenolysis. Thus, condensation of 1-[2-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)ethyl]indole-5-carboxylic acid with L-glutamic acid di-Et ester hydrochloride followed by hydrolysis with aq. NaOH gave

N-[1-[2-(2,4-diamino-6,7-dihydro-5H-cyclopenta[d]pyrimidin-5-yl)ethyl]indole-5-carbonyl]-L-glutamic acid (III). III showed inhibitory activities against dihydrofolate reductase and P388 cell.

IT 163915-73-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antitumor cyclopentapyrimidine derivs.)

RN 163915-73-9 CAPLUS

CN L-Glutamic acid, N-[[1-[2-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)ethyl]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 163915-82-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antitumor cyclopentapyrimidine derivs.)

RN 163915-82-0 CAPLUS

CN L-Glutamic acid, N-[[1-[3-(2,4-diamino-6,7-dihydro-5H-cyclopentapyrimidin-5-yl)propyl]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L42 ANSWER 44 OF 63 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:164208 CAPLUS

DOCUMENT NUMBER: 120:164208

TITLE: Preparation of methotrexate derivatives as antitumor agents

INVENTOR(S): Matsuoka, Hiroharu; Suzuki, Hiroshi; Kato, Nobuaki; Tsuji, Keiichiro; Kuroki, Toshio; Maruyama, Noriaki

PATENT ASSIGNEE(S): Chugai Seiyaku K. K., Japan

SOURCE: RCT Int. Appl., 70 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9315077	A1	19930805	WO 1993-JP96	19930127
W: AT, AU, BR, CA, CH, DE, ES, GB, HU, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SE, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
JP 05339268	A2	19931221	JP 1993-44301	19930125
JP 3207285	B2	20010910		
ZA 9300556	A	19931004	ZA 1993-556	19930126
CN 1077956	A	19931103	CN 1993-102057	19930126
CN 1039907	B	19980923		
AU 9333676	A1	19930901	AU 1993-33676	19930127
EP 632038	A1	19950104	EP 1993-902536	19930127
EP 632038	B1	20010822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 204576	E	20010915	AT 1993-902536	19930127
ES 2161713	T3	20011216	ES 1993-902536	19930127
JP 06016669	A2	19940125	JP 1993-64581	19930212
JP 3145533	B2	20010312		
JP 06016670	A2	19940125	JP 1993-99005	19930318
JP 3274532	B2	20020415		
US 6559149	B1	20030506	US 1994-256441	19940712
PRIORITY APPLN. INFO.:				
			JP 1992-53051	A 19920127
			JP 1992-75106	A 19920213
			JP 1992-108320	A 19920316
			JP 1992-115126	A 19920324
			WO 1993-JP96	A 19930127
OTHER SOURCE(S):				
GI				
MARPAT 120:164208				



AB Title compds. I [W = Q, Q1, Q2; R1, R4 = H, C1-4 alkyl; R2 = C1-4 alkyl, CF3; R3 = H, C1-4 alkyl, CF3; R5 = CO2H, alkoxycarbonyl, SO3H, H, C1-4 alkyl; n, m, l = 1-4 integer; R7 = C1-4 alkyl; R8 = H, C1-4 alkyl; R9 = CO2H, alkoxycarbonyl, SO3H; R11, R12 = H, C1-4 alkyl; R13 = CO2H, alkoxycarbonyl, SO3H] are prep'd. A suspension of N-[N'-methyl-(4-amino-3-methylbenzoyl)]-L-glutamic di-Et ester (prepn. given) and 6-(bromomethyl)-2,4-diaminopteridine HBr-isopropanol adduct in DMF was heated at 55-60.degree. for 4 h to give the title compd. di-Et N-[4-[N'-(2,4-diamino-6-pteridinyl)methyl-N'-methylamino]-3-methylbenzoyl]-L-glutamate, which was hydrolyzed to give the free carboxylic acid (II). In an in vitro study using a culture of lymphocytes from human peripheral blood, II inhibited the uptake of 3H-deoxyuridine in phytohemagglutinin-stimulated lymphocytes.

IT 153304-37-1P 153304-38-2P 153304-39-3P
153304-40-6P


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of, as antitumor agent)

RN 153304-37-1 CAPLUS

CN Hexanedioic acid, 2-[[[1-[(2,4-diamino-6-pteridiny)methyl]-1H-indol-5-yl]carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153304-38-2 CAPLUS

CN Butanoic acid, 2-[[[1-[(2,4-diamino-6-pteridiny)methyl]-1H-indol-5-yl]carbonyl]amino]-4-sulfo-, monoammonium salt, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● NH3

RN 153304-39-3 CAPLUS


CN L-Glutamic acid, N-[[[1-[(2,4-diamino-6-pteridiny)methyl]-1H-indol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153304-40-6 CAPLUS
CN Hexanedioic acid, 2-[[[1-[(2,4-diamino-6-pteridiny)methyl]-7-methyl-1H-indol-5-yl]carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L42 ANSWER 45 OF 63 USPATFULL

ACCESSION NUMBER: 2003:30934 USPATFULL
TITLE: Compounds and their use
INVENTOR(S): Ferraris, Dana V., Eldersburg, MD, UNITED STATES
Li, Jia-He, Cockeysville, MD, UNITED STATES
Kalish, Vincent J., Annapolis, MD, UNITED STATES
Zhang, Jie, Ellicott City, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022883	A1	20030130
APPLICATION INFO.:	US 2001-996776	A1	20011130 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-250132P	20001201 (60)
	US 2001-310274P	20010807 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	4519	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **433728-52-0P**

(intermediate; prepn. of benzazepinones, isoquinolinones and related compds. as inhibitors of poly(ADP-ribose) polymerase (PARP))

RN 433728-52-0 USPATFULL
CN 1H-Indole-4-carboxylic acid, 3-(4-morpholinylacetyl)-, methyl ester (9CI)
(CA INDEX NAME)



L42 ANSWER 46 OF 63 USPATFULL

ACCESSION NUMBER: 2002:133898 USPATFULL

TITLE: PDE IV inhibiting amides, compositions and methods of treatment

INVENTOR(S): Labelle, Marc, St. Lazare, CANADA
 Sturino, Claudio, Dorval, CANADA
 Lachance, Nicolas, Pierrefonds, CANADA
 Macdonald, Dwight, L'ile Bizard, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002068756	A1	20020606
	US 6436965	B2	20020820
APPLICATION INFO.:	US 2001-797083	A1	20010301 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-186571P	20000302 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2355	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds represented by formula I: ##STR1##

as well as pharmaceutically acceptable salts and hydrates thereof are disclosed as useful for treating or preventing diseases and conditions mediated by PDE-IV.

Pharmaceutical compositions and methods of treatment are also included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 359002-36-1P 359002-38-3P 359002-42-9P

359002-44-1P 359002-48-5P 359002-50-9P

359002-54-3P 359002-56-5P 359002-60-1P

359002-62-3P 359002-66-7P 359002-68-9P

359002-72-5P 359002-74-7P 359002-78-1P


359002-80-5P 359002-84-9P 359002-86-1P

359002-90-7P 359002-92-9P

(drug; synthesis of N-benzyl-indolyl(benzyloxy)amido derivs. as PDE-IV inhibitors)


RN 359002-36-1 USPATFULL

CN 1H-Indole-7-carboxylic acid, 3-(4-pyridinylmethoxy)-2-[(1H-tetrazol-5-ylamino)carbonyl]-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA. INDEX NAME)





RN 359002-38-3 USPATFULL

CN 1H-Indole-2,7-dicarboxamide, N7,N7-dimethyl-3-(4-pyridinylmethoxy)-N2-1H-tetrazol-5-yl-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 359002-42-9 USPATFULL


CN 1H-Indole-4-carboxylic acid, 3-(4-pyridinylmethoxy)-2-[(1H-tetrazol-5-ylamino)carbonyl]-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-44-1 USPATFULL

CN 1H-Indole-2,4-dicarboxamide, N4,N4-dimethyl-3-(4-pyridinylmethoxy)-N2-1H-tetrazol-5-yl-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 359002-48-5 USPATFULL


CN 1H-Indole-4-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA

INDEX NAME)




RN 359002-50-9 USPATFULL

CN 1H-Indole-2,4-dicarboxamide, N4,N4-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-54-3 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[[4-(trifluoromethyl)phenyl]methyl]-3-(phenylmethoxy)-2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-56-5 USPATFULL

CN 1H-Indole-2,4-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N4,N4-dimethyl-3-(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-60-1 USPATFULL

CN 1H-Indole-7-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-62-3 USPATFULL

CN 1H-Indole-2,7-dicarboxamide, N4,N4-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-66-7 USPATFULL

CN 1H-Indole-7-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-
2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-68-9 USPATFULL

CN 1H-Indole-2,7-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N7,N7-dimethyl-3-
(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-72-5 USPATFULL

CN 1H-Indole-6-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-
pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA
INDEX NAME)




RN 359002-74-7 USPATFULL

CN 1H-Indole-2,6-dicarboxamide, N6,N6-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-78-1 USPATFULL

CN 1H-Indole-6-carboxylic acid, 1-[[4-(trifluoromethyl)phenyl]methyl]-3-(phenylmethoxy)-2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 359002-80-5 USPATFULL

CN 1H-Indole-2,6-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N6,N6-dimethyl-3-(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 359002-84-9 USPATFULL

CN 1H-Indole-5-carboxylic acid, 2-[(4-pyridinylamino)carbonyl]-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 359002-86-1 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N5,N5-dimethyl-N2-4-pyridinyl-3-(4-pyridinylmethoxy)-1-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 359002-90-7 USPATFULL

CN 1H-Indole-5-carboxylic acid, 1-[(4-fluorophenyl)methyl]-3-(phenylmethoxy)-
2-[(3-pyridinylamino)carbonyl]- (9CI) (CA INDEX NAME)

RN 359002-92-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, 1-[(4-fluorophenyl)methyl]-N5,N5-dimethyl-3-
(phenylmethoxy)-N2-3-pyridinyl- (9CI) (CA INDEX NAME)

L42 ANSWER 47 OF 63 USPATFULL

ACCESSION NUMBER: 2002:67203 USPATFULL

TITLE: Novel compounds possessing antibacterial, antifungal or
antitumor activity

Searched by Barb O'Bryen, STIC 308-4291

INVENTOR(S): Zhang, Wentao, Foster City, CA, UNITED STATES
Liehr, Sebastian Johannes Reinhard, East Palo Alto, CA,
UNITED STATES
Velligan, Mark Douglas, Montara, CA, UNITED STATES
Dyatkina, Natalia B., Mountain View, CA, UNITED STATES
Botyanszki, Janos, Cupertino, CA, UNITED STATES
Shi, Dong-Fang, San Mateo, CA, UNITED STATES
Roberts, Christopher Don, Belmont, CA, UNITED STATES
Khorlin, Alexander, Mountain View, CA, UNITED STATES
Nelson, Peter Harold, Los Altos, CA, UNITED STATES
Muchowski, Joseph Martin, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037856	A1	20020328
APPLICATION INFO.:	US 2001-892327	A1	20010626 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-214478P	20000627 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gerald F. Swiss, Esq., BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA, 22313-1404	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	3872	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): ##STR1##

Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 386252-72-8P

(prepn. of)

RN 386252-72-8 USPATFULL

CN 1H-Benzimidazole-2-carboxylic acid, 5-[[[5-[(pentafluorophenoxy)carbonyl]-1H-indol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



IT 386250-55-1P 386251-09-8P 386251-11-2P
386251-12-3P


(prepn. of novel compds. possessing antibacterial, antifungal or antitumor activity)

RN 386250-55-1 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-

iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-09-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N-[2-[[[2-(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N'-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-11-2 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-12-3 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 386250-57-3P 386250-58-4P 386250-59-5P
386250-60-8P 386250-61-9P 386250-63-1P
386250-65-3P 386250-67-5P 386250-85-7P
386250-86-8P 386250-87-9P 386250-88-0P
386250-91-5P 386250-94-8P 386250-95-9P
386250-97-1P 386250-99-3P 386251-01-0P
386251-02-1P 386251-03-2P 386251-06-5P
386251-10-1P 386251-13-4P 386251-24-7P
386251-25-8P 386251-26-9P 386251-27-0P
386251-28-1P 386251-29-2P 386251-30-5P
386251-31-6P 386251-32-7P 386251-33-8P
386251-34-9P 386251-35-0P 386251-36-1P
386251-37-2P 386251-38-3P 386251-39-4P
386251-40-7P 386251-41-8P 386251-42-9P
386251-43-0P 386251-44-1P 386251-45-2P

386251-46-3P 386251-47-4P 386251-48-5P
386251-49-6P 386251-50-9P 386251-51-0P
386251-52-1P 386251-53-2P 386251-54-3P
386251-55-4P 386251-56-5P 386251-57-6P
386251-58-7P 386251-59-8P 386251-60-1P
386251-61-2P 386251-62-3P 386251-63-4P
386251-66-7P 386251-67-8P 386251-68-9P
386251-69-0P 386251-70-3P 386251-71-4P
386251-72-5P 386251-99-6P 386252-00-2P
386252-01-3P 386252-02-4P 386252-03-5P
386252-04-6P 386252-05-7P 386252-06-8P
386252-07-9P 386252-08-0P 386252-09-1P
386252-10-4P 386252-11-5P 386252-12-6P
386252-13-7P 386252-14-8P 386252-15-9P
386252-16-0P 386252-17-1P 386252-18-2P
386252-34-2P 386252-36-4P 386252-37-5P
386252-38-6P 386252-40-0P 386252-41-1P
386252-42-2P 386252-44-4P 386252-46-6P
386252-47-7P 386252-60-4P 386252-61-5P
386252-62-6P 386252-63-7P 386252-64-8P
386252-65-9P 386252-66-0P 386252-67-1P
386253-08-3P 386253-09-4P 386253-10-7P
386253-11-8P

(prepn. of novel compds. possessing antibacterial, antifungal or
antitumor activity)

RN 386250-57-3 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[(2-aminoethyl)amino]carbonyl]-1-
methyl-1H-pyrrol-3-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 386250-56-2

CMF C26 H31 N9 O4

PAGE 1-A




PAGE 1-B

-CH2-CH2-NH2

CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 386250-58-4 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386250-59-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-(aminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₃—NH₂

RN 386250-60-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₃—NMe₂


RN 386250-61-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[1-methyl-5-[[[3-(1-piperidinyl)propyl]amino]carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386250-63-1 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-methyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386250-62-0

CMF C29 H35 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386250-65-3 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-aminoethyl)amino]carbonyl]-1H-
indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386250-64-2

CMF C32 H31 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386250-67-5 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[2-[(aminoiminomethyl)amino]ethyl
1]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)

CM 1


CRN 386250-66-4

CMF C28 H35 N13 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2





RN 386250-85-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[4-amino-4-
iminobutyl)amino]carbonyl]-1-(3-methylbutyl)-1H-pyrrol-3-yl]- (9CI) (CA
INDEX NAME)

PAGE 1-A




PAGE 1-B





RN 386250-86-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[5-amino-5-
iminopentyl)amino]carbonyl]-1-(3-methylbutyl)-1H-pyrrol-3-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386250-87-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(ethylamino)ethyl]amino]carbo-
nyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386250-88-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(propylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386250-91-5 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-octyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



2 HCl


PAGE 1-B



RN 386250-94-8 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-propyl-,
dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386250-95-9 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl

PAGE 1-B



RN 386250-97-1 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]-, hexakis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386250-96-0

CMF C40 H51 N13 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386250-99-3 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(3-aminopropyl)amino]propyl]amino]carbonyl]-1H-indol-5-yl]-, tetrakis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386250-98-2

CMF C40 H49 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 386251-01-0 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-aminoethyl]amino]carbonyl]-1-propyl-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386251-02-1 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-((2-aminoethyl)amino)carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386251-03-2 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-((2-aminoethyl)amino)carbonyl]-1H-indol-5-yl]-1-propyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B



RN 386251-06-5 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-3-iminopropyl)amino]carbonyl]-1H-indol-5-yl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 2 HCl


PAGE 1-B




RN 386251-10-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[2-[[[2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N2-[2-[[[2-(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-13-4 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(3-aminopropyl)amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-24-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-25-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-26-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-27-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-(dimethylamino)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-28-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]-2,3-dihydro-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-29-2 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-(dimethylamino)propyl]amino]carbonyl]-2,3-dihydro-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-30-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-31-6 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(3-amino-2-hydroxypropyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386251-32-7 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●x HCl


PAGE 1-B




RN 386251-33-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(aminoiminomethyl)amino]propyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-34-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-[(aminoiminomethyl)amino]-2-hydroxypropyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-35-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1-(ethoxymethyl)-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-36-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1-[(2-methoxyethoxy)methyl]-1H-indol-5-yl]]- (9CI) (CA INDEX NAME)

PAGE 1-A

MeO-CH₂-


PAGE 1-B




RN 386251-37-2 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1-(methoxymethyl)-1H-indol-5-yl]]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-38-3 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




●x HCl


RN 386251-39-4 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-1-oxo-3-phenylpropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 =O

●x HCl


RN 386251-40-7 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[2S]-2-amino-4-methyl-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-41-8 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S,3S)-2-amino-3-methyl-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B


$$= 0$$


RN 386251-42-9 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2S)-2-amino-3-methyl-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-43-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoacetyl)amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386251-44-1 USPATFULL


CN Pentanoic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-6,2-diylcarbonylimino-2,1-ethanediylimino)]bis[4-amino-5-oxo-, (4S,4'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C


—CO₂H

RN 386251-45-2 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,5-diamino-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C


—NH₂

RN 386251-46-3 USPATFULL


CN L-Glutamine, N,N'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-6,2-diylcarbonylimino-2,1-ethanediyl)]bis[N2-acetyl-, hydrochloride (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

—CO₂H


● x HCl

RN 386251-47-4 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2-amino-1-oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386251-48-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[(2S)-2,6-diamino-1-


oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-49-6 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[2S]-2,3-diamino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386251-50-9 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,4-diamino-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-51-0 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-52-1 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2-amino-5-
[(aminoiminomethyl)amino]-1-oxopentyl]amino]ethyl]amino]carbonyl]-1H-
indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B




PAGE 1-C




RN 386251-53-2 USPATFULL
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,3-diamino-1-oxopropyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-54-3 USPATFULL
 CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-2,4-diamino-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




PAGE 1-C

—NH₂


RN 386251-55-4 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-56-5 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




=O


RN 386251-57-6 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[(2S,3R)-2-amino-3-hydroxy-1-oxobutyl]amino]ethyl]amino]carbonyl]-1H-indol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




=O


RN 386251-58-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(aminoacetyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-59-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-(acetamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386251-60-1 USPATFULL


CN Pentanoic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino-1H-indole-5,2-diylcarbonylimino-2,1-ethanediylimino)]bis[4-amino-5-oxo-, (4S,4'S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

CO₂H


RN 386251-61-2 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[[[2S]-2,6-diamino-1-oxohexyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NC(=O)c1ccc2c(c1)c(c[nH]2)C(=O)NCCNC(=O)[C@H](N)CCCCNCc1ccc2c(c1)c(c[nH]2)C(=O)Nc3ccc4c(c3)c(c[nH]4)C(=O)NCCNC(=O)C(S)(C)NCCCC —NH_2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386251-63-4 USPATFULL


CN Butanoic acid, 4,4'-[1H-indole-2,5-diylbis(carboxylimino-1H-indole-5,2-diylcarbonylimino-2,1-ethanediylimino)]bis[3-amino-4-oxo-, (3S,3'S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 386251-66-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386251-67-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(methylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CH₂—NH₂


RN 386251-68-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-69-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]-N5-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-70-3 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-2,2-bis(hydroxymethyl)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386251-71-4 USPATFULL

CN Carbamic acid, [2-[[[5-[[[2-[[[2-[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-5-yl]carbonyl]amino]-1H-indol-2-yl]carbonyl]amino]ethyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386251-72-5 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-[(2-aminoethyl)amino]carbonyl]-1H-benzimidazol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




● x HCl

PAGE 1-B



RN 386251-99-6 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(methylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)



RN 386252-00-2 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[5-[[[(4-aminobutyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₄—NH₂


RN 386252-01-3 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[(2-aminoethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-02-4 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[3-[[3-[(3-aminopropyl)amino]propyl]amino]propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-03-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[[(4-aminobutyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-04-6 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-05-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-06-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-07-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[2-[bis(2-aminoethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-08-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(methylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-09-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-10-4 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[1-methyl-5-[(octylamino)carbonyl]-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-11-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N2-[5-[[[2-aminoethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386252-12-6 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(octylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


— Me




RN 386252-13-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[(butylamino)carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-14-8 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[[[2-(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-(methyl-2-pyridinylamino)carbonyl]-1H-indol-5-yl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-15-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[2-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]-N2-[5-[[[2-[(aminoiminomethyl)amino]ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-16-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[3-amino-2,2-dimethylpropyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-17-1 USPATFULL

CN Carbamic acid, [2-[[[5-[[[2-[[[2-[[[2-aminoethyl]amino]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-5-yl]carbonyl]amino]-1H-indol-2-yl]carbonyl]amino]ethyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-18-2 USPATFULL

CN 1H-Benzimidazole-2-carboxylic acid, 5-[[[5-[[[2-[[2-aminoethyl)amino]carbonyl]-1H-indol-6-yl]amino]carbonyl]-1H-indol-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B.



RN 386252-34-2 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-octyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-33-1

CMF C36 H49 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 386252-36-4 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[3-amino-3-
iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-propyl-,
bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 386252-35-3
CMF C31 H39 N11 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 386252-37-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386252-38-6 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[2-(methylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME).

CM 1


CRN 386252-37-5

CMF C34 H35 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386252-40-0 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-39-7

CMF C38 H43 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 386252-41-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 386252-42-2 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[(2-aminoethyl)amino]carbonyl]-1-propyl-1H-indol-5-yl]-1-propyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-41-1

CMF C41 H49 N9 O4

PAGE 1-A




PAGE 1-B



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 386252-44-4 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]-1-propyl-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 386252-43-3

CMF C35 H37 N9 O4

PAGE 1-A




PAGE 1-B




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 386252-46-6 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[3-amino-3-
iminopropyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B




RN 386252-47-7 USPATFULL
CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[3-amino-3-
iminopropyl)amino]carbonyl]-1H-indol-5-yl]-, bis(trifluoroacetate) (9CI)
(CA INDEX NAME)


CM 1

CRN 386252-46-6
CMF C34 H33 N11 O4

PAGE 1-A




PAGE 1-B



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 386252-60-4 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N-[5-[[[(4-aminobutyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N'-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-
(9CI) (CA INDEX NAME)



RN 386252-61-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N-[5-[[[(2-aminoethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-N'-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NH₂

RN 386252-62-6 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A.




PAGE 1-B

—NMe₂

RN 386252-63-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[[2-(dimethylamino)ethyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—NMe₂

RN 386252-64-8 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N2-[2-[[4-(aminobutyl)amino]carbonyl]-1H-indol-5-yl]-N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 1-B


—Me




RN 386252-65-9 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[3-(dimethylamino)propyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-66-0 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[2-[[2-(dimethylamino)ethyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386252-67-1 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N5-[5-[(butylamino)carbonyl]-1-methyl-1H-pyrrol-3-yl]-N2-[5-[[2-(hydroxyethyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)




RN 386253-08-3 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N-[2-[[[(1R,2R)-2-aminocyclohexyl]amino]carbonyl]-1H-indol-5-yl]-N'-[2-[[[(1S,2S)-2-aminocyclohexyl]amino]carbonyl]-1H-indol-5-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 1-B




RN 386253-09-4 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[5-[[[(3-amino-3-

iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-1-(phenylmethyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386253-10-7 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[2-aminopropyl]amino]carbonyl]-1H-indol-5-yl]-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386253-11-8 USPATFULL

CN 1H-Indole-2,4-dicarboxamide, N,N'-bis[2-[[3-aminopropyl]amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)




IT 386250-64-2 386252-95-5 386252-96-6
386253-02-7

(prepn. of novel compds. possessing antibacterial, antifungal or
antitumor activity)


RN 386250-64-2 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[(2-aminoethyl)amino]carbonyl]-1H-indol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-95-5 USPATFULL

CN 1H-Indole-2,5-dicarboxamide, N,N'-bis(pentafluorophenyl)- (9CI) (CA INDEX NAME)




RN 386252-96-6 USPATFULL

CN 1H-Indole-2-carboxylic acid, 6,6'-[1H-indole-2,5-diylbis(carbonylimino)]bis-, diethyl ester (9CI) (CA INDEX NAME)



RN 386253-02-7 USPATFULL

CN 1H-Benzimidazole-2-carboxylic acid, 5-[[[(5-carboxy-1H-indol-2-yl)carbonyl]amino]-, 2-methyl ester (9CI) (CA INDEX NAME)



IT 129655-48-7P 386250-90-4P 386250-93-7P

386252-19-3P 386252-20-6P 386252-21-7P

386252-24-0P 386252-52-4DP, amide with


aminomethyl-polystyrene 386252-53-5P 386252-58-0P

386252-70-6P 386252-71-7P

(prepn. of novel compds. possessing antibacterial, antifungal or antitumor activity)


RN 129655-48-7 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 386250-90-4 USPATFULL


CN 1H-Indole-2,5-dicarboxylic acid, 1-octyl-, bis(pentafluorophenyl) ester (9CI) (CA INDEX NAME)




RN 386250-93-7 USPATFULL

CN 1H-Indole-2,5-dicarboxylic acid, 1-propyl-, bis(pentafluorophenyl) ester
(9CI) (CA INDEX NAME)

RN 386252-19-3 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4,4'-[1H-indole-2,5-
diylbis(carbonylimino)]bis[1-methyl-, dimethyl ester (9CI) (CA INDEX
NAME)


RN 386252-20-6 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4,4'-[1H-indole-2,5-
diylbis(carbonylimino)]bis[1-methyl- (9CI) (CA INDEX NAME)


RN 386252-21-7 USPATFULL

CN 1H-Pyrrole-2-carboxylic acid, 4,4'-[1H-indole-2,5-
diylbis(carbonylimino)]bis[1-methyl-, bis(pentafluorophenyl) ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386252-24-0 USPATFULL


CN 1H-Indole-2,5-dicarboxylic acid, 1-methyl-, bis(2,3,5,6-tetrafluorophenyl) ester (9CI) (CA INDEX NAME)




RN 386252-52-4 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5-[[[5-[[[2-[[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]amino]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-2-yl]carbonyl]amino]-, 4-carboxyphenyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 386252-53-5 USPATFULL


CN 1H-Indole-2-carboxylic acid, 6,6'-[1H-indole-2,5-diylbis(carbonylimino)]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 386252-58-0 USPATFULL

CN Carbamic acid, [1H-indole-2,5-diylbis(carbonylimino-1H-indole-5,2-diylcarbonylimino-2,1-ethanediyl)]bis[(2-hydroxyethyl)-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 386252-70-6 USPATFULL

CN 1H-Indole-2,5-dicarboxylic acid, bis(pentafluorophenyl) ester (9CI) (CA INDEX NAME)



RN 386252-71-7 USPATFULL

CN 1H-Benzimidazole-2-carboxylic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino)]bis-, dimethyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 48 OF 63 USPATFULL

ACCESSION NUMBER: 2002-27488 USPATFULL

TITLE: Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha

INVENTOR(S):

Duan, Jingwu, Newark, DE, UNITED STATES
Ott, Gregory R., Philadelphia, PA, UNITED STATES
Chen, Lihua, Wilmington, DE, UNITED STATES
Decicco, Carl, Kennett Square, PA, UNITED STATES
Lu, Zhonghui, Wilmington, DE, UNITED STATES
Maduskuie, Thomas P., JR., Wilmington, DE, UNITED STATES
Voss, Matthew E., Lincoln University, PA, UNITED STATES
Xue, Chu-Biao, Hockessin, DE, UNITED STATES

PATENT INFORMATION:

APPLICATION INFO.:

NUMBER	KIND	DATE
US 2002016336	A1	20020207
US 2001-811233	A1	20010316 (9)

PRIORITY INFORMATION:

NUMBER	DATE
US 2000-190182P	20000317 (60)
US 2000-233373P	20000918 (60)
US 2000-255539P	20001214 (60)

DOCUMENT TYPE:

FILE SEGMENT:

LEGAL REPRESENTATIVE:

Utility
APPLICATION
Dupont Pharmaceuticals Company, Legal Department -
Patents, 1007 Market Street, Wilmington, DE, 19898

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

LINE COUNT:

10
1
7801

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes novel cyclic .beta.-amino acid
derivatives of formula I: ##STR1##

or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR.sup.a, and S(O).sub.p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-.alpha. inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 362491-05-2P 362491-06-3P 362491-08-5P

362491-09-6P 362491-26-7P 362491-27-8P

(prepn. of cyclic .beta.-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-.alpha.)

RN 362491-05-2 USPATFULL

CN 1H-Indole-5-carboxamide, N-[4-[(hydroxyamino)carbonyl]-3-pyrrolidinyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-06-3 USPATFULL

CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl]carbonyl]amino]-, bis(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362491-05-2


CMF C25 H25 N5 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362491-08-5 USPATFULL

CN 1H-Indole-5-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-09-6 USPATFULL

CN 1H-Indole-5-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362491-08-5


CMF C26 H26 N4 O3



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362491-26-7 USPATFULL

CN 1H-Indole-4-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-27-8 USPATFULL

CN 1H-Indole-4-carboxamide, N-[2-[(hydroxyamino)carbonyl]cyclopentyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 362491-26-7


CMF C26 H26 N4 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 362491-89-2P 362491-92-7P 362491-94-9P


(prepn. of cyclic .beta.-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-.alpha.)

RN 362491-89-2 USPATFULL

CN 1H-Indole-5-carboxylic acid, 1-[(4a,8a-dihydro-2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362491-92-7 USPATFULL

CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[[1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl]carbonyl]amino]-, 1-(1,1-dimethylethyl) 3-methyl ester
(9CI) (CA INDEX NAME)

RN 362491-94-9 USPATFULL

CN 3-Pyrrolidinecarboxylic acid, 4-[[[1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 49 OF 63 USPATFULL

ACCESSION NUMBER:

2002:22505 USPATFULL

TITLE:


Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha

INVENTOR(S):

Duan, Jingwu, Newark, DE, UNITED STATES
King, Bryan W., Wilmington, DE, UNITED STATES
Decicco, Carl, Kennett Square, PA, UNITED STATES
Maduskuie, Thomas P., JR., Wilmington, DE, UNITED STATES
Voss, Matthew E., Lincoln University, PA, UNITED STATES

PATENT INFORMATION:


NUMBER	KIND	DATE
US 2002013341	A1	20020131



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 362701-23-3 USPATFULL

CN. 1H-Indole-5-carboxamide, N-[3-(hydroxyamino)-3-oxopropyl]-1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362701-24-4 USPATFULL

CN 1H-Indole-5-carboxamide, N-[3-(hydroxyamino)-3-oxopropyl]-1-[(2-methyl-4-quinolinyl)methyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 362701-23-3

CMF C23 H22 N4 O3




CM 2

CRN 76-05-1
 CMF C2 H F3 O2



RN 362701-25-5 USPATFULL

CN 1H-Indole-5-carboxamide, N-[4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl]-
 1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)




RN 362701-26-6 USPATFULL

CN 1H-Indole-5-carboxamide, N-[4-[2-(hydroxyamino)-2-oxoethyl]-4-piperidinyl]-
 1-[(2-methyl-4-quinolinyl)methyl]-, bis(trifluoroacetate) (salt) (9CI)
 (CA INDEX NAME)

CM 1


CRN 362701-25-5
 CMF C27 H29 N5 O3



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 362706-29-4P 362706-31-8P

(prepn. of .beta.-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-.alpha.)


RN 362706-29-4 USPATFULL

CN 1H-Indole-5-carboxylic acid, 1-[(2-methyl-4-quinolinyl)methyl]- (9CI) (CA INDEX NAME)



RN 362706-31-8 USPATFULL

CN 2H-Pyran-4-acetic acid, tetrahydro-4-[[[1-[(2-methyl-4-quinolinyl)methyl]-1H-indol-5-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 50 OF 63 USPATEFULL

ACCESSION NUMBER:

2001:117009 USPATFULL

TITLE:

Angiogenesis inhibitors

INVENTOR(S):

Fraley, Mark E., North Wales, PA, United States

Hungate, Randall W., Lansdale, PA, United States

Tebben, Andrew J., Wallingford, PA, United States

PATENT ASSIGNEE(S):

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6265403	B1	20010724
APPLICATION INFO.:	US 2000-480717		20000107 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Ford, John M.		
ASSISTANT EXAMINER:	Liu, Hong		
LEGAL REPRESENTATIVE:	Garcia-Rivas, J. Antonio, Daniel, Mark R.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1937		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds which inhibit tyrosine kinase enzymes, compositions which contain tyrosine kinase inhibiting compounds and methods of using tyrosine kinase inhibitors to treat tyrosine kinase-dependent diseases and conditions such as angiogenesis, cancer, atherosclerosis, diabetic retinopathy, and the like in mammals.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 286002-39-9P 286002-40-2P 286002-41-3P
 286002-43-5P 286002-44-6P 286002-47-9P
 286003-31-4P 286003-32-5P 286003-33-6P
 286003-35-8P 286003-36-9P 286003-39-2P
 286004-20-4P 286004-21-5P 286004-22-6P
 286004-24-8P 286004-25-9P 286004-28-2P
 286005-11-6P 286005-12-7P 286005-13-8P
 286005-15-0P 286005-16-1P 286005-19-4P
 286006-06-2P 286006-07-3P 286006-08-4P
 286006-10-8P 286006-11-9P 286006-15-3P
 286007-07-6P 286007-08-7P 286007-09-8P
 286007-11-2P 286007-12-3P 286007-15-6P

(prepn. of pyridinylindoles, pyridinylpyrrolopyridines, and related compds. as tyrosine kinase inhibitors)


RN 286002-39-9 USPATEFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-morpholinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-40-2 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(1-piperidinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-41-3 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[3-(1-piperidinyl)propyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-43-5 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[(1-methyl-3-piperidinyl)methyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-44-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[3-(4-methyl-1-piperazinyl)propyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286002-47-9 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(3-thienyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-31-4 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-morpholinyl)ethyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-32-5 USPATFULL

1H-Indole-4-carboxylic acid, 3-(5-phenyl-3-pyridinyl)-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-33-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-(5-phenyl-3-pyridinyl)-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-35-8 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[(1-methyl-3-piperidinyl)methyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-36-9 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[3-(4-methyl-1-piperazinyl)propyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286003-39-2 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-(5-phenyl-3-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-20-4 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[2-(4-cyano-1-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-21-5 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-22-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-24-8 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-25-9 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-methoxyphenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286004-28-2 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(3-methoxyphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-11-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-12-7 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-13-8 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286005-15-0 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286005-16-1 USPATFULL


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-methoxyphenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286005-19-4 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-[2-(4-cyano-1-piperidinyl)ethyl]-3-[5-(4-methoxyphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

|
OMe


RN 286006-06-2 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-07-3 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-08-4 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[3-(1-piperidinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-10-8 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-11-9 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286006-15-3 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(3-chlorophenyl)-3-pyridinyl]-1-[2-(4-cyano-1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-07-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(4-morpholinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-08-7 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(1-piperidiny)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-09-8 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[3-(1-piperidiny)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 286007-11-2 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[(1-methyl-3-piperidinyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286007-12-3 USPATFULL


CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[3-(4-methyl-1-piperazinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 286007-15-6 USPATFULL

CN 1H-Indole-4-carboxylic acid, 3-[5-(4-chlorophenyl)-3-pyridinyl]-1-[2-(4-cyano-1-piperidinyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

C1

L42 ANSWER 51 OF 63 USPATFULL

ACCESSION NUMBER:

2000:164523- USPATFULL

TITLE:

Antagonists of gonadotropin releasing hormone

INVENTOR(S):

Goulet, Mark, Westfield, NJ, United States

Wyvratt, Jr., Matthew J., Mountainside, NJ, United States

Lin, Peter, Edison, NJ, United States

Chu, Lin, Scotch Plains, NJ, United States

Giretra, Narindar N., Old Bridge, NJ, United States

PATENT ASSIGNEE(S):

Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6156767		20001205
APPLICATION INFO.:	US 1998-83477		19980522 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-48638P	19970605 (60)
	US 1997-48642P	19970605 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Seaman, D. Margaret

LEGAL REPRESENTATIVE: Korsen, Elliott, Daniel, Mark R.

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

LINE COUNT: 1975

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 217316-02-4P 217316-08-0P 217316-13-7P

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)


RN 217316-02-4 USPATFULL

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(7-chloro-4-quinolinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 217316-08-0 USPATFULL

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(3,5-dichloro-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 217316-13-7 USPATFULL

CN 1H-Indole-5-carboxamide, 3-[2-[bis[4-(3-chloro-4-pyridinyl)butyl]amino]ethyl]-2-(3,5-dimethylphenyl)-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)



L42 ANSWER 52 OF 63 USPATFULL

ACCESSION NUMBER: 2000:77373 USPATFULL

TITLE: Antagonists of gonadotropin releasing hormone

INVENTOR(S): Goulet, Mark, Westfield, NJ, United States

Ujjainwalla, Feroze, Edison, NJ, United States

Walsh, Thomas F., Watchung, NJ, United States

Wyvratt, Jr., Matthew J., Mountainside, NJ, United States

Young, Jonathan R., Dayton, NJ, United States

Chu, Lin, Scotch Plains, NJ, United States

PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6077858		20000620
APPLICATION INFO.:	US 1999-401416		19990921 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-83574, filed on 22 May 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-48639P	19970605 (60)
	US 1997-48742P	19970605 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted

PRIMARY EXAMINER: Jarvis, William R. A.

ASSISTANT EXAMINER: Kim, Vickie

LEGAL REPRESENTATIVE: Korsen, Elliot, Daniel, Mark R.

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

LINE COUNT: 2230

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 217199-91-2P

(invention compd.; prepn. of indole derivs. as non-peptide GnRH antagonists)

RN 217199-91-2 USPATFULL
CN 1H-Indole-5-carboxamide, 2-(3,5-dimethylphenyl)-N,N-bis(1-methylethyl)-3-[2-[[[5-(3-pyridinyl)-2-thienyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 53 OF 63 USPATFULL
ACCESSION NUMBER: 1999:146608 USPATFULL
TITLE: Cyclopropylindoles and their seco precursors, and their use as prodrugs
INVENTOR(S): Denny, William Alexander, Auckland, New Zealand
Tercel, Moana, Auckland, New Zealand
PATENT ASSIGNEE(S): Cancer Research Campaign Technology Limited, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5985909		19991116
	WO 9707097		19970227
APPLICATION INFO.:	US 1998-11883		19980218 (9)
	WO 1996-NZ83		19960819
			19980218 PCT 371 date
			19980218 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-16943	19950818
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ramsuer, Robert W.	
LEGAL REPRESENTATIVE:	Sherwood, Pamela J.Bozicevic, Field & Francis LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1518	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula (I) and (II) which may be used as anticancer drugs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 188538-03-6P 188538-04-7P 188538-05-8P

188538-06-9P 188538-07-0P 188538-08-1P

(prepn. of seco precursors of cyclopropylindoles as anticancer drugs)

RN 188538-03-6 USPATFULL


CN 1H-Indole-6-carboxamide, 2-[[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(2-pyridinyl)ethyl]-, hydrochloride (4:1) (9CI) (CA INDEX NAME)



● 1/4 HCl


RN 188538-04-7 USPATFULL

CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 188538-05-8 USPATFULL


CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(4-morpholinyl)ethyl]-; monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 188538-06-9 USPATFULL

CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 188538-07-0 USPATFULL

CN 1H-Indole-6-carboxamide, 2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI) (CA INDEX NAME)



RN 188538-08-1 USPATFULL

CN Glycine, N-[[2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-1H-indol-6-yl]carbonyl]- (9CI) (CA INDEX NAME)




IT 188538-23-0P

(prepn. of seco precursors of cyclopropylindoles as anticancer drugs)

RN 188538-23-0 USPATFULL

CN Glycine, N-[[2-[[3-(chloromethyl)-2,3-dihydro-6-nitro-1H-indol-1-yl]carbonyl]-1H-indol-6-yl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 54 OF 63 USPATFULL

ACCESSION NUMBER: 1998:147460 USPATFULL
TITLE: Hydrosoluble 3-arylidene-2-oxindole derivatives as
tyrosine kinase inhibitors
INVENTOR(S): Buzzetti, Franco, Monza, Italy
Brasca, Maria Gabriella, Cusago, Italy
Longo, Antonio, Milan, Italy
Ballinari, Dario, San Donato Milanese, Italy
PATENT ASSIGNEE(S): Pharmacia S. p. A., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5840745		19981124
	WO 9622976		19960801
APPLICATION INFO.:	US 1996-704760		19960925 (8)
	WO 1995-EP5176		19951222
			19960925 PCT 371 date
			19960925 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-1567	19950126
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1423	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel hydrosoluble 3-arylidene-2-oxindole derivatives, having tyrosine kinase inhibitor activity, encompassed by general formula (I), wherein m is zero, 1 or 2; A is a bicyclic ring chosen from tetralin, naphthalene, quinoline and indole; R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl; one of R.sup.2 and R.sup.3 independently is hydrogen and the other is a substituent selected from: a C.sub.1 -C.sub.6 alkyl group substituted by 1, 2 or 3 hydroxy groups; --SO.sub.3 R.sup.4 in which R.sup.4 is hydrogen or C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by 1, 2 or 3 hydroxy groups; --SO.sub.2 NHR.sup.5 in which R.sup.5 is as R.sup.4 defined above or a --(CH.sub.2).sub.n --N(C.sub.1 -C.sub.6 alkyl).sub.2 group in which n is 2 or 3; --COOR.sup.6 in which R.sup.6 is C.sub.1 -C.sub.6 alkyl unsubstituted or substituted by phenyl or by 1, 2 or 3 hydroxy groups or phenyl; --CONHR.sup.7 in which R.sup.7 is hydrogen, phenyl or C.sub.1 -C.sub.6 alkyl substituted by 1, 2 or 3 hydroxy groups or by phenyl; --NHSO.sub.2 R.sup.8 in which R.sup.8 is C.sub.1 -C.sub.6 alkyl or phenyl unsubstituted or substituted by halogen or by C.sub.1 -C.sub.4 alkyl; --N(R.sup.9).sub.2, --NHR.sup.9 or --OR.sup.9 wherein R.sup.9 is C.sub.2 -C.sub.6 alkyl substituted by 1, 2 or 3 hydroxy groups; --NHCOR.sup.10, --OOCR.sup.10 or --CH.sub.2 OOCR.sup.10 in which R.sup.10 is C.sub.1 -C.sub.6 alkyl substituted by 1, 2 or 3 hydroxy groups; --NHCONH.sub.2 ; --NH--C(NH.sub.2).dbd.NH; --C(NH.sub.2).dbd.NH; --CH.sub.2 NHC(NH.sub.2).dbd.NH; --CH.sub.2 NH.sub.2 ; --OPO(OH).sub.2 ; --CH.sub.2 OPO(OH).sub.2 ; --PO(OH).sub.2 ; or (a), (b), (c), or (d) group, wherein p is 1, 2 or 3 and Z is --CH.sub.2 --, --O-- or (e), in which R.sup.11 is hydrogen or is as R.sup.9 defined above; and the pharmaceutically acceptable salts thereof, are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 181222-47-9P 181223-83-6P 181223-87-0P

181223-91-6P 181223-94-9P

(prepn. of hydrosol. 3-arylidene-2-oxindole tyrosine kinase inhibitors)


RN 181222-47-9 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 181223-83-6 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 181223-87-0 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 181223-91-6 USPATFULL

CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 181223-94-9 USPATFULL

CN 1H-Indole-5-carboxamide, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L42 ANSWER 55 OF 63 USPATFULL

ACCESSION NUMBER: 1998:39732 USPATFULL

TITLE: CC-1065 analogs

INVENTOR(S): Kelly, Robert C., Augusta, MI, United States

Mitchell, Mark A., Kalamazoo, MI, United States

Aristoff, Paul A., Kalamazoo, MI, United States

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5739350		19980414
APPLICATION INFO.:	US 1995-479231		19950607 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-279767, filed on 25 Jul 1994, now abandoned which is a continuation of Ser. No. US 1992-966139, filed on 23 Oct 1992, now abandoned which is a continuation of Ser. No. US 1990-513501, filed on 25 Apr 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Sripada, Pavanaram K.		
LEGAL REPRESENTATIVE:	Jameson, William G.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	3071		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides some new synthetically obtained compounds of formula I and II ##STR1## which are useful as chemical intermediates. Representative formula I or II compounds have also been shown to possess useful ranges of antitumor activity in standard laboratory animal tests.

In addition, the compounds of formula I or II can be linked to monoclonal antibodies, either directly or via known linking group, as a means of selectively delivering the CC-1065 analogs (Compounds of Formula I and II) to those target cells expressing the target antigen and thus selectively eliminating those diseased cells from the animal or human. Further, the compounds of formula I and II can be linked to soluble human CD4 or a soluble human CD4 protein fragment capable of binding to the gp120 envelope protein of the human immuno-virus and thus eliminate virally infected cells.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 138731-17-6P 138731-18-7P

(prepn. and reaction of, in prepn. of neoplasm inhibitors)


RN 138731-17-6 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5-[[[5-[[2-[(1,1-dimethylethoxy)carbonyl]hydrazino]carbonyl]-1H-indol-2-yl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 138731-18-7 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5-[[[5-[[2-[(1,1-dimethylethoxy)carbonyl]hydrazino]carbonyl]-1H-indol-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 138730-89-9P 138730-90-2P


```
(prepn. of, as neoplasm inhibitor and intermediate)
```

RN 138730-89-9 USPATFULL


CN Hydrazinecarboxylic acid, 2-[[[2-[[[2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-1H-indol-5-yl]carbonyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 138730-90-2 USPATFULL
CN 1H-Indole-5-carboxylic acid, 2-[[[2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]amino]carbonyl]-, hydrazide, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B

—NH₂

L42 ANSWER 56 OF 63 USPATFULL
ACCESSION NUMBER: 1998:17299 USPATFULL
TITLE: Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
INVENTOR(S): Buzzetti, Franco, Monza, Italy
Brasca, Gabriella Maria, Cusago, Italy
Longo, Antonio, Milan, Italy
Ballinari, Dario, San Donato Milanese, Italy
PATENT ASSIGNEE(S): Pharmacia S.p.A., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5719135		19980217

Searched by Barb O'Bryen, STIC 308-4291

APPLICATION INFO.: WO 9616964 19960606
US 1996-669315 19960709 (8)
WO 1995-EP4247 19951030
19960709 PCT 371 date
19960709 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-23997	19941128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Shah, Mukund J.	
ASSISTANT EXAMINER:	Coleman, Brenda	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1297	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compound of formula (I) ##STR1## wherein A is benzene, naphthalene, 5,6,7,8,-tetrahydronaphthalene, quinoline, isoquinoline, indole or 7-azaindole;

R.sub.1 is --H, --CN, --SO.sub.3 R.sub.4 --, --SO.sub.2 NHR.sub.5, ##STR2## --COOR.sub.6, --CONHCH.sub.2 (CHOH).sub.n CH.sub.2 OH, ##STR3## --NR.sub.7 R.sub.8, --N(CH.sub.2 CH.sub.2 OH).sub.2, --NHCH.sub.2 (CHOH).sub.n CH.sub.2 OH, --NHCONH.sub.2, --NH--C(NH.sub.2).dbd.NH, --NHCO(CHOH).sub.n CH.sub.2 OH, ##STR4## --NHSO.sub.2 R.sub.9, --OR.sub.10, --OCH.sub.2 (CHOH).sub.n CH.sub.2 OH, --OOC(CHOH).sub.n CH.sub.2 OH, --OPO(OH).sub.2, --CH.sub.2 NH.sub.2, --C(NH.sub.2).dbd.NH, --CH.sub.2 NHC(NH.sub.2).dbd.NH, ##STR5## --CH.sub.2 OH, --CH.sub.2 OOC(CHOH).sub.n CH.sub.2 OH, --CH.sub.2 OPO(OH).sub.2 or --PO(OH).sub.2 ;

R.sub.2 is C.sub.1 -C.sub.6 alkyl, halogen, or hydroxy;

R.sub.3 is --H or C.sub.1 -C.sub.6 alkyl;

R.sub.4 is --H, C.sub.1 -C.sub.6 alkyl or --CH.sub.2 (CHOH).sub.n CH.sub.2 OH;

R.sub.5 is --H, C.sub.1 -C.sub.6 alkyl, --CH.sub.2 (CHOH).sub.n CH.sub.2 OH or --(CH.sub.2).sub.m NMe.sub.2 ;

R.sub.6 is --H, C.sub.1 -C.sub.6 alkyl or --CH.sub.2 (CHOH).sub.n CH.sub.2 OH;

each of R.sub.7 and R.sub.8 independently is --H or C.sub.1 -C.sub.6 alkyl;

R.sub.9 is methyl or tolyl;

R.sub.10 is --H, C.sub.1 -C.sub.6 alkyl, or C.sub.2 -C.sub.6 alkanoyl;

Z is >CH.sub.2, >O, >NH, or >NCH.sub.2 CH.sub.2 OH; n is zero or 1;

m is 2 or 3; p is 1, 2 or 3; q is zero, 1 or 2;

and the pharmaceutically acceptable salt thereof, for use as tyrosine kinase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 179341-45-8 179341-46-9

(prepn. of substituted 3-arylidene-7-azaoxindoles as tyrosine kinase

inhibitors)


RN 179341-45-8 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 179341-46-9 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-pyrrolo[2,3-b]pyridin-3-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 57 OF 63 USPATFULL

ACCESSION NUMBER: 97:96887 USPATFULL

TITLE: Tetracyclic compounds, intermediates for their preparation and their use as antitumor agentsINVENTOR(S): Franzmann, Karl Witold, Beckenham, Great Britain
Stables, Jeremy Nigel, Beckenham, Great Britain
Shannon, Patrick Vivian Richard, Penarth, Great Britain
Rao, Nagaraja Kodanda Ranganatha, Birchgrove, Great BritainPATENT ASSIGNEE(S): Chunchatprasert, Laddawan, Khon Kaen, Thailand
The Wellcome Foundation Ltd., United Kingdom (non-U.S. corporation)
University College Cardiff Consultants Limited, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5679694		19971021
APPLICATION INFO.:	US 1996-743283		19961104 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-373285, filed on 31 Jan 1995, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1992-15361	19920720
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Haley, Jacqueline	
LEGAL REPRESENTATIVE:	Nixon & Vanderhye	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1992	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of formula (I) which have been found to possess anti-tumor activity. Pharmaceutical compositions and methods

of treating tumors are also disclosed. ##STR1##


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 157578-95-5P

(prepn. of, as intermediate for tetracyclic neoplasm inhibitor)

RN 157578-95-5 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[[3-acetyl-5-(ethoxycarbonyl)-4-methyl-1H-pyrrol-2-yl]methyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 58 OF 63 USPATFULL

ACCESSION NUMBER: 97:66137 USPATFULL

TITLE: N-substituted .beta.-aryl- and .beta.-heteroaryl-.alpha.-cyanoacrylamide derivatives and process for their preparation

INVENTOR(S): Buzzetti, Franco, Milan, Italy
Crugnola, Angelo, Varese, Italy
Longo, Antonio, Milan, Italy
Brasca, Maria Gabriella, Milan, Italy
Ballinari, Dario, Milan, Italy
PATENT ASSIGNEE(S): Pharmacia S.p.A., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5652250		19970729
	WO 9526341		19951005
APPLICATION INFO.:	US 1995-537947		19951121 (8)
	WO 1995-EP758		19950302
			19951121 PCT 371 date
			19951121 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-6137	19940328
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rotman, Alan L.	
ASSISTANT EXAMINER:	Smith, Lyman H.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	978	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to new compounds of formula ##STR1## wherein A is a bicyclic ring chosen from naphthalene, tetrahydronaphthalene, quinoline, isoquinoline and indole.

B is a R^{sup.2} substituted benzene ring or an unsubstituted pyridine or thiophene ring;

R is hydrogen, C_{sub.1}-C_{sub.6} alkyl, halogen, nitro, cyano, carboxy or a group NR^{sup.3} R^{sup.4} wherein each of R^{sup.3} and R^{sup.4} is

independently hydrogen or C.sub.1 -C.sub.6 alkyl;

R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkanoyl;

R.sup.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, nitro, cyano, carboxy, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkanoyloxy or a group NR.sup.3 R.sup.4 wherein R.sup.3 and R.sup.4 are as defined above;

n is zero or an integer of 1 to 2;

x is zero or an integer of 1 to 5;

and the pharmaceutically acceptable salts thereof.

The compounds of the invention are useful as tyrosine kinase inhibitors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 173085-93-3P 173085-94-4P 173085-95-5P

173086-04-9P 173086-05-0P 173086-06-1P

(prepn. of substituted .beta.-aryl and .beta.-heteroaryl-.alpha.-cyanoacrylamide derivs. as tyrosine kinase inhibitors)


RN 173085-93-3 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-(phenylamino)-1-propenyl]-
(9CI) (CA INDEX NAME)




RN 173085-94-4 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-[(phenylmethyl)amino]-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173085-95-5 USPATFULL


CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-oxo-3-[(2-phenylethyl)amino]-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173086-04-9 USPATFULL


CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[(4-hydroxyphenyl)amino]-3-oxo-1-

propenyl]- (9CI) (CA INDEX NAME)




RN 173086-05-0 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[[[4-hydroxyphenyl)methyl]amino]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



RN 173086-06-1 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[2-cyano-3-[[2-(4-hydroxyphenyl)ethyl]amino]-3-oxo-1-propenyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 59 OF 63 USPATFULL

ACCESSION NUMBER: 96:106502 USPATFULL

TITLE: Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents

INVENTOR(S): Buzzetti, Franco, Monza, Italy
Longo, Antonio, Milan, Italy
Brasca, Maria G., Cusago, Italy
Orzi, Fabrizio, Milan, Italy
Crugnola, Angelo, Varese, Italy
Ballinari, Dario, S. Donato Mil., Italy
Mariani, Mariangela, Desio, Italy

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5576330		19961119
APPLICATION INFO.:	US 1994-354215		19941212 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-26136	19931222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rollins, John W.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	

LINE COUNT: 586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The new use of a compound of formula (I) ##STR1## wherein Y is a bicyclic ring selected from naphthalene, tetralin, quinoline, isoquinoline and indole;

n is zero or an integer of 1 to 3;

R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl;

R.sub.2 is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, cyano, carboxy, nitro, or NHR, wherein R is hydrogen or C.sub.1 -C.sub.6 alkyl;

R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl;

R.sub.4 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyloxy, carboxy, nitro or NHR, wherein R is as defined above;

R.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen; or a pharmaceutically acceptable salt thereof;

and wherein when Y is naphthalene then n is zero or an integer of 1 to 3, whereas when Y is tetralin, quinoline, isoquinoline or indole then n is zero, 1 or 2; and wherein when the bicyclic ring Y is naphthalene, quinoline, isoquinoline or indole, then each of the substituents OR.sub.1, R.sub.2 and oxindolylidene may be independently on either of the aryl or heteroaryl moieties of said bicyclic ring, whereas only the benzene moiety is substituted when Y is tetralin;

and wherein when Y is naphthalene, tetralin, quinoline or isoquinoline, then R.sub.2 is hydrogen, halogen, cyano or C.sub.1 -C.sub.6 alkyl and R.sub.3, R.sub.4 and R.sub.5 are hydrogen; whereas when Y is indole, then R.sub.2 is hydrogen, halogen, C.sub.1 -C.sub.6 alkyl, cyano, carboxy, nitro or --NHR, in which R is as defined above, R.sub.3 is hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.4 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkanoyloxy, carboxy, nitro or --NHR, wherein R is as defined above, and R.sub.5 is hydrogen, halogen or C.sub.1 -C.sub.6 alkyl;

as anti-angiogenic agent is disclosed.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148563-52-4 148563-57-9

(oxindole derivs. as anti-angiogenic agents)


RN 148563-52-4 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-5-hydroxy-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 148563-57-9 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



L42 ANSWER 60 OF 63 USPATFULL

ACCESSION NUMBER: 96:72988 USPATFULL

TITLE: Cyano naphthalene compounds

INVENTOR(S): Varney, Michael D., Carlsbad, CA, United States

Palmer, Cindy L., La Mesa, CA, United States

Deal, Judy G., Temecula, CA, United States

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545744		19960813
APPLICATION INFO.:	US 1995-450801		19950525 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-276929, filed on 19 Jul 1994, now patented, Pat. No. US 5498727		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Haley, Jacqueline		
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P.		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1002		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for preparing a substituted 2-amino-benz[cd]indole of the Formula I: ##STR1## The nitro group of a substituted 1-nitro-8-cyano-naphthalene compound is reduced to an amine group to form a substituted 1-amino-8-cyano-naphthalene compound, which is cyclized to form the substituted 2-amino-benz[cd]indole. The reduction and cyclization may be effected in a one-pot procedure using a reducing agent such as stannous chloride, which generates an acid that cyclizes the reduction product. The syntheses of the 1-nitro-8-cyano-naphthalene compound and its precursors are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146073-02-1P

(prepn. of 2-aminobenz[cd]indole inhibitors of thymidylate synthase)

RN 146073-02-1 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-(phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 61 OF 63 USPATFULL

ACCESSION NUMBER: 96:68156 USPATFULL

TITLE: CC-1065 analogs having two CPI subunits

INVENTOR(S): Kelly, Robert C., Augusta, MI, United States

Aristoff, Paul A., Portage, MI, United States

PATENT ASSIGNEE(S): The Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5541339		19960730
	WO 9002746		19900322
APPLICATION INFO.:	US 1991-659415		19910308 (7)
	WO 1989-US3329		19890807
			19910308 PCT 371 date
			19910308 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1988-243350, filed on 12 Sep 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Richter, Johann		
ASSISTANT EXAMINER:	Cross, Laura R.		
LEGAL REPRESENTATIVE:	Jameson, William G.		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1548		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	This invention concerns chemical compounds of general Formula I		

CPI.sub.1 -R.sub.5 -T-R'.sub.5 -CPI.sub.2

I

The compounds of Formula I are useful as uv light absorbers, antibacterial agents, and are particularly useful as antitumor agents. Representative compounds of Formula I have been shown to possess useful ranges of antitumor activity in standard laboratory animal tests.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 129655-48-7P 129655-49-8P 129655-52-3P
129655-53-4P

(prepn. and reaction of, in prepn. of antitumors and UV absorbers)


RN 129655-48-7 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino)]bis-, diethyl ester (9CI) (CA INDEX NAME)




RN 129655-49-8 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5,5'-[1H-indole-2,5-diylbis(carbonylimino)]bis- (9CI) (CA INDEX NAME)




RN 129655-52-3 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5-[[[5-(ethoxycarbonyl)-1H-indol-2-yl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 129655-53-4 USPATFULL

CN 1H-Indole-2-carboxylic acid, 5-[[[5-carboxy-1H-indol-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 129655-31-8P 129655-32-9P


(prepn. of, as antitumor and UV absorber)

RN 129655-31-8 USPATFULL


CN 1H-Indole-2,5-dicarboxamide, N,N'-bis[2-[[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A




RN 129655-32-9 USPATFULL


CN 1H-Indole-5-carboxamide, 2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-N-[2-[[1-(chloromethyl)-1,6-dihydro-5-hydroxy-8-methylbenzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-, [S-(R*,R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L42 ANSWER 62 OF 63 USPATFULL
ACCESSION NUMBER: 96:21207 USPATFULL
TITLE: Preparation of benzindole compounds from naphthalene compounds
INVENTOR(S): Varney, Michael D., Carlsbad, CA, United States
Palmer, Cindy L., La Mesa, CA, United States
Deal, Judy G., Temecula, CA, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5498727		19960312
APPLICATION INFO.:	US 1994-276929		19940719 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Haley, Jacqueline		

Searched by Barb O'Bryen, STIC 308-4291

LEGAL REPRESENTATIVE: Finnegan, Henderson, Farabow, Garrett & Dunner
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 1065

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a process for preparing a substituted 2-amino-benz[cd]indole of the Formula I: ##STR1## The nitro group of a substituted 1-nitro-8-cyano-naphthalene compound is reduced to an amine group to form a substituted 1-amino-8-cyano-naphthalene compound, which is cyclized to form the substituted 2-amino-benz[cd]indole. The reduction and cyclization may be effected in a one-pot procedure using a reducing agent such as stannous chloride, which generates an acid that cyclizes the reduction product. The syntheses of the 1-nitro-8-cyanonaphthalene compound and its precursors are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 146073-02-1P

(prepn. of 2-aminobenz[cd]indole inhibitors of thymidylate synthase)

RN 146073-02-1 USPATFULL

CN 1H-Indole-4-carboxylic acid, 1-(phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)



L42 ANSWER 63 OF 63 USPATFULL

ACCESSION NUMBER: 95:36423 USPATFULL

TITLE: Methylen-oxindole derivatives compositions and tyrosine kinase inhibition therewith

INVENTOR(S): Buzzetti, Franco, Monza, Italy

Longo, Antonio, Milan, Italy

Colombo, Maristella, Cesano Boscone, Italy

PATENT ASSIGNEE(S): Farmitalia Carlo Erba S.r.l., Milan, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5409949		19950425
	WO 9301182		19930121
APPLICATION INFO.:	US 1993-987280		19930312 (7)
	WO 1992-EP1569		19920710
			19930312 PCT 371 date
			19930312 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-15160	19910712
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	

PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new methylen-indole derivatives of formula (I) ##STR1## wherein R is a group ##STR2## in which R.sub.4 is hydrogen, hydroxy, C.sub.1 -C.sub.6 alkoxy, C.sub.2 -C.sub.6 alkanoyloxy, carboxy, nitro or NHR.sub.7, wherein R.sub.7 is hydrogen or C.sub.1 -C.sub.6 alkyl;

R.sub.5 is hydrogen, C.sub.1 -C.sub.6 alkyl or halogen; and

R.sub.6 is hydrogen or C.sub.1 -C.sub.6 alkyl;

n is zero, 1 or 2;

R.sub.1 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl;

R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, halogen, cyano, carboxyl, nitro or --NHR.sub.7 in which R.sub.7 is as defined above;

R.sub.3 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.2 -C.sub.6 alkanoyl; and the pharmaceutically acceptable salts thereof; and wherein, when, at the same time, R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl, halogen or cyano and R.sub.3 is hydrogen, R.sub.1 and n being as defined above, then at least one of R.sub.4, R.sub.5 and R.sub.6 is other than hydrogen, which are useful as tyrosine kinase inhibitors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 148563-52-4P 148563-57-9P

(prepn. of, as tyrosine kinase inhibitor)

RN 148563-52-4 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-5-hydroxy-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)



RN 148563-57-9 USPATFULL

CN 1H-Indole-5-carboxylic acid, 3-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]- (9CI) (CA INDEX NAME)